Patent Application
20230174486
The instant application contains a Sequence Listing previously submitted to WIPO in ASCII format and the entire content of the electronic submission of the sequence listing is incorporated by reference in its entirety for all purposes. The ASCII file is named “229407_Sequence_Listing.txt,” and was last modified on Nov. 3, 2022, and is 8,251 bytes in size.
This application relates in part to compounds that inhibit glucosylceramidases and uses thereof.
The glucosylceramidases are a group of enzymes that catalyze the hydrolytic cleavage of the beta-glucosidic linkage of the glycosphingolipid glucosylceramide (GlcCer, also known as glucocerebroside) to produce D-glucose and ceramide. In humans, there are three distinct enzymes that possess glucosylceramidase activity: the lysosomal beta-glucocerebrosidase (GCase or GBA1, EC 3.2.1.45), the non-lysosomal glucosylceramidase (GBA2, EC 3.2.1.45), and the cytosolic beta-glucosidase (GBA3, EC 3.2.1.21). GCase is a lysosomal enzyme encoded by the gene GBA; homozygous loss of function mutations in GBA cause the lysosomal storage disorder Gaucher disease, which is characterized by the pathological accumulation of glucosylceramide within lysosomes.1 GBA2 is a membrane-associated protein located at the cytoplasmic side of the endoplasmic reticulum (ER) and Golgi membrane, and is expressed at high levels in the central nervous system (CNS).2,3 _ENREF _2 GBA3 is cytosolic enzyme predominantly expressed in the liver.3,4 _ENREF _3
The glucosylceramidases play an important role in regulating cellular levels of their substrate molecule, glucosylceramide, which is the simplest member and biosynthetic precursor of an extensive class of cellular membrane lipids, the glycosphingolipids (GSLs).3,5 _ENREF _2 Dysregulation of GSL metabolism and homeostasis is implicated in a broad range of diseases, including: the neurological disorders Alzheimer’s disease (AD),6 Parkinson’s disease (PD),7 multiple sclerosis (MS),8 Huntington’s disease (HD),9 amyotrophic lateral sclerosis (ALS),10 and neuronal ceroid lipofuscinosis (Batten disease);11 the lysosomal storage diseases Niemann-Pick type C disease (NPC),12 mucolipidosis type IV (MLIV),13 and Sandhoff disease;14 and the liver diseases non-alcoholic fatty liver disease (NAFLD)15 and non-alcoholic steatohepatitis (NASH).15 Small-molecule GBA2 inhibitors have been shown to extend lifespan and improve motor coordination in a rodent model of NPC.16,17 Similarly, evidence indicates that GBA2 inhibition improves lifespan and delays motor deficits in rodent models of MLIV13 and Sandhoff disease.14 In a murine model with synucleinopathy, small-molecule GBA2 inhibitors have been shown to reduce the accumulation of alpha-synuclein aggregates in the brain. 14 As well, treatment with a small-molecule GBA2 inhibitor reduces neuroinflammation and neurodegeneration in a murine model of neuronal ceroid lipofuscinosis (Batten disease).18 Reduction of GBA2 activity has also been demonstrated to rescue the clinical phenotype in a rodent model of Gaucher disease.19 In addition, studies have shown that GBA2 is involved in regulating the inflammatory response,2 and that reduction of GBA2 activity reduces inflammation in a cell model of cystic fibrosis (CF).20 Increased levels of glucosylceramide have also demonstrated beneficial effects in rodent models of liver disease, including non-alcoholic steatohepatitis (NASH),21 hepatitis,22 hepatocellular carcinoma (HCC),23 autoimmune cholangitis,24 and drug-induced liver injury (DILI).25
The enzymatic activity of GBA2 can be pharmacologically blocked by the iminosugars (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol (NB-DNJ, miglustat) and (2R,3R,4R,5S)-1-(5-((3R,5R,7R)-adamantan-1-ylmethoxy)pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol (AMP-DNM, Genz-529648); however, these compounds are not selective for GBA2 as they also exhibit inhibitory activity toward other enzymes, including GCase, glucosylceramide synthase (GCS, EC 2.4.1.80), and intestinal alpha-glucosidases.26
International patent applications PCT/GB2003/003099, filed 17 Jul. 2003, published under No. WO 2004/007453 on 22 Jan. 2004; PCT/GB2004/002450, filed 9 Jun. 2004, published under No. WO 2004/111001 on 23 Dec. 2004; PCT/GB2004/002451, filed 9 Jun. 2004, published under No. WO 2004/111002 on 23 Dec. 2004; PCT/GB2005/000071, filed 11 Jan. 2005, published under No. WO 2005/068426 on 28 Jul. 2005; PCT/NL2015/050188, filed 23 Mar. 2015, published under No. WO 2015/147639 on 1 Oct. 2015; and PCT/IB2020/054355, filed 7 May 2020, published under WO 2020/229968 on 19 November, 2020, are directed to small-molecule inhibitors of GBA2.
The invention provides, in part, compounds for inhibiting a non-lysosomal glucosylceramidase (GBA2), prodrugs of the compounds, uses of the compounds and the prodrugs, pharmaceutical compositions including the compounds or prodrugs of the compounds, and methods of treating diseases and disorders modulated by levels of GBA2 activity, and/or levels of glucosylceramide, and/or dysregulation of glycosphingolipid metabolism or homeostasis. In some embodiments, the invention provides compositions and methods to prevent and/or treat a neurological disease, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington’s disease, and amyotrophic lateral sclerosis (ALS), or a lysosomal storage disease, including Gaucher disease, Niemann-Pick type C disease, mucolipidosis type IV, and Sandhoff disease, or a liver disease, including non-alcoholic steatohepatitis (NASH), by administering to a patient in need thereof an effective amount of one or more of the compounds or prodrugs of the compounds described herein.
In one aspect, the invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof:
In alternative embodiments, the invention provides a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof:
In alternative embodiments, the invention provides a compound of Formula (Ib) or a pharmaceutically acceptable salt thereof:
In alternative embodiments, the invention provides a compound of Formula (Ic) or a pharmaceutically acceptable salt thereof:
where R6 and R7 may be independently selected from the group consisting of: H, F, Cl, C1-6 alkyl, OCH3, phenyl, cyclopropyl, vinyl, methoxymethyl, 2-fluoropropan-2-yl, CHF2, CF2CH3, and/or CF3, with the proviso that at least one of R6 and R7 is other than H. In some embodiments, R6 may be H, and R7 may be CF3, 2-fluoropropan-2-yl, CHF2, CF2CH3, isopropyl, or tert-butyl. In some embodiments, R6 may be CF3, 2-fluoropropan-2-yl, CHF2, CF2CH3, isopropyl, or tert-butyl, and R7 may be H.
In alternative embodiments, the invention provides a compound of Formula (Id) or a pharmaceutically acceptable salt thereof:
where R6 and R7 may be independently selected from the group consisting of: H, F, Cl, C1-6 alkyl, OCH3, phenyl, cyclopropyl, vinyl, methoxymethyl, 2-fluoropropan-2-yl, CHF2, CF2CH3, and/or CF3, with the proviso that at least one of R6 and R7 is other than H.
In alternative embodiments, the invention provides a compound of Formula (Ie) or a pharmaceutically acceptable salt thereof:
where R8, R9 and R10 may be independently selected from the group consisting of: pyrrolidin-1-yl, piperidin-1-yl, 4-morpholino, cyclopropylmethoxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, phenoxy, (tetrahydrofuran-3-yl)methoxy, tetrahydro-2H-pyran-4-yl, 3,5-dimethylisoxazol-4-yl, 3,5-dimethyl-1H-pyrazol-4-yl, H, F, Cl, C1-6 alkyl, cyclopropyl, propen-2-yl, OCH3, and/or CF3., with the proviso that at least one of R8, R9 and R10 is other than H. In some embodiments, R8, R9 and R10 may be independently selected from the group consisting of: H, F, Cl, tetrahydro-2H-pyran-4-yl, 4-morpholino, pyrrolidin-1-yl, and piperidin-1-yl, with the proviso that at least one of R8, R9 and R10 is other than H.
In alternative embodiments, the invention provides a compound of Formula (If) or a pharmaceutically acceptable salt thereof:
where R8, R9 and R10 may be independently selected from the group consisting of: H, F, Cl, C1-6 alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C1-5 alkoxy, and/or CF3, with the proviso that the compound is not (2R,3R,4R,5S)-2-(hydroxymethyl)-1-(4-phenylbutyl)piperidine-3,4,5-triol, (2R,3R,4R,5S)-2-(hydroxymethyl)-1-(3-(2-propoxyphenyl)propyl)piperidine-3,4,5-triol, (2R,3R,4R,5S)-2-(hydroxymethyl)-1-(3-(3-propoxyphenyl)propyl)piperidine-3,4,5-triol, or (2R,3R,4R,5S)-2-(hydroxymethyl)-1-(3-(4-propoxyphenyl)propyl)piperidine-3,4,5-triol.
In alternative embodiments, the invention provides a compound of Formula (Ig) or a pharmaceutically acceptable salt thereof:
where R8, R9 and R10 may be independently selected from the group consisting of: H, F, Cl, C1-6 alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C1-5 alkoxy, and/or CF3. In some embodiments, R8, R9 and R10 may be independently selected from the group consisting of: H, F, and CF3.
In alternative embodiments, the invention provides a compound of Formula (Ih) or a pharmaceutically acceptable salt thereof:
where R11 may be selected from the group consisting of: C1-6 alkyl, C3-7 cycloalkyl, phenyl, thiophen-3-yl, phenylmethyl, or cyclopentylmethyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, C1-6 alkyl, OCH3, and/or CF3.
In alternative embodiments, the invention provides a compound of Formula (Ii) or a pharmaceutically acceptable salt thereof:
where R12 may be selected from the group consisting of: phenyl, pyridin-2-yl, pyridin-3-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, or phenylcarbonyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C1-6 alkyl, C1-6 alkoxyl, OCF3, and/or CF3. In some embodiments, R12 may be selected from the group consisting of: 2-(trifluoromethyl)phenyl, 2-(trifluoromethyl)pyridin-3-yl, 3-(trifluoromethyl)pyridin-2-yl, 4-(trifluoromethyl)pyridin-2-yl, 5-(trifluoromethyl)pyridin-3-yl, 6-(trifluoromethyl)pyridin-2-yl, 4-(trifluoromethyl)pyrimidin-5-yl, and 4-(trifluoromethyl)thiazol-2-yl.
In alternative embodiments, the invention provides a compound of Formula (Ij) or a pharmaceutically acceptable salt thereof:
where R12 may be selected from the group consisting of: phenyl, pyridin-2-yl, pyridin-3-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, or phenylcarbonyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C1-6 alkyl, C1-6 alkoxyl, OCF3, and/or CF3. In some embodiments, R12 may be selected from the group consisting of: 2-(trifluoromethyl)phenyl, 2-(trifluoromethyl)pyridin-3-yl, 3-(trifluoromethyl)pyridin-2-yl, 4-(trifluoromethyl)pyridin-2-yl, 5-(trifluoromethyl)pyridin-3-yl, 6-(trifluoromethyl)pyridin-2-yl, 4-(trifluoromethyl)pyrimidin-5-yl, and 4-(trifluoromethyl)thiazol-2-yl.
In alternative embodiments, the invention provides a compound of Formula (Ik) or a pharmaceutically acceptable salt thereof:
where R12 may be selected from the group consisting of: phenyl, pyridin-2-yl, pyridin-3-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, or phenylcarbonyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C1-6 alkyl, C1-6 alkoxyl, OCF3, and/or CF3. In some embodiments, R12 may be selected from the group consisting of: 2-(trifluoromethyl)phenyl, 2-(trifluoromethyl)pyridin-3-yl, 3-(trifluoromethyl)pyridin-2-yl, 4-(trifluoromethyl)pyridin-2-yl, 5-(trifluoromethyl)pyridin-3-yl, 6-(trifluoromethyl)pyridin-2-yl, 4-(trifluoromethyl)pyrimidin-5-yl, and 4-(trifluoromethyl)thiazol-2-yl.
In alternative embodiments, the invention provides a compound of Formula (Il) or a pharmaceutically acceptable salt thereof:
where R12 may be selected from the group consisting of: phenyl, pyridin-2-yl, pyridin-3-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, or phenylcarbonyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C1-6 alkyl, C1-6 alkoxyl, OCF3, and/or CF3. In some embodiments, R12 may be selected from the group consisting of: 2-(trifluoromethyl)phenyl, 2-(trifluoromethyl)pyridin-3-yl, 3-(trifluoromethyl)pyridin-2-yl, 4-(trifluoromethyl)pyridin-2-yl, 5-(trifluoromethyl)pyridin-3-yl, 6-(trifluoromethyl)pyridin-2-yl, 4-(trifluoromethyl)pyrimidin-5-yl, and 4-(trifluoromethyl)thiazol-2-yl.
In alternative embodiments, the invention provides a compound of Formula (Im) or a pharmaceutically acceptable salt thereof:
where R6 and R7 may be independently selected from the group consisting of: H, F, Cl, C1-6 alkyl, OCH3, phenyl, cyclopropyl, vinyl, methoxymethyl, 2-fluoropropan-2-yl, CHF2, CF2CH3, and/or CF3. In some embodiments, R6 may be H, and R7 may be CF3, 2-fluoropropan-2-yl, CHF2, CF2CH3, isopropyl, or tert-butyl. In some embodiments, R6 may be CF3, 2-fluoropropan-2-yl, CHF2, CF2CH3, isopropyl, or tert-butyl, and R7 may be H.
In alternative embodiments, the invention provides a compound of Formula (In) or a pharmaceutically acceptable salt thereof:
where R6 and R7 may be independently selected from the group consisting of: H, F, Cl, C1-6 alkyl, OCH3, phenyl, cyclopropyl, vinyl, methoxymethyl, 2-fluoropropan-2-yl, CHF2, CF2CH3, and/or CF3.
In alternative embodiments, the invention provides a compound of Formula (Io) or a pharmaceutically acceptable salt thereof:
where R8, R9 and R10 may be independently selected from the group consisting of: pyrrolidin-1-yl, piperidin-1-yl, 4-morpholino, cyclopropylmethoxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, phenoxy, (tetrahydrofuran-3-yl)methoxy, tetrahydro-2H-pyran-4-yl, 3,5-dimethylisoxazol-4-yl, 3,5-dimethyl-1H-pyrazol-4-yl, H, F, Cl, C1-6 alkyl, cyclopropyl, propen-2-yl, OCH3, and/or CF3., with the proviso that the compound is not (2S,3R,4R,5S)-2-(hydroxymethyl)-1-phenethylpiperidine-3,4,5-triol, (2S,3R,4R,5S)-2-(hydroxymethyl)-1-((R)-2-phenylpropyl)piperidine-3,4,5-triol, or (2S,3R,4R,5S)-2-(hydroxymethyl)-1-((S)-2-phenylpropyl)piperidine-3,4,5-triol. In some embodiments, R8, R9 and R10 may be independently selected from the group consisting of: H, F, Cl, tetrahydro-2H-pyran-4-yl, 4-morpholino, pyrrolidin-1-yl, and piperidin-1-yl, with the proviso that at least one of R8, R9 and R10 is other than H.
In alternative embodiments, the invention provides a compound of Formula (Ip) or a pharmaceutically acceptable salt thereof:
where R8, R9 and R10 may be independently selected from the group consisting of: H, F, Cl, C1-6 alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C1-5 alkoxy, and/or CF3, with the proviso that at least one of R8, R9 and R10 is other than H.
In alternative embodiments, the invention provides a compound of Formula (Iq) or a pharmaceutically acceptable salt thereof:
where R8, R9 and R10 may be independently selected from the group consisting of: H, F, Cl, C1-6 alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C1-5 alkoxy, and/or CF3. In some embodiments, R8, R9 and R10 may be independently selected from the group consisting of: H, F, and CF3.
In alternative embodiments, the invention provides a compound of Formula (Ir) or a pharmaceutically acceptable salt thereof:
where R11 may be selected from the group consisting of: C1-6 alkyl, C3-7 cycloalkyl, phenyl, thiophen-3-yl, phenylmethyl, or cyclopentylmethyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, C1-6 alkyl, OCH3, and/or CF3.
In alternative embodiments, the invention provides a compound of Formula (Is) or a pharmaceutically acceptable salt thereof:
where R12 may be selected from the group consisting of: phenyl, pyridin-2-yl, pyridin-3-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, or phenylcarbonyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C1-6 alkyl, C1-6 alkoxyl, OCF3, and/or CF3. In some embodiments, R12 may be selected from the group consisting of: 2-(trifluoromethyl)phenyl, 2-(trifluoromethyl)pyridin-3-yl, 3-(trifluoromethyl)pyridin-2-yl, 4-(trifluoromethyl)pyridin-2-yl, 5-(trifluoromethyl)pyridin-3-yl, 6-(trifluoromethyl)pyridin-2-yl, 4-(trifluoromethyl)pyrimidin-5-yl, and 4-(trifluoromethyl)thiazol-2-yl.
In alternative embodiments, the invention provides a compound of Formula (It) or a pharmaceutically acceptable salt thereof:
where R12 may be selected from the group consisting of: phenyl, pyridin-2-yl, pyridin-3-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, or phenylcarbonyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C1-6 alkyl, C1-6 alkoxyl, OCF3, and/or CF3. In some embodiments, R12 may be selected from the group consisting of: 2-(trifluoromethyl)phenyl, 2-(trifluoromethyl)pyridin-3-yl, 3-(trifluoromethyl)pyridin-2-yl, 4-(trifluoromethyl)pyridin-2-yl, 5-(trifluoromethyl)pyridin-3-yl, 6-(trifluoromethyl)pyridin-2-yl, 4-(trifluoromethyl)pyrimidin-5-yl, and 4-(trifluoromethyl)thiazol-2-yl.
In alternative embodiments, the invention provides a compound of Formula (Iu) or a pharmaceutically acceptable salt thereof:
where R12 may be selected from the group consisting of: phenyl, pyridin-2-yl, pyridin-3-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, or phenylcarbonyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C1-6 alkyl, C1-6 alkoxyl, OCF3, and/or CF3. In some embodiments, R12 may be selected from the group consisting of: 2-(trifluoromethyl)phenyl, 2-(trifluoromethyl)pyridin-3-yl, 3-(trifluoromethyl)pyridin-2-yl, 4-(trifluoromethyl)pyridin-2-yl, 5-(trifluoromethyl)pyridin-3-yl, 6-(trifluoromethyl)pyridin-2-yl, 4-(trifluoromethyl)pyrimidin-5-yl, and 4-(trifluoromethyl)thiazol-2-yl.
In alternative embodiments, the invention provides a compound of Formula (Iv) or a pharmaceutically acceptable salt thereof:
where R12 may be selected from the group consisting of: phenyl, pyridin-2-yl, pyridin-3-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, or phenylcarbonyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C1-6 alkyl, C1-6 alkoxyl, OCF3, and/or CF3. In some embodiments, R12 may be selected from the group consisting of: 2-(trifluoromethyl)phenyl, 2-(trifluoromethyl)pyridin-3-yl, 3-(trifluoromethyl)pyridin-2-yl, 4-(trifluoromethyl)pyridin-2-yl, 5-(trifluoromethyl)pyridin-3-yl, 6-(trifluoromethyl)pyridin-2-yl, 4-(trifluoromethyl)pyrimidin-5-yl, and 4-(trifluoromethyl)thiazol-2-yl.
In alternative embodiments, the compound may be a prodrug; the compound may inhibit a non-lysosomal glucosylceramidase (GBA2); the compound may inhibit a GBA2 (e.g., a mammalian GBA2); the compound may inhibit a wild-type GBA2; or the compound may inhibit a mutant GBA2.
In alternative embodiments, a compound according to Formula (I), Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), Formula (If), Formula (Ig), Formula (Ih), Formula (Ii), Formula (Ij), Formula (Ik), Formula (Il), Formula (Im), Formula (In), Formula (Io), Formula (Ip), Formula (Iq), Formula (Ir), Formula (Is), Formula (It), Formula (Iu), or Formula (Iv) may exhibit enhanced selectivity and/or permeability.
In alternative embodiments, a compound according to Formula (Ic), Formula (Ie), Formula (Ig), Formula (Im), Formula (Io), or Formula (Iq) may exhibit enhanced selectivity and/or permeability.
In alternative embodiments, a compound according to Formula (Ic), Formula (Ie), Formula (Ig), Formula (Im), Formula (Io), or Formula (Iq) may exhibit enhanced selectivity.
In alternative embodiments, a compound according to Formula (Ic), Formula (Ie), Formula (Ig), Formula (Im), Formula (Io), or Formula (Iq) may achieve higher brain concentrations when administered in vivo.
In alternative aspects, the invention provides a pharmaceutical composition including a compound according to the invention, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.
In alternative aspects, the invention provides methods of inhibiting a GBA2 in a subject in need thereof, or of treating a neurological disease, or a lysosomal storage disease, or a liver disease, in a subject in need thereof, by administering to the subject an effective amount of a compound of Formula (I), including any one or more of Formula (Ia) - (Iv), or a pharmaceutically acceptable salt thereof, as described herein. The neurological disease may be, without limitation, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington’s disease, amyotrophic lateral sclerosis (ALS), amyotrophic lateral sclerosis with cognitive impairment (ALSci), addiction, anxiety, argyrophilic grain dementia, ataxiatelangiectasia (A-T), attention deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), Becker muscular dystrophy (BMD), bipolar disorder (BD), Bluit disease, cerebellar ataxia, Charcot-Marie-Tooth disease (CMT), chronic fatigue syndrome, corticobasal degeneration (CBD), dementia pugilistica, dementia with Lewy bodies (DLB), Dejerine-Sottas disease, diffuse neurofibrillary tangles with calcification, Down’s syndrome, Duchenne muscular dystrophy (DMD), epilepsy, essential tremor (ET), familial British dementia, familial Danish dementia, fibromyalgia, frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), Friedreich’s ataxia, Gerstmann-Straussler-Scheinker disease, glaucoma, Guadeloupean parkinsonism, Guillain-Barré syndrome, Hallevorden-Spatz disease (neurodegeneration with brain iron accumulation type 1), insomnia, Lambert-Eaton myasthenic syndrome (LEMS), major depressive disorder (MDD), migraine, mild cognitive impairment (MCI), multi-infarct dementia, multiple system atrophy (MSA), myasthenia gravis, myotonic dystrophy (including types DM1 and DM2), neuronal ceroid lipofuscinosis (including types 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10), neuropathy (including peripheral neuropathy, autonomic neuropathy, neuritis, and diabetic neuropathy), oculopharyngeal muscular dystrophy, pain, pallido-ponto-nigral degeneration, parkinsonismdementia complex of Guam, Pick’s disease (PiD), post-encephalitic parkinsonism (PEP), primary lateral sclerosis (PLS), prion diseases (including Creutzfeldt-Jakob Disease (CJD), variant Creutzfeldt-Jakob Disease (vCJD), fatal familial insomnia, and kuru), progressive supercortical gliosis, progressive supranuclear palsy (PSP), Richardson’s syndrome, schizophrenia, seizures, spinal cord injury, spinal muscular atrophy (SMA), spinocerebellar ataxia (including types 1, 2, 3, 4, 5, 6, 7, 8, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, and 29), stroke, subacute sclerosing panencephalitis, tangle-only dementia, tardive dyskinesia, Tourette syndrome (TS), vascular dementia, or Wilson’s disease.
The lysosomal storage disease may be, without limitation, Gaucher disease (including types I, II, and III), Niemann-Pick disease (including types A, B, and C), mucolipidosis (including types I, II, III, IV, VI, and VII), cerebrotendineous xanthomatosis, Fabry disease, Farber disease, GM1 gangliosidosis, Krabbe disease, metachromatic leukodystrophy (MLD), multiple sulfatase deficiency, Pompe disease, Sandhoff disease, or Tay-Sach’s disease.
The liver disease may be, without limitation, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), Alagille syndrome, alcohol-related liver disease, alpha-1 antitrypsin deficiency, autoimmune hepatitis, autoimmune cholangitis, benign liver tumors, biliary atresia, cirrhosis, Crigler-Najjar syndrome, drug-induced liver injury (DILI), galactosemia, Gilbert syndrome, hemochromatosis, hepatic encephalopathy, hepatocellular carcinoma (HCC), intrahepatic cholestasis of pregnancy (ICP), lysosomal acid lipase deficiency (LAL-D), liver cysts, liver cancer, newborn jaundice, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), Reye syndrome, type I glycogen storage disease, or viral hepatitis (including types A, B, C, D, and E).
In alternative embodiments, the invention provides methods of treating a neurological disease in a subject in need thereof by administering to the subject an effective amount of a compound of any one or more of Formula (Ic), Formula (Ie), Formula (Ig), Formula (Im), Formula (Io), or Formula (Iq) or a pharmaceutically acceptable salt thereof, as described herein.
In alternative embodiments, the administering may reduce the enzymatic activity level of GBA2 in a subject. In alternative embodiments, the administering may modulate the levels of glucosylceramide and/or glycosphingolipids in a subject. In alternative embodiments, the administering may elevate the levels of glucosylceramide in a subject. In alternative embodiments, the administering may elevate the levels of the ganglioside GM1 in a subject. In alternative embodiments, the administering may modulate the levels of ceramide and/or sphingosine and/or sphingosine-1-phosphate (S1P) in a subject. The subject may be a human.
In alternative aspects, the invention provides use of a compound of an effective amount of a compound of Formula (I), including any one or more of Formula (Ia) - (Iv), or a pharmaceutically acceptable salt thereof, as described herein, in the preparation of a medicament. The medicament may be for inhibiting a GBA2, for treating a condition modulated by a GBA2, or for treating a neurological disease or a lysosomal storage disease or a liver disease.
This summary of the invention does not necessarily describe all features of the invention.
The invention provides, in part, compounds for inhibiting a non-lysosomal glucosylceramidase (GBA2) and uses thereof.
By a “non-lysosomal glucosylceramidase” or “GBA2” is meant a non-lysosomal membrane-associated enzyme located at the cytoplasmic side of the ER and Golgi membrane with glucosylceramidase activity (EC 3.2.1.45) that catalyzes the hydrolytic cleavage of the beta-glucosidic linkage of the glycolipid glucosylceramide. Alternative names for a GBA2 include: NLGase, glucosylceramidase beta 2, beta-glucocerebrosidase 2, beta-glucosidase 2, glucosylceramidase 2, bile acid beta-glucosidase, “glucosidase, beta (bile acid) 2”, KIAA1605, DKFZp762K054, SPG46, and AD035. In some embodiments, the GBA2 may be a mammalian GBA2, such as a rat, mouse, or human GBA2. The GBA2 may be a wild-type GBA2 or a mutant GBA2. In some embodiments, the GBA2 may be a wild-type mammalian GBA2, such as a rat, mouse, or human wild-type GBA2. In some embodiments, the GBA2 may be a mutant mammalian GBA2, such as a rat, mouse, or human mutant GBA2. In some embodiments, the GBA2 may have a sequence as set forth in any one of the following Accession numbers: Q9HCG7, Q69ZF3, D3DRP2, Q5TCV6, Q96A51, Q96LY1, Q96SJ2, Q9H2L8, Q5M868, or 016581. In alternative embodiments, the GBA2 may have an alternative splice isoform sequence as set forth in any one of the following Accession numbers: Q9HCG7-1, Q9HCG7-2, Q9HCG7-3. In alternative embodiments, the GBA2 may be encoded by a sequence as set forth in any one of the following Accession numbers: NP_065995.1, NP_001317589.1, NP_766280.2, NP_001013109.2, NM_020944, NM_172692, NM_001330660, XM_011517973, XP_005251583.1, XP_006716872.1, XP_011516275.1, XP_016870426.1, XP_016870427.1, XP_016870428.1, XP_016870429.1, XP_016870430.1, XP_016870431.1, XP_016870432.1, XP_016870433.1, XP_016870434.1, or XP_016870435.1. In alternative embodiments, the human GBA2 may have the sequence set forth below:
In alternative embodiments, the human GBA2 may have the nucleic acid sequence of a nucleic acid molecule encoding the sequence set forth in SEQ ID NO: 1.
In some embodiments, one or more of the compounds according to the invention may inhibit the activity of a GBA2, for example, the ability to inhibit the cleavage of glucose from glucosylceramide or the ability to inhibit the cleavage of glucose from a suitable substrate molecule such as, for example, 4-methylumbelliferone-β-D glucopyranoside. By “inhibit,” “inhibition” or “inhibiting” means a decrease in the activity of a GBA2 by any value between about 10% and about 90%, or of any value between about 30% and about 60%, or over about 100%, or a decrease by about 1-fold, 2-fold, 5-fold, 10-fold or more, in comparison to a reference sample or compound, or in comparison to a wild-type GBA2. It is to be understood that the inhibiting does not require full inhibition. In some embodiments, the inhibition may be transient, for example, for a period of 5 min - 60 min, 1 h - 5 h, 1 h - 12 h, 1 h - 24 h, 24 h - 48 h, 1 day - 2 days, 1 day - 5 days, 1 day - 7 days, 1 day - 14 days, 1 day - 28 days, or any specific time within any of these ranges, such as 5 min, 10 min, 15 min, 20 min, 25 min, 30 min, 60 min, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 7 h, 8 h, 9 h, 10 h, 11 h, 12 h, 13 h, 14 h, 15 h, 16 h, 17 h, 18 h, 19 h, 20 h, 21 h, 22 h, 23 h, 24 h, 1.5 days, 2 days, 2.5 days, 3 days, 3.5 days, 4 days, 4.5 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, or 14 days. In some embodiments, the inhibition may be localized. For example, one or more of the compounds according to the invention may inhibit a GBA2 within a specific cellular compartment, such as the endoplasmic reticulum (ER) or Golgi apparatus (Golgi); or one or more of the compounds according to the invention may inhibit a GBA2 within a specific tissue type, such as brain or liver.
In some embodiments, one or more of the compounds according to the invention may specifically bind a GBA2. In alternative embodiments, one or more of the compounds according to the invention may specifically bind the active site of a GBA2. In some embodiments, one or more of the compounds according to the invention that specifically bind the active site of a GBA2 may also inhibit the activity of a GBA2. In alternative embodiments, one or more of the compounds according to the invention may specifically bind the human non-lysosomal glucosylceramidase (GBA2) over the human lysosomal glucosylceramidase (GCase) and/or the human cytosolic glucosylceramidase (GBA3). In alternative embodiments, one or more of the compounds according to the invention may specifically bind the human non-lysosomal glucosylceramidase (GBA2) over the human glucosylceramide synthase (GCS). In alternative embodiments, one or more of the compounds according to the invention may specifically bind the human non-lysosomal glucosylceramidase (GBA2) over an intestinal alpha-glucosidase, where the intestinal alpha-glucosidase may be a sucrase-isomaltase or a maltase-glucoamylase. By “specifically binds” is meant a compound that binds a GBA2 but does not substantially bind other molecules in a sample, such as a lactase, a sucrase, a maltase, an isomaltase, a sucrase-isomaltase, a glucoamylase, a maltase-glucoamylase, a glucosylceramide synthase, an alpha-glucosidase II, an ER alpha-glucosidase, an intestinal alpha-glucosidase, a glycogen phosphorylase, an acid alpha-glucosidase, a beta-hexosaminidase, an O-GlcNAcase, a GCase, or a GBA3. By “not substantially bind” is meant a binding specificity in the range of about 5-fold to about 100,000-fold, or about 10-fold to about 100,000-fold, or in the range of about 100-fold to about 100,000-fold, or in the range of about 1000-fold to about 100,000-fold, or at least about 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, 200-fold, 500-fold, 1000-fold, 1500-fold, 2000-fold, 2500-fold, 3000-fold, 3500-fold, 4000-fold, 4500-fold, 5000-fold, 6000-fold, 7000-fold, 10,000-fold, 25,000-fold, 50,000-fold, 75,000-fold, or any value within or about the described range, where “binding specificity” means the ratio of the respective binding constants, that is, Ki(othermolecule)/Ki(GBA2), or the ratio of the respective IC50 values, that is IC50(othermolecule)/IC50(GBA2). Examples of compounds that exhibit enhanced binding specificity include, without limitation, the compounds of Examples 4, 8, 12, 13, 14, 15, 16, 20, 21, 22, 23, 24, 25, 27, 28, 29, 31, 32, 311, 312, 313, or 314. In some embodiments, one or more compounds according to the invention may exhibit enhanced binding specificity or enhanced selectivity compared to a suitable reference compound such as, for example, (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol (NB-DNJ, miglustat) or (2R,3R,4R,5S)-1-(5-((3R,5R,7R)-adamantan-1-ylmethoxy)pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol (AMP-DNM, Genz-529648). In some embodiments, “enhanced binding specificity” or “enhanced selectivity” means an increase in measured binding specificity (as defined above) by any value between about 10% and about 100%, or of any integer value between about 10% and about 100%, for example, about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or over 100%, or an increase by about 1-fold to about 100,000-fold, or about 5-fold to about 100,000-fold, or about 10-fold to about 100,000-fold, or in the range of about 100-fold to about 100,000-fold, or in the range of about 1000-fold to about 100,000-fold, or at least about 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 100-fold, 150-fold, 200-fold, 250-fold, 300-fold, 350-fold, 400-fold, 450-fold, 500-fold, 1000-fold, 1500-fold, 2000-fold, 2500-fold, 3000-fold, 3500-fold, 4000-fold, 4500-fold, 5000-fold, 6000-fold, 7000-fold, 10,000-fold, 25,000-fold, 50,000-fold, 75,000-fold, 100,000-fold, or any value within or about the described range, or more, as compared to a suitable reference compound.
In alternative embodiments, one or more of the compounds according to the invention may specifically bind the human non-lysosomal glucosylceramidase (GBA2) over a rat intestinal alpha-glucosidase, where the rat intestinal alpha-glucosidase may be a sucrase-isomaltase or a maltase-glucoamylase. In some embodiments, one or more compounds according to the invention may not substantially inhibit a rat intestinal alpha-glucosidase, compared to a suitable reference compound such as, for example, (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol (NB-DNJ, miglustat) or (2R,3R,4R,5S)-1-(5-((3R,5R,7R)-adamantan-1-ylmethoxy)pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol (AMP-DNM, Genz-529648). In some embodiments, “not substantially inhibit” means a percent inhibition of less than about 30% in the assay described below for inhibition of a rat intestinal glucosidase. In some embodiments, “not substantially inhibit” means a percent inhibition of less than about 20% in the assay described below for inhibition of a rat intestinal glucosidase. In some embodiments, “not substantially inhibit” means a percent inhibition of less than about 10% in the assay described below for inhibition of a rat intestinal glucosidase.
In some embodiments, one or more of the compounds of the present invention may inhibit the cleavage of glucose from glucosylceramide by a GBA2. In some embodiments, one or more of the compounds of the present invention may inhibit aggregation of an alpha-synuclein protein and/or inhibit formation of Lewy bodies. By “inhibit,” “inhibition” or “inhibiting” means a decrease by any value between about 10% and about 90%, or of any value between about 30% and about 60%, or over about 100%, or a decrease by about 1-fold, 2-fold, 5-fold, 10-fold or more, in comparison to a reference sample or compound, or in comparison to a wild-type GBA2. It is to be understood that the inhibiting does not require full inhibition. In some embodiments, the inhibition may be transient.
In some embodiments, one or more of the compounds of the present invention may decrease inflammation in the CNS. In some embodiments, one or more of the compounds of the present invention may decrease alpha-synuclein aggregation and/or Lewy body formation. By “decreasing” or “decrease” is meant a decrease by any value between about 5% and about 90%, or of any value between about 30% and about 60%, or over 100 about%, or a decrease by about 1-fold, 2-fold, 5-fold, 10-fold, 15-fold, 25-fold, 50-fold, 100-fold or more, in comparison to a reference sample or compound.
In some embodiments, one or more of the compounds of the present invention may elevate glucosylceramide levels. In some embodiments, one or more of the compounds of the present invention may elevate glycosphingolipid levels. In some embodiments, one or more of the compounds of the present invention may elevate GM1 ganglioside levels. By “elevating” or “enhancing” or “increasing” is meant an increase by any value between about 5% and about 90%, or of any value between about 30% and about 60%, or over about 100%, or an increase by about 1-fold, 2-fold, 5-fold, 10-fold, 15-fold, 25-fold, 50-fold, 100-fold, or more, in comparison to a reference sample. In some embodiments, one or more of the compounds according to the invention may elevate glucosylceramide levels and/or glycosphingolipid levels and/or GM1 ganglioside levels, in brain.
In some embodiments, one or more of the compounds of the present invention may elevate GCase activity levels, and/or GCase protein levels, in vivo and may be effective in treating conditions which require or respond to enhancement of GCase activity. In some embodiments, one or more of the compounds of the present invention may elevate GCase activity levels, and/or GCase protein levels, in vivo specifically via interaction with a GBA2, and may be effective in treating conditions which require or respond to enhancement of GCase activity. By “elevating” or “enhancing” or “increasing” is meant an increase by any value between about 5% and about 100%, for example, about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or over 100%, or an increase by about 1-fold, 2-fold, 5-fold, 10-fold, 15-fold, 25-fold, 50-fold, 100-fold or more, in comparison to a reference sample or compound, or in comparison to a wild type or mutant GCase.
In some embodiments, one or more of the compounds according to the invention may exhibit enhanced permeability. Permeability can be assessed using a variety of standard experimental techniques, including without limitation in situ perfusion, ex vivo tissue diffusion, in vitro cell monolayers (e.g. Caco-2 cells, MDCK cells, LLC-PK1 cells), and artificial cell membranes (e.g. PAMPA assay); suitable techniques for measuring effective permeability (P eff) or apparent permeability (P app) are reviewed for example by Volpe in The AAPS Journal, 2010, 12(4), 670-678. In some embodiments, one or more of the compounds according to the invention may show enhanced permeability when tested in one or more of these assays for determining Peff or Papp. In some embodiments, a compound that exhibits enhanced permeability may exhibit greater oral absorption. In some embodiments, a compound that exhibits enhanced permeability may exhibit greater brain penetrance when administered in vivo. In some embodiments, a compound that exhibits enhanced permeability may achieve higher brain concentrations when administered in vivo. In some embodiments, a compound that exhibits enhanced permeability may exhibit a higher brain/plasma concentration ratio when administered in vivo. In some embodiments, “enhanced permeability” means an increase in measured P eff or Papp by any value between about 10% and about 100%, or of any integer value between about 10% and about 100%, for example, about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or over 100%, or an increase by about 1-fold, 2-fold, or 3-fold, or more, as compared to a suitable reference compound such as, for example, (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol (NB-DNJ, miglustat) or (2R,3R,4R,5S)-1-(5-((3R,5R,7R)-adamantan-1-ylmethoxy)pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol (AMP-DNM, Genz-529648). In some embodiments, “enhanced permeability” means a measurable Papp value (i.e. a value greater than zero) in a suitable assay to measure Papp using in vitro cell monolayers. In some embodiments, “enhanced permeability” means a Papp value greater than 2 x 10-6 cm/s in a suitable assay to measure Papp using in vitro cell monolayers. In alternative embodiments, “enhanced permeability” means a Papp value in the range 2 x 10-6 cm/s to 40 x 10-6 cm/s in a suitable assay to measure Papp using in vitro cell monolayers. In some embodiments, “higher brain concentration” means an increase in measured brain concentration when the compound is administered in vivo by any value between about 10% and about 100%, or of any integer value between about 10% and about 100%, for example, about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or over 100%, or an increase by about 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 30-fold, 40-fold, or 50-fold, or more, as compared to a suitable reference compound such as, for example, (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol (NB-DNJ, miglustat) or (2R,3R,4R,5S)-1-(5-((3R,5R,7R)-adamantan-1-ylmethoxy)pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol (AMP-DNM, Genz-529648).
A “reference compound” or “control” may be a carbohydrate mimetic iminosugar described in the literature that is a GBA2 inhibitor. Examples of reference compounds or controls that are GBA2 inhibitors include, without limitation, (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol (NB-DNJ, miglustat) and (2R,3R,4R,5S)-1-(5-((3R,5R,7R)-adamantan-1-ylmethoxy)pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol (AMP-DNM, Genz-529648).26
In some embodiments, the invention provides compounds described generally by Formula (I), including any one or more of Formula (Ia) - (Iv), and the salts, prodrugs, and enantiomeric forms thereof:
In some embodiments, R1 as set forth in Formula (I) may be H, and R2 may be CH2OH. In some embodiments, R1 may be CH2OH, and R2 may be H.
In some embodiments, R3 as set forth in Formula (I) may be (CH2)nR4, wherein n may be 1 or 2, and R4 may be cyclohexyl, cyclohexylmethyl, phenylethyl, 4-phenylcyclohexyl, spiro[2.5]octan-6-yl, spiro[3.5]nonan-7-yl, spiro[4.5]decan-8-yl, (5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, 2,3-dihydro-1H-inden-2-yl, (adamantyl)methyl, (pyridine-2-yl)methyl, (benzo[d][1,3]dioxol-5-yl)methyl, (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl, ([1,1′-biphenyl]-4-yl)methyl, 1-(2,2,2-trifluoroethyl)piperidin-4-yl, 1-(pyridin-3-yl)piperidin-4-yl, 1-(cyclohexylcarbamoyl)piperidin-4-yl, 1-(cyclohexylcarbamothioyl)piperidin-4-yl, 1-phenylpiperidin-4-yl, 1-cyclohexylazetidin-3-yl, 2-(thiophen-2-yl)methyl, or 2-(thiophen-3-yl)methyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C1-6 alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C1-5 alkoxy, CHF2, CF2CH3, and/or CF3; or R3 may be phenylethyl, substituted from one up to the maximum number of substituents with one or more of pyrrolidin-1-yl, piperidin-1-yl, 4-morpholino, cyclopropylmethoxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, phenoxy, (tetrahydrofuran-3-yl)methoxy, tetrahydro-2H-pyran-4-yl, 3,5-dimethylisoxazol-4-yl, 3,5-dimethyl-1H-pyrazol-4-yl, F, Cl, C1-6 alkyl, cyclopropyl, propen-2-yl, OCH3, and/or CF3; or R3 may be (1-formylpiperidin-4-yl)methyl, substituted on the formyl group with one of: C1-6 alkyl, C3-7 cycloalkyl, phenyl, thiophen-3-yl, phenylmethyl, or cyclopentylmethyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, C1-6 alkyl, OCH3, and/or CF3; or R3 may be
or
where R5 may be selected from the group consisting of: phenyl, pyridin-2-yl, pyridin-3-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, phenylcarbonyl, thiazol-2-yl, benzo[d]oxazol-2-yl, and benzo[d]thiazol-2-yl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C1-6 alkyl, C1-6 alkoxyl, OCF3, and/or CF3, with the proviso that when R1 is H and R2 is CH2OH, then R3 is not cyclohexylmethyl, 2-cyclohexylethyl, 3-cyclohexylpropyl, phenylethyl, 3-phenylpropyl, 3-(2-propoxyphenyl)propyl, 3-(3-propoxyphenyl)propyl, 3-(4-propoxyphenyl)propyl, or 4-phenylbutyl; and with the proviso that when R1 is CH2OH and R2 is H, then R3 is not phenylethyl, 3-phenylpropyl, (R)-2-phenylpropyl, or (S)-2-phenylpropyl.
In some embodiments, R3 may be (CH2)nR4, wherein n may be 1 or 2, and R4 may be cyclohexyl, cyclohexylmethyl, phenylethyl, 4-phenylcyclohexyl, spiro[2.5]octan-6-yl, spiro[3.5]nonan-7-yl, spiro[4.5]decan-8-yl, (5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, 2,3-dihydro-1H-inden-2-yl, (adamantyl)methyl, (pyridine-2-yl)methyl, (benzo[d][1,3]dioxol-5-yl)methyl, (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl, ([1,1 ‘-biphenyl]-4-yl)methyl, 1-(2,2,2-trifluoroethyl)piperidin-4-yl, 1-(pyridin-3-yl)piperidin-4-yl, 1-(cyclohexylcarbamoyl)piperidin-4-yl, 1-(cyclohexylcarbamothioyl)piperidin-4-yl, 1-phenylpiperidin-4-yl, 1-cyclohexylazetidin-3-yl, 2-(thiophen-2-yl)methyl, or 2-(thiophen-3-yl)methyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C1-6 alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C1-5 alkoxy, CHF2, CF2CH3, and/or CF3, with the proviso that when R1 is H and R2 is CH2OH, then R3 is not cyclohexylmethyl, 2-cyclohexylethyl, 3-cyclohexylpropyl, 3-phenylpropyl, 3-(2-propoxyphenyl)propyl, 3-(3-propoxyphenyl)propyl, 3-(4-propoxyphenyl)propyl, or 4-phenylbutyl; and with the proviso that when R1 is CH2OH and R2 is H, then R3 is not 3-phenylpropyl, (R)-2-phenylpropyl, or (S)-2-phenylpropyl.
In some embodiments, R3 may be phenylethyl, substituted from one up to the maximum number of substituents with one or more of pyrrolidin-1-yl, piperidin-1-yl, 4-morpholino, cyclopropylmethoxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy, phenoxy, (tetrahydrofuran-3-yl)methoxy, tetrahydro-2H-pyran-4-yl, 3,5-dimethylisoxazol-4-yl, 3,5-dimethyl-1H-pyrazol-4-yl, F, Cl, C1-6 alkyl, cyclopropyl, propen-2-yl, OCH3, and/or CF3, with the proviso that R3 is not phenylethyl.
In some embodiments, R3 may be (1-formylpiperidin-4-yl)methyl, substituted on the formyl group with one of: C1-6 alkyl, C3-7 cycloalkyl, phenyl, thiophen-3-yl, phenylmethyl, or cyclopentylmethyl, each optionally substituted from one up to the maximum number of substituents with one or more of F, C1-6 alkyl, OCH3, and/or CF3.
In some embodiments, R3 may be may be
or
where R5 may be selected from the group consisting of: phenyl, pyridin-2-yl, pyridin-3-yl, pyrimidin-5-yl, thiophen-3-yl, benzo[d]thiazol-4-yl, benzo[d]thiazol-2-yl, phenylcarbonyl, thiazol-2-yl, benzo[d]oxazol-2-yl, and benzo[d]thiazol-2-yl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C1-6 alkyl, C1-6 alkoxyl, OCF3, and/or CF3.
In some embodiments, R1 may be H; R2 may be CH2OH; and R3 may be (CH2)nR4, where n may be 1, and R4 may be cyclohexyl or 1-phenylpiperidin-4-yl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C1-6 alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C1-5 alkoxy, CHF2, CF2CH3, and/or CF3., with the proviso that R3 is not cyclohexylmethyl.
In some embodiments, R1 may be CH2OH; R2 may be H; and R3 may be (CH2)nR4, where n may be 1, and R4 may be cyclohexyl or 1-phenylpiperidin-4-yl, each optionally substituted from one up to the maximum number of substituents with one or more of F, Cl, C1-6 alkyl, cyclopropyl, vinyl, 2-fluoropropan-2-yl, methoxymethyl, C1-5 alkoxy, CHF2, CF2CH3, and/or CF3.
In some embodiments, R1 may be H; R2 may be CH2OH; and R3 may be (4,4-dimethylcyclohexyl)methyl, (4,4-difluorocyclohexyl)methyl, (4,4-dichlorocyclohexyl)methyl, (4-ethylcyclohexyl)methyl, ((1s,4S)-4-vinylcyclohexyl )methyl, ((1 s,4S)-4-isopropylcyclohexyl)methyl, ((lr,4R)-4-isopropylcyclohexyl)methyl, 4-(tert-butyl)cyclohexyl)methyl, ((1 s,4S)-4-(tert-butyl)cyclohexyl)methyl, ((lr,4R)-4-(tert-butyl)cyclohexyl)methyl, ((1 s,4S)-4-(trifluoromethyl)cyclohexyl)methyl, ((1r,4R)-4-(trifluoromethyl)cyclohexyl)methyl, ((ls,4S)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl, ((lr,4R)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl, ((trans)-3-(trifluoromethyl)cyclohexyl)methyl, ((cis)-3-(trifluoromethyl)cyclohexyl)methyl, ((1 s,4S)-4-methoxycyclohexyl)methyl, ((Ir,4R)-4-methoxycyclohexyl)methyl, (4-(methoxymethyl)cyclohexyl)methyl, ((1 s,4S)-4-cyclopropylcyclohexyl)methyl, ((1r,4R)-4-cyclopropylcyclohexyl)methyl, (4-phenylcyclohexyl)methyl, (spiro[2.5]octan-6-yl)methyl, (spiro[3.5]nonan-7-yl)methyl, (spiro[4.5]decan-8-yl)methyl, 2-(4,4-difluorocyclohexyl)ethyl, 2-( (1 s,4S)-4-(trifluoromethyl)cyclohexyl)ethyl, 2-((lr,4R)-4-(trifluoromethyl)cyclohexyl)ethyl, 2-(adamantan-1-yl)ethyl, 2-methylphenethyl, 2-methoxyphenethyl, 2-fluorophenethyl, 2-chlorophenethyl, 2,3-difluorophenethyl, 2,4-difluorophenethyl, 2,5-difluorophenethyl, 3,4-difluorophenethyl, 2-fluoro-4-methoxyphenethyl, 3-chloro-2-fluorophenethyl, 4-chloro-2-fluorophenethyl, 5-chloro-2-fluorophenethyl, 2,6-difluorophenethyl, 3-chloro-2,6-difluorophenethyl, 2,6-difluoro-4-(prop-1-en-2-yl)phenethyl, 2,6-difluoro-4-isopropylphenethyl, 2,6-difluoro-3-isopropylphenethyl, 4-cyclopropyl-2,6-difluorophenethyl, 2,6-difluoro-4-(trifluoromethyl)phenethyl, 2,6-difluoro-4-(pyrrolidin-1-yl)phenethyl, 2,6-difluoro-4-(piperidin-1-yl)phenethyl, 2,6-difluoro-4-morpholinophenethyl, 4-butoxy-2,6-difluorophenethyl, 4-(cyclopropylmethoxy)-2,6-difluorophenethyl, 4-((tetrahydrofuran-3-yl)oxy)phenethyl, 4-((tetrahydro-2H-pyran-3-yl)oxy)phenethyl, 4-((tetrahydro-2H-pyran-4-yl)oxy)phenethyl, 4-phenoxyphenethyl, 4-((tetrahydrofuran-3-yl)methoxy)phenethyl, (R)-2-phenylpropyl, (S)-2-phenylpropyl, 2-([1,1′-biphenyl]-4-yl)ethyl, 2-(3,5-difluoro-[1,1′-biphenyl]-4-yl)ethyl, 2-(benzo[d][1,3]dioxol-5-yl)ethyl, 2-(6-fluorobenzo[d][1,3]dioxol-5-yl)ethyl, 2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)ethyl, 2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethyl, 2-(thiophen-2-yl)ethyl, 2-(thiophen-3-yl)ethyl, 2-(pyridine-2-yl)ethyl, 3-(2-fluorophenyl)propyl, 3-(4-fluorophenyl)propyl, 3-(thiophen-2-yl)propyl, 3-(thiophen-3-yl)propyl, (1-phenylpiperidin-4-yl)methyl, (1-(2-fluorophenyl)piperidin-4-yl)methyl, (1-(3-fluorophenyl)piperidin-4-yl)methyl, (1-(4-fluorophenyl)piperidin-4-yl)methyl, (1-(4-(trifluoromethyl)phenyl)piperidin-4-yl)methyl, (4-methyl-1-phenylpiperidin-4-yl)methyl, (4-fluoro-1-phenylpiperidin-4-yl)methyl, 2-(1-phenylpiperidin-4-yl)ethyl, (1-(2,2,2-trifluoroethyl)piperidin-4-yl)methyl, (1-isobutyrylpiperidin-4-yl)methyl, (1-pivaloylpiperidin-4-yl)methyl, (1-butyrylpiperidin-4-yl)methyl, (1-(3-methylbutanoyl)piperidin-4-yl)methyl, (1-(3,3-dimethylbutanoyl)piperidin-4-yl)methyl, (1-(2-cyclopentylacetyl)piperidin-4-yl)methyl, (1-(cyclopropanecarbonyl)piperidin-4-yl)methyl, (1-(cyclobutanecarbonyl)piperidin-4-yl)methyl, (1-(cyclopentanecarbonyl)piperidin-4-yl)methyl, (1-(cyclohexanecarbonyl)piperidin-4-yl)methyl, (1-((1 s,4s )-4-(tert-butyl)cyclohexanecarbonyl)piperidin-4-yl)methyl, (l-((lr,4r)-4-(tert-butyl)cyclohexanecarbonyl)piperidin-4-yl)methyl, (1-(4-methoxycyclohexanecarbonyl)piperidin-4-yl)methyl, (1-(4-(trifluoromethyl)cyclohexanecarbonyl)piperidin-4-yl)methyl, (1-benzoylpiperidin-4-yl)methyl, (1-(3-(trifluoromethyl)benzoyl)piperidin-4-yl)methyl, (1-(2-phenylacetyl)piperidin-4-yl)methyl, (1-(thiophene-3-carbonyl)piperidin-4-yl)methyl, ((5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl)methyl, (1,2,3,4-tetrahydronaphthalen-2-yl)methyl, (2,3-dihydro-1H-inden-2-yl)methyl, 2,6-difluoro-4-(tetrahydro-2H-pyran-4-yl)phenethyl, (1-(pyridin-3-yl)piperidin-4-yl)methyl, (1-(cyclohexylcarbamoyl)piperidin-4-yl)methyl, (1-(cyclohexylcarbamothioyl)piperidin-4-yl)methyl, (1-((1S,2R)-2-(trifluoromethyl)cyclohexyl)azetidin-3-yl)methyl, ((R)-1-phenylpyrrolidin-3-yl)methyl, ((R)-1-(o-tolyl)pyrrolidin-3-yl)methyl, ((R)-1-(2-(trifluoromethyl)phenyl)pyrrolidin-3-yl)methyl, ((S)-1-(2-(trifluoromethyl)phenyl)pyrrolidin-3-yl)methyl, (R)-1-(2-fluorophenyl)pyrrolidin-3-yl)methyl, (R)-1-(3-fluorophenyl)pyrrolidin-3-yl)methyl, ((R)-1-(2-(trifluoromethoxy)phenyl)pyrrolidin-3-yl)methyl, ((R)-1-(6-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(3-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(pyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(4-methylpyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(5-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(2-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)pyrimidin-5-yl)pyrrolidin-3-yl)methyl, ((R)-1-(thiophen-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(benzo[d]thiazol-4-yl)pyrrolidin-3-yl)methyl, (S)-(1-(4-(trifluoromethyl)benzoyl)pyrrolidin-3-yl)methyl, ((R)-1-(o-tolyl)piperidin-3-yl)methyl, ((R)-1-(2-fluorophenyl)piperidin-3-yl)methyl, ((R)-1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, ((R)-1-(6-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl, 3-fluorophenethyl, 4-fluorophenethyl, 3,4-dichlorophenethyl, 3-(trifluoromethyl)phenethyl, 4-(trifluoromethyl)phenethyl, ((R)-1-(benzo[d]thiazol-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(2-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl, 4-(3,5-dimethylisoxazol-4-yl)-2,6-difluorophenethyl, 4-(3,5-dimethyl-1H-pyrazol-4-yl)-2,6-difluorophenethyl, ((R)-1-(4-(trifluoromethyl)thiazol-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(benzo[d]oxazol-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(5-isopropylthiazol-2-yl)piperidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)thiazol-2-yl)piperidin-3-yl)methyl, ((R)-1-(benzo[d]thiazol-2-yl)piperidin-3-yl)methyl, ((R)-1-(benzo[d]thiazol-4-yl)piperidin-3-yl)methyl, ((S)-1-(3-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)pyrimidin-5-yl)pyrrolidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)thiazol-2-yl)pyrrolidin-3-yl)methyl, ((S)-1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl, ((S)-1-(6-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, or ((S)-1-(4-(trifluoromethyl)thiazol-2-yl)piperidin-3-yl)methyl.
In some embodiments, R1 may be CH2OH; R2 may be H; and R3 may be cyclohexylmethyl, (4,4-dimethylcyclohexyl)methyl, (4,4-difluorocyclohexyl)methyl, (4,4-dichlorocyclohexyl)methyl, (4-ethylcyclohexyl)methyl, ((1s, 4S)-4-vinylcyclohexyl)methyl, ((1 s,4S)-4-isopropylcyclohexyl)methyl, ((lr,4R)-4-isopropylcyclohexyl)methyl, 4-(tert-butyl)cyclohexyl)methyl, ((1 s,4S)-4-(tert-butyl)cyclohexyl)methyl, ((lr,4R)-4-(tert-butyl)cyclohexyl)methyl, ((1 s,4S)-4-(trifluoromethyl)cyclohexyl)methyl, ((1r,4R)-4-(trifluoromethyl)cyclohexyl)methyl, ((ls,4S)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl, ((lr,4R)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl, ((trans)-3-(trifluoromethyl)cyclohexyl)methyl, ((cis)-3-(trifluoromethyl)cyclohexyl)methyl, ((1 s,4S)-4-methoxycyclohexyl)methyl, ((lr,4R)-4-methoxycyclohexyl)methyl, (4-(methoxymethyl)cyclohexyl)methyl, ((1 s,4S)-4-cyclopropylcyclohexyl)methyl, ((1r,4R)-4-cyclopropylcyclohexyl)methyl, (4-phenylcyclohexyl)methyl, (spiro[2.5]octan-6-yl)methyl, (spiro[3.5]nonan-7-yl)methyl, (spiro[4.5]decan-8-yl)methyl, 2-cyclohexylethyl, 2-(4,4-difluorocyclohexyl)ethyl, 2-((1 s,4S)-4-(trifluoromethyl)cyclohexyl)ethyl, 2-((lr,4R)-4-(trifluoromethyl)cyclohexyl)ethyl, 2-(adamantan-1-yl)ethyl, 3-cyclohexylpropyl, 2-methylphenethyl, 2-methoxyphenethyl, 2-fluorophenethyl, 2-chlorophenethyl, 2,3-difluorophenethyl, 2,4-difluorophenethyl, 2,5-difluorophenethyl, 3,4-difluorophenethyl, 2-fluoro-4-methoxyphenethyl, 3-chloro-2-fluorophenethyl, 4-chloro-2-fluorophenethyl, 5-chloro-2-fluorophenethyl, 2,6-difluorophenethyl, 3-chloro-2,6-difluorophenethyl, 2,6-difluoro-4-(prop-1-en-2-yl)phenethyl, 2,6-difluoro-4-isopropylphenethyl, 2,6-difluoro-3-isopropylphenethyl, 4-cyclopropyl-2,6-difluorophenethyl, 2,6-difluoro-4-(trifluoromethyl)phenethyl, 2,6-difluoro-4-(pyrrolidin-1-yl)phenethyl, 2,6-difluoro-4-(piperidin-1-yl)phenethyl, 2,6-difluoro-4-morpholinophenethyl, 4-butoxy-2,6-difluorophenethyl, 4-(cyclopropylmethoxy)-2,6-difluorophenethyl, 4-((tetrahydrofuran-3-yl)oxy)phenethyl, 4-((tetrahydro-2H-pyran-3-yl)oxy)phenethyl, 4-((tetrahydro-2H-pyran-4-yl)oxy)phenethyl, 4-phenoxyphenethyl, 4-((tetrahydrofuran-3-yl)methoxy)phenethyl, 2-([1,1′-biphenyl]-4-yl)ethyl, 2-(3,5-difluoro-[1,1′-biphenyl]-4-yl)ethyl, 2-(benzo[d][1,3]dioxol-5-yl)ethyl, 2-(6-fluorobenzo[d][1,3]dioxol-5-yl)ethyl, 2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)ethyl, 2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethyl, 2-(thiophen-2-yl)ethyl, 2-(thiophen-3-yl)ethyl, 2-(pyridine-2-yl)ethyl, 3-(2-fluorophenyl)propyl, 3-(4-fluorophenyl)propyl, 3-(thiophen-2-yl)propyl, 3-(thiophen-3-yl)propyl, (1-phenylpiperidin-4-yl)methyl, (1-(2-fluorophenyl)piperidin-4-yl)methyl, (1-(3-fluorophenyl)piperidin-4-yl)methyl, (1-(4-fluorophenyl)piperidin-4-yl)methyl, (1-(4-(trifluoromethyl)phenyl)piperidin-4-yl)methyl, (4-methyl-1-phenylpiperidin-4-yl)methyl, (4-fluoro-1-phenylpiperidin-4-yl)methyl, 2-(1-phenylpiperidin-4-yl)ethyl, (1-(2,2,2-trifluoroethyl)piperidin-4-yl)methyl, (1-isobutyrylpiperidin-4-yl)methyl, (1-pivaloylpiperidin-4-yl)methyl, (1-butyrylpiperidin-4-yl)methyl, (1-(3-methylbutanoyl)piperidin-4-yl)methyl, (1-(3,3-dimethylbutanoyl)piperidin-4-yl)methyl, (1-(2-cyclopentylacetyl)piperidin-4-yl)methyl, (1-(cyclopropanecarbonyl)piperidin-4-yl)methyl, (1-(cyclobutanecarbonyl)piperidin-4-yl)methyl, (1-(cyclopentanecarbonyl)piperidin-4-yl)methyl, (1-(cyclohexanecarbonyl)piperidin-4-yl)methyl, (l-((ls,4s)-4-(tert-butyl)cyclohexanecarbonyl)piperidin-4-yl)methyl, (l-((lr,4r)-4-(tert-butyl)cyclohexanecarbonyl)piperidin-4-yl)methyl, (1-(4-methoxycyclohexanecarbonyl)piperidin-4-yl)methyl, (1-(4-(trifluoromethyl)cyclohexanecarbonyl)piperidin-4-yl)methyl, (1-benzoylpiperidin-4-yl)methyl, (1-(3-(trifluoromethyl)benzoyl)piperidin-4-yl)methyl, (1-(2-phenylacetyl)piperidin-4-yl)methyl, (1-(thiophene-3-carbonyl)piperidin-4-yl)methyl, ((5S,8s)-3,3-dimethyl-2-oxaspiro[4.5]decan-8-yl)methyl, (1,2,3,4-tetrahydronaphthalen-2-yl)methyl, (2,3-dihydro-1H-inden-2-yl)methyl, 2,6-difluoro-4-(tetrahydro-2H-pyran-4-yl)phenethyl, (1-(pyridin-3-yl)piperidin-4-yl)methyl, (1-(cyclohexylcarbamoyl)piperidin-4-yl)methyl, (1-(cyclohexylcarbamothioyl)piperidin-4-yl)methyl, (1-((1S,2R)-2-(trifluoromethyl)cyclohexyl)azetidin-3-yl)methyl, ((R)-1-phenylpyrrolidin-3-yl)methyl, ((R)-1-(o-tolyl)pyrrolidin-3-yl)methyl, ((R)-1-(2-(trifluoromethyl)phenyl)pyrrolidin-3-yl)methyl, ((S)-1-(2-(trifluoromethyl)phenyl)pyrrolidin-3-yl)methyl, (R)-1-(2-fluorophenyl)pyrrolidin-3-yl)methyl, (R)-1-(3-fluorophenyl)pyrrolidin-3-yl)methyl, ((R)-1-(2-(trifluoromethoxy)phenyl)pyrrolidin-3-yl)methyl, ((R)-1-(6-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(3-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(pyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(4-methylpyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(5-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(2-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)pyrimidin-5-yl)pyrrolidin-3-yl)methyl, ((R)-1-(thiophen-3-yl)pyrrolidin-3-yl)methyl, ((R)-1-(benzo[d]thiazol-4-yl)pyrrolidin-3-yl)methyl, (S)-(1-(4-(trifluoromethyl)benzoyl)pyrrolidin-3-yl)methyl, ((R)-1-(o-tolyl)piperidin-3-yl)methyl, ((R)-1-(2-fluorophenyl)piperidin-3-yl)methyl, ((R)-1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, ((R)-1-(6-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl, 3-fluorophenethyl, 4-fluorophenethyl, 3,4-dichlorophenethyl, 3-(trifluoromethyl)phenethyl, 4-(trifluoromethyl)phenethyl, ((R)-1-(benzo[d]thiazol-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(2-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl, 4-(3,5-dimethylisoxazol-4-yl)-2,6-difluorophenethyl, 4-(3,5-dimethyl-1H-pyrazol-4-yl)-2,6-difluorophenethyl, ((R)-1-(4-(trifluoromethyl)thiazol-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(benzo[d]oxazol-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(5-isopropylthiazol-2-yl)piperidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)thiazol-2-yl)piperidin-3-yl)methyl, ((R)-1-(benzo[d]thiazol-2-yl)piperidin-3-yl)methyl, ((R)-1-(benzo[d]thiazol-4-yl)piperidin-3-yl)methyl, ((S)-1-(3-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)pyrimidin-5-yl)pyrrolidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)thiazol-2-yl)pyrrolidin-3-yl)methyl, ((S)-1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)methyl, ((S)-1-(6-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)thiazol-2-yl)piperidin-3-yl)methyl, 4-butoxyphenethyl, ((1s,4R)-4-(difluoromethyl)cyclohexyl)methyl, ((lr,4S)-4-(difluoromethyl)cyclohexyl)methyl, ((1s,4R)-4-(1,1-difluoroethyl)cyclohexyl)methyl, or ((1r,4S)-4-(1,1-difluoroethyl)cyclohexyl)methyl.
In some embodiments, R1 may be H; R2 may be CH2OH; and R3 may be 2-fluorophenethyl, 3-fluorophenethyl, 4-fluorophenethyl, 2,6-difluorophenethyl, 3-(trifluoromethyl)phenethyl, 4-(trifluoromethyl)phenethyl, (R)-2-phenylpropyl, (S)-2-phenylpropyl, 2-(pyridin-2-yl)ethyl, 2-(thiophen-2-yl)ethyl, or 2-(thiophen-3-yl)ethyl.
In some embodiments, R1 may be CH2OH; R2 may be OH; and R3 may be cyclohexylmethyl, ((1r, 4R)-4-(trifluoromethyl )cyclohexyl )methyl, ((1s, 4S)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl, (2,3-dihydro-1H-inden-2-yl)methyl, 2-cyclohexylethyl, 3-cyclohexylpropyl, 2-fluorophenethyl, 3-chloro-2-fluorophenethyl, 2-([ 1,1′-biphenyl]-4-yl)ethyl, 2,6-difluoro-4-(tetrahydro-2H-pyran-4-yl)phenethyl, 4-butoxyphenethyl, 4-butoxy-2,6-difluorophenethyl, (1-(4-fluorophenyl)piperidin-4-yl)methyl, ((R)-1-(3-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)thiazol-2-yl)pyrrolidin-3-yl)methyl, ((S)-1-(3-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)thiazol-2-yl)pyrrolidin-3-yl)methyl, ((R)-1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, ((R)-1-(4-(trifluoromethyl)thiazol-2-yl)piperidin-3-yl)methyl, ((S)-1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl, ((S)-1-(4-(trifluoromethyl)thiazol-2-yl)piperidin-3-yl)methyl, ((1s,4R)-4-(difluoromethyl)cyclohexyl)methyl, ((lr,4S)-4-(difluoromethyl)cyclohexyl)methyl, ((ls,4R)-4-(l,l-difluoroethyl)cyclohexyl)methyl, or((1r,4S)-4-(1,1-difluoroethyl)cyclohexyl)methyl.
In specific embodiments of the invention, compounds according to Formula (I) include the compounds described in Table 1.
As will be appreciated by a person skilled in the art, Formula (I) above may also be represented alternatively as follows:
In alternative embodiments of the invention, one or more of the compounds in Table 2 are specifically excluded from the compounds described in Formula (I) or any one or more of Formula (Ia) - (Iv).
As used herein the singular forms “a”, “and”, and “the” include plural referents unless the context clearly dictates otherwise. For example, “a compound” refers to one or more of such compounds, while “the enzyme” includes a particular enzyme as well as other family member equivalents thereof as known to those skilled in the art.
Throughout this application, it is contemplated that the term “compound” or “compounds” refers to the compounds discussed herein and includes precursors and derivatives of the compounds, including acyl-protected derivatives, and pharmaceutically acceptable salts of the compounds, precursors, and derivatives. The invention also includes prodrugs of the compounds, pharmaceutical compositions including the compounds and a pharmaceutically acceptable carrier, and pharmaceutical compositions including prodrugs of the compounds and a pharmaceutically acceptable carrier.
The compounds of the present invention may contain one or more additional asymmetric centers beyond those specified in Formula (I), including any one or more of Formula (Ia) - (Iv), and can thus occur as single enantiomers, diastereomeric mixtures and individual diastereomers. Such additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Each such additional asymmetric center will independently produce two optical isomers and it is intended that all such possible optical isomers and diastereomers in mixtures and as pure or partially purified compounds are included within the ambit of this invention. Any formulas, structures or names of compounds described in this specification that do not specify a particular stereochemistry of an additional asymmetric center are meant to encompass any and all existing isomers as described above and mixtures thereof in any proportion. When stereochemistry of an additional asymmetric center is specified, the invention is meant to encompass that particular isomer in pure form or as part of a mixture with other isomers in any proportion.
“Alkyl” refers to a straight or branched hydrocarbon chain group consisting solely of carbon and hydrogen atoms, containing no unsaturation and including, for example, from one to ten carbon atoms, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms, and which is attached to the rest of the molecule by a single bond. In alternative embodiments, the alkyl group may contain from one to eight carbon atoms, such as 1, 2, 3, 4, 5, 6, 7, or 8 carbon atoms. In alternative embodiments, the alkyl group may contain from one to six carbon atoms, such as 1, 2, 3, 4, 5, or 6 carbon atoms. In alternative embodiments, the alkyl group may contain from one to five carbon atoms, such as 1, 2, 3, 4, or 5 carbon atoms. Unless stated otherwise specifically in the specification, the alkyl group may be optionally substituted by one or more substituents as described herein. Unless stated otherwise specifically herein, it is understood that the substitution can occur on any carbon of the alkyl group.
“Cycloalkyl” refers to a stable monovalent monocyclic, bicyclic or tricyclic hydrocarbon group consisting solely of carbon and hydrogen atoms, having for example from 3 to 15 carbon atoms, and which is saturated and attached to the rest of the molecule by a single bond. In alternative embodiments, the cycloalkyl group may contain from three to six carbon atoms, such as 3, 4, 5, or 6 carbon atoms. Unless otherwise stated specifically herein, the term “cycloalkyl” is meant to include cycloalkyl groups which are optionally substituted as described herein.
“Alkoxy” refers to a group of the formula —ORa, where each Ra is independently a C1-10 alkyl or a C1-6 alkyl or a C1-5 alkyl group as described herein. The alkoxy group(s) may be optionally substituted as described herein.
“Optional” or “optionally” means that the subsequently described event of circumstances may or may not occur, and that the description includes instances where the event or circumstance occurs one or more times and instances in which it does not. For example, “optionally substituted alkyl” means that the alkyl group may or may not be substituted and that the description includes both substituted alkyl groups and alkyl groups having no substitution, and that the alkyl groups may be substituted one or more times. Examples of optionally substituted alkyl groups include, without limitation, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, etc. Examples of suitable optional substituents include, without limitation, H, F, Cl, CH3, OH, OCH3, CF3, CHF2, CH2F, and CN.
The invention provides, in part, methods of treating conditions that are modulated, directly or indirectly, by a GBA2 enzyme or GBA2 activity levels, for example, a condition that is benefited by inhibiting a GBA2 enzyme or by a reduction of GBA2 enzyme activity levels. Such conditions may include, without limitation, neurological diseases, such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington’s disease, and amyotrophic lateral sclerosis (ALS), and lysosomal storage diseases, such as Gaucher disease, Niemann-Pick type C disease, mucolipidosis type IV, and Sandhoff disease, and liver diseases, such as non-alcoholic steatohepatitis (NASH). Thus, one or more of the compounds of the invention may be used to treat a subject at risk for developing, or already diagnosed with, various neurological or other diseases. The term “treating” as used herein may include treatment, prevention, and/or amelioration.
In alternative embodiments, one or more of the compounds of the invention may also be useful in the treatment of diseases or disorders related to deficiency or over-expression of GBA2 or accumulation or depletion of glucosylceramide, or any disease or disorder responsive to glycosidase inhibitor therapy, or glycosidase inhibition therapy. Such diseases and disorders may include, but are not limited to, neurological diseases, such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington’s disease, and amyotrophic lateral sclerosis (ALS), and lysosomal storage diseases, such as Gaucher disease, Niemann-Pick type C disease, mucolipidosis type IV, and Sandhoff disease, and liver diseases, such as non-alcoholic steatohepatitis (NASH). Such diseases and disorders may also include diseases or disorders related to accumulation or deficiency in the enzyme glucosylceramide synthase, or dysregulation of glycosphingolipid metabolism and/or homeostasis. Also included is a method of protecting or treating target cells expressing GBA2, the dysregulation of which may result in disease or pathology.
In alternative embodiments, the invention provides methods of reducing levels of GBA2 enzyme activity in animal subjects, such as veterinary and human subjects. This reduction of GBA2 activity levels may be useful for the prevention or treatment of neurological or neurodegenerative diseases (e.g. Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington’s disease, and amyotrophic lateral sclerosis (ALS)); providing neuroprotective effects; preventing damage to dopaminergic neurons; and the prevention or treatment of lysosomal storage diseases (e.g. Gaucher disease, Niemann-Pick type C disease, mucolipidosis type IV, and Sandhoff disease); and the prevention or treatment of liver diseases (e.g. non-alcoholic steatohepatitis (NASH)).
In alternative embodiments, the invention provides methods of inhibiting a GBA2 enzyme in animal subjects, such as veterinary and human subjects.
In alternative embodiments, the invention provides methods of reducing CNS inflammation in animal subjects, such as veterinary and human subjects. Disease states of interest may include neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington’s disease, and amyotrophic lateral sclerosis (ALS), in which neuroinflammation is implicated in disease pathogenesis. In some embodiments, a compound according to the invention may be used to prevent, treat, or ameliorate neuroinflammation by reducing GBA2 enzyme activity levels, thereby providing therapeutic benefit.
In alternative embodiments, the invention provides methods of inhibiting aggregation of alpha-synuclein protein, or inhibiting formation of Lewy bodies, in animal subjects, such as veterinary and human subjects. Disease states of interest may include Parkinson’s disease (PD) and related neurodegenerative synucleinopathies, in which abnormal aggregation of the alpha-synuclein protein is implicated in disease pathogenesis. In some embodiments, a compound according to the invention may be used to block aggregation of alpha-synuclein protein by reducing GBA2 enzyme activity levels, thereby providing therapeutic benefit.
Neurological diseases that may be treated with a compound of the invention include, without limitation: Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington’s disease, amyotrophic lateral sclerosis (ALS), amyotrophic lateral sclerosis with cognitive impairment (ALSci), addiction, anxiety, argyrophilic grain dementia, ataxia-telangiectasia (A-T), attention deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), Becker muscular dystrophy (BMD), bipolar disorder (BD), Bluit disease, cerebellar ataxia, Charcot-Marie-Tooth disease (CMT), chronic fatigue syndrome, corticobasal degeneration (CBD), dementia pugilistica, dementia with Lewy bodies (DLB), Dejerine-Sottas disease, diffuse neurofibrillary tangles with calcification, Down’s syndrome, Duchenne muscular dystrophy (DMD), epilepsy, essential tremor (ET), familial British dementia, familial Danish dementia, fibromyalgia, frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), Friedreich’s ataxia, Gerstmann-Straussler-Scheinker disease, glaucoma, Guadeloupean parkinsonism, Guillain-Barre syndrome, Hallevorden-Spatz disease (neurodegeneration with brain iron accumulation type 1), insomnia, Lambert-Eaton myasthenic syndrome (LEMS), major depressive disorder (MDD), migraine, mild cognitive impairment (MCI), multi-infarct dementia, multiple system atrophy (MSA), myasthenia gravis, myotonic dystrophy (including types DM1 and DM2), neuronal ceroid lipofuscinosis (including types 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10), neuropathy (including peripheral neuropathy, autonomic neuropathy, neuritis, and diabetic neuropathy), oculopharyngeal muscular dystrophy, pain, pallido-ponto-nigral degeneration, parkinsonism-dementia complex of Guam, Pick’s disease (PiD), post-encephalitic parkinsonism (PEP), primary lateral sclerosis (PLS), prion diseases (including Creutzfeldt-Jakob Disease (CJD), variant Creutzfeldt-Jakob Disease (vCJD), fatal familial insomnia, and kuru), progressive supercortical gliosis, progressive supranuclear palsy (PSP), Richardson’s syndrome, schizophrenia, seizures, spinal cord injury, spinal muscular atrophy (SMA), spinocerebellar ataxia (including types 1, 2, 3, 4, 5, 6, 7, 8, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 22, 23, 25, 26, 27, 28, and 29), stroke, subacute sclerosing panencephalitis, tangle-only dementia, tardive dyskinesia, Tourette syndrome (TS), vascular dementia, and Wilson’s disease.
Lysosomal storage diseases that may be treated with a compound of the invention may include, without limitation: Gaucher disease (including types I, II, and III), Niemann-Pick disease (including types A, B, and C), mucolipidosis (including types I, II, III, IV, VI, and VII), cerebrotendineous xanthomatosis, Fabry disease, Farber disease, GM1 gangliosidosis, Krabbe disease, metachromatic leukodystrophy (MLD), multiple sulfatase deficiency, Pompe disease, Sandhoff disease, and Tay-Sach’s disease.
Liver diseases that may be treated with a compound of the invention may include, without limitation: non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), Alagille syndrome, alcohol-related liver disease, alpha-1 antitrypsin deficiency, autoimmune hepatitis, autoimmune cholangitis, benign liver tumors, biliary atresia, cirrhosis, Crigler-Najjar syndrome, drug-induced liver injury (DILI), galactosemia, Gilbert syndrome, hemochromatosis, hepatic encephalopathy, hepatocellular carcinoma (HCC), intrahepatic cholestasis of pregnancy (ICP), lysosomal acid lipase deficiency (LAL-D), liver cysts, liver cancer, newborn jaundice, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), Reye syndrome, type I glycogen storage disease, or viral hepatitis (including types A, B, C, D, and E).
In some embodiments, a compound according to the invention may be useful in the treatment of a disorder in which the regulation of GBA2 enzyme activity levels is implicated, or any condition as described herein.
Other conditions that may be treated using one or more of the compounds according the invention are those triggered, affected, or in any other way correlated with levels of GBA2 enzyme activity. It is expected that one or more of the compounds of this invention may be useful for the treatment of such conditions and in particular, but not limited to, Parkinson’s disease, neuronal ceroid lipofuscinosis (Batten disease), Gaucher disease, Niemann-Pick type C disease, mucolipidosis type IV, and Sandhoff disease.
Pharmaceutical compositions including compounds according to the invention, or for use according to the invention, are contemplated as being within the scope of the invention. In some embodiments, pharmaceutical compositions including an effective amount of a compound of Formula (I), including any one or more of Formula (Ia) - (Iv), are provided.
The compounds of Formula (I), including any one or more of Formula (Ia) - (Iv), and their pharmaceutically acceptable salts, enantiomers, solvates, or derivatives may be useful because they may have pharmacological activity in animals, including humans. In some embodiments, one or more of the compounds according to the invention may be stable in plasma, when administered to a subject, such as a human.
In general, a compound according to the invention may be administered to a subject in need thereof, or by contacting a cell or a sample, for example, with a pharmaceutical composition comprising a therapeutically effective amount of the compound according to Formula (I), including any one or more of Formula (Ia) - (Iv).
In some embodiments, a compound according to the invention, or for use according to the invention, may be provided in combination with any other active agents or pharmaceutical compositions where such combined therapy may be useful to inhibit GBA2 activity levels, for example, to treat neurological diseases, or lysosomal storage diseases, or liver diseases, or any condition described herein. In some embodiments, a compound according to the invention, or for use according to the invention, may be provided in combination with one or more agents useful in the prevention or treatment of Parkinson’s disease. Examples of such agents may include, without limitation:
It is to be understood that combination of compounds according to the invention, or for use according to the invention, with agents useful for the treatment of Parkinson’s disease is not limited to the examples described herein, but may include combination with any agent useful for the treatment of Parkinson’s disease. Combination of compounds according to the invention, or for use according to the invention, and other agents useful for the treatment of Parkinson’s disease may be administered separately or in conjunction. The administration of one agent may be prior to, concurrent to, or subsequent to the administration of other agent(s).
In some embodiments, a compound according to the invention, or for use according to the invention, may be provided in combination with one or more agents useful in the prevention or treatment of Gaucher disease. Examples of such agents may include, without limitation:
It is to be understood that combination of compounds according to the invention, or for use according to the invention, with agents useful for the treatment of Gaucher disease is not limited to the examples described herein, but may include combination with any agent useful for the treatment of Gaucher disease. Combination of compounds according to the invention, or for use according to the invention, and other agents useful for the treatment of Gaucher disease may be administered separately or in conjunction. The administration of one agent may be prior to, concurrent to, or subsequent to the administration of other agent(s).
In alternative embodiments, a compound according to the invention may be supplied as a “prodrug” or as protected forms, which release the compound after administration to a subject. For example, a compound may carry a protective group which is split off by hydrolysis in body fluids, e.g., in the bloodstream, thus releasing the active compound or is oxidized or reduced in body fluids to release the compound. Accordingly, a “prodrug” is meant to indicate a compound that may be converted under physiological conditions or by solvolysis to a biologically active compound of the invention. Thus, the term “prodrug” refers to a metabolic precursor of a compound of the invention that is pharmaceutically acceptable. A prodrug may be inactive when administered to a subject in need thereof, but may be converted in vivo to an active compound of the invention. Prodrugs are typically rapidly transformed in vivo to yield the parent compound of the invention, for example, by hydrolysis in blood. The prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a subject.
The term “prodrug” is also meant to include any covalently bonded carriers which release the active compound of the invention in vivo when such prodrug is administered to a subject. Prodrugs of a compound of the invention may be prepared by modifying functional groups present in the compound of the invention in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound of the invention. Prodrugs include compounds of the invention where a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the compound of the invention is administered to a mammalian subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and acetamide, formamide, and benzamide derivatives of amine functional groups in one or more of the compounds of the invention and the like.
A discussion of prodrugs may be found in “Smith and Williams’ Introduction to the Principles of Drug Design,” H.J. Smith, Wright, Second Edition, London (1988); Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam); The Practice of Medicinal Chemistry, Camille G. Wermuth et al., Ch 31, (Academic Press, 1996); A Textbook of Drug Design and Development, P. Krogsgaard-Larson and H. Bundgaard, eds. Ch 5, pgs 113 191 (Harwood Academic Publishers, 1991); Higuchi, T., et al., “Pro-drugs as Novel Delivery Systems,” A.C.S. Symposium Series, Vol. 14; or in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
Suitable prodrug forms of one or more of the compounds of the invention may include embodiments in which one or more OH groups as set forth in Formula (I), including any one or more of Formula (Ia) - (Iv), may be protected as OC(O)R, where R may be optionally substituted C1-6 alkyl. In these cases, the ester groups may be hydrolyzed in vivo (e.g. in bodily fluids), liberating the OH groups and releasing the active compounds. Preferred prodrug embodiments of the invention may include compounds of Formula (I), including any one or more of Formula (Ia) - (Iv), where one or more OH groups may be protected with acetate, for example as OC(O)CH3.
Compounds according to the invention, or for use according to the invention, may be provided alone or in combination with other compounds in the presence of a liposome, a nanoparticle, an adjuvant, or any pharmaceutically acceptable carrier, diluent or excipient, in a form suitable for administration to a subject such as a mammal, for example, humans, cattle, sheep, etc. If desired, treatment with a compound according to the invention may be combined with more traditional and existing therapies for the therapeutic indications described herein. Compounds according to the invention may be provided chronically or intermittently. “Chronic” administration refers to administration of the compound(s) in a continuous mode as opposed to an acute mode, so as to maintain the initial therapeutic effect (activity) for an extended period of time. “Intermittent” administration is treatment that is not consecutively done without interruption, but rather is cyclic in nature. The terms “administration,” “administrable,” or “administering” as used herein should be understood to mean providing a compound of the invention to the subject in need of treatment.
“Pharmaceutically acceptable carrier, diluent or excipient” may include, without limitation, any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier that has been approved, for example, by the United States Food and Drug Administration or other governmental agency as being acceptable for use in humans or domestic animals.
A compound of the present invention may be administered in the form of a pharmaceutically acceptable salt. In such cases, pharmaceutical compositions in accordance with this invention may comprise a salt of such a compound, preferably a physiologically acceptable salt, which are known in the art. In some embodiments, the term “pharmaceutically acceptable salt” as used herein means an active ingredient comprising compounds of Formula I, including any one or more of Formula (Ia) - (Iv), used in the form of a salt thereof, particularly where the salt form confers on the active ingredient improved pharmacokinetic properties as compared to the free form of the active ingredient or other previously disclosed salt form.
A “pharmaceutically acceptable salt” may include both acid and base addition salts. A “pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which may be formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
A “pharmaceutically acceptable base addition salt” refers to those salts which may retain the biological effectiveness and properties of the free acids, which may not be biologically or otherwise undesirable. These salts may be prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases may include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Preferred inorganic salts may be the ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases may include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine,methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like. Particularly preferred organic bases may be isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.
Thus, the term “pharmaceutically acceptable salt” encompasses all acceptable salts including but not limited to acetate, lactobionate, benzenesulfonate, laurate, benzoate, malate, bicarbonate, maleate, bisulfate, mandelate, bitartarate, mesylate, borate, methylbromide, bromide, methylnitrite, calcium edetate, methylsulfate, camsylate, mucate, carbonate, napsylate, chloride, nitrate, clavulanate, N-methylglucamine, citrate, ammonium salt, dihydrochloride, oleate, edetate, oxalate, edisylate, pamoate (embonate), estolate, palmitate, esylate, pantothenate, fumarate, phosphate/diphosphate, gluceptate, polygalacturonate, gluconate, salicylate, glutame, stearate, glycollylarsanilate, sulfate, hexylresorcinate, subacetate, hydradamine, succinate, hydrobromide, tannate, hydrochloride, tartrate, hydroxynaphthoate, teoclate, iodide, tosylate, isothionate, triethiodide, lactate, panoate, valerate, and the like.
Pharmaceutically acceptable salts of a compound of the present invention may be used as a dosage for modifying solubility or hydrolysis characteristics, or may be used in sustained release or prodrug formulations. Also, pharmaceutically acceptable salts of a compound of this invention may include those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc, and from bases such as ammonia, ethylenediamine, N-methyl-glutamine, lysine, arginine, ornithine, choline, N,N′-dibenzylethylene-diamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethyl-amine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, and tetramethylammonium hydroxide.
Pharmaceutical formulations may typically include one or more carriers acceptable for the mode of administration of the preparation, be it by injection, inhalation, topical administration, lavage, or other modes suitable for the selected treatment. Suitable carriers may be those known in the art for use in such modes of administration.
Suitable pharmaceutical compositions may be formulated by means known in the art and their mode of administration and dose determined by the skilled practitioner. For parenteral administration, a compound may be dissolved in sterile water or saline or a pharmaceutically acceptable vehicle used for administration of non-water-soluble compounds such as those used for vitamin K. For enteral administration, the compound may be administered in a tablet, capsule or dissolved in liquid form. The table or capsule may be enteric coated, or in a formulation for sustained release. Many suitable formulations are known, including, polymeric or protein microparticles encapsulating a compound to be released, ointments, gels, hydrogels, or solutions which can be used topically or locally to administer a compound. A sustained release patch or implant may be employed to provide release over a prolonged period of time. Many techniques known to skilled practitioners are described in Remington: The Science & Practice of Pharmacy by Alfonso Gennaro, 20th ed., Williams & Wilkins, (2000). Formulations for parenteral administration may, for example, contain excipients, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated naphthalenes. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of a compound. Other potentially useful parenteral delivery systems for modulatory compounds may include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation may contain excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel.
A compound or a pharmaceutical composition according to the present invention may be administered by oral or non-oral, e.g., intramuscular, intraperitoneal, intravenous, intracisternal injection or infusion, subcutaneous injection, transdermal or transmucosal routes. In some embodiments, a compound or pharmaceutical composition in accordance with this invention or for use in this invention may be administered by means of a medical device or appliance such as an implant, graft, prosthesis, stent, etc. Implants may be devised which are intended to contain and release such compounds or compositions. An example would be an implant made of a polymeric material adapted to release the compound over a period of time. A compound may be administered alone or as a mixture with a pharmaceutically acceptable carrier e.g., as solid formulations such as tablets, capsules, granules, powders, etc.; liquid formulations such as syrups, injections, etc.; injections, drops, suppositories, pessaryies. In some embodiments, compounds or pharmaceutical compositions in accordance with this invention or for use in this invention may be administered by inhalation spray, nasal, vaginal, rectal, sublingual, or topical routes and may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles appropriate for each route of administration.
A compound of the invention may be used to treat animals, including mice, rats, horses, cattle, sheep, dogs, cats, and monkeys. However, a compound of the invention may also be used in other organisms, such as avian species (e.g., chickens). One or more of the compounds of the invention may also be effective for use in humans. The term “subject” or alternatively referred to herein as “patient” is intended to be referred to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment. However, one or more of the compounds, methods and pharmaceutical compositions of the present invention may be used in the treatment of animals. Accordingly, as used herein, a “subject” may be a human, non-human primate, rat, mouse, cow, horse, pig, sheep, goat, dog, cat, etc. The subject may be suspected of having or at risk for having a condition that may require inhibition of GBA2 activity.
An “effective amount” of a compound according to the invention may include a therapeutically effective amount or a prophylactically effective amount. A “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, such as inhibition of a GBA2, reducing GBA2 enzyme activity levels, inhibition of alpha-synuclein aggregation, or any condition described herein. A therapeutically effective amount of a compound may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the compound to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. A therapeutically effective amount may also be one in which any toxic or detrimental effects of the compound are outweighed by the therapeutically beneficial effects. A “prophylactically effective amount” may refer to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result, such as inhibition of a GBA2, reduction of GBA2 enzyme activity levels, inhibition of alpha-synuclein aggregation, or any condition described herein. Typically, a prophylactic dose may be used in subjects prior to or at an earlier stage of disease, so that a prophylactically effective amount may be less than a therapeutically effective amount. A suitable range for therapeutically or prophylactically effective amounts of a compound may be any integer from 0.1 nM - 0.1 M, 0.1 nM - 0.05 M, 0.05 nM - 15 µM or 0.01 nM - 10 µM.
In alternative embodiments, in the treatment or prevention of conditions which may require inhibition of GBA2 activity, an appropriate dosage level may generally be about 0.01 to 500 mg per kg subject body weight per day and may be administered in single or multiple doses. In some embodiments, the dosage level may be about 0.1 to about 250 mg/kg per day. It will be understood that the specific dose level and frequency of dosage for any particular patient may be varied and may depend upon a variety of factors including the activity of the specific compound used, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the patient undergoing therapy.
It is to be noted that dosage values may vary with the severity of the condition to be alleviated. For any particular subject, specific dosage regimens may be adjusted over time according to the individual need and the professional judgement of the person administering or supervising the administration of the compositions. Dosage ranges set forth herein are exemplary only and do not limit the dosage ranges that may be selected by medical practitioners. The amount of active compound(s) in the composition may vary according to factors such as the disease state, age, sex, and weight of the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It may be advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. In general, compounds of the invention should be used without causing substantial toxicity, and as described herein, one or more of the compounds may exhibit a suitable safety profile for therapeutic use. Toxicity of a compound of the invention may be determined using standard techniques, for example, by testing in cell cultures or experimental animals and determining the therapeutic index, i.e., the ratio between the LD50 (the dose lethal to 50% of the population) and the LD100 (the dose lethal to 100% of the population). In some circumstances however, such as in severe disease conditions, it may be necessary to administer substantial excesses of the compositions.
In the compounds of generic Formula (I), including any one or more of Formula (Ia) - (Iv), the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present invention is meant to include all suitable isotopic variations of the compounds of generic Formula (I), including any one or more of Formula (Ia) - (Iv). For example, different isotopic forms of hydrogen (H) include protium (1H), deuterium (2H) and tritium (3H). Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples. Isotopically-enriched compounds within generic Formula (I), including any one or more of Formula (Ia) - (Iv), may be prepared by conventional techniques well known to those skilled in the art or by processes analogous to those described in the schemes and examples herein using appropriate isotopically-enriched reagents and/or intermediates.
In alternative embodiments, one or more of the compounds of the invention may be used in studying the physiological role of GBA2 at the cellular and organismal level. In some embodiments, one or more of the compounds may be useful in the development of animal models for studying diseases or disorders that may be related to deficiencies in GBA2, over-expression of GBA2, accumulation of glucosylceramide, depletion of glucosylceramide, accumulation of glycosphingolipids, depletion of glycosphingolipids, and for studying treatment of diseases and disorders that may be related to deficiency or over-expression of GBA2, or accumulation or depletion of glucosylceramide, or accumulation or depletion of glycosphingolipids. Such diseases and disorders may include, without limitation, neurological diseases, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington’s disease, amyotrophic lateral sclerosis (ALS), and neuronal ceroid lipofuscinosis (Batten disease); lysosomal storage diseases, including Gaucher disease, Niemann-Pick type C disease, mucolipidosis type IV and Sandhoff disease; or liver diseases, including non-alcoholic steatohepatitis (NASH).
The effectiveness of a compound in treating pathology associated with a lysosomal storage disease (for example, Gaucher disease, Niemann-Pick type C disease, mucolipidosis type IV, or Sandhoff disease) may be confirmed using standard techniques, for example, by testing the ability of a compound to prevent, treat, or ameliorate disease symptoms in established cellular and/or transgenic animal models of disease. 13,14,16,17,27 ENREF 18
Various alternative embodiments and examples of the invention are described herein. These embodiments and examples are illustrative and should not be construed as limiting the scope of the invention.
The followi ng examples are intended to illustrate embodiments of the invention and are not intended to be construed in a limiting manner.
(2R,3R,4R,SS)-1-(2-fluorophenethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
K2CO3 (210 mg, 1.52 mmol) was added to a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (100 mg, 0.19 mmol) and 1-(2-bromoethyl)-2-fluorobenzene (194 mg, 0.95 mmol) in DMF (5 mL) in a sealed tube. The mixture was stirred at 80° C. for 18 h, and cooled to ambient temperature. The reaction mixture was poured into ice water (30 mL) and extracted with EtOAc (3 x 20 mL). The combined organic layer was washed with water (2 x 20 mL), separated, dried over Na2SO4. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography affording (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-(2-fluorophenethyl)piperidine as a white solid (63 mg, 51%). ESI MS m/z 646.32 [M + H]+.
To a solution of the above material (63 mg, 0.098 mmol) in EtOH (10 mL) was added Pd(OH)2/C (20 wt.%, 8.6 mg, 0.012 mmol) and 6N HCl (0.1 mL). The mixture was treated with hydrogen (1 atm) for 18 h. Catalyst was filtered off through celite and the solvent was evaporated under reduced pressure. The residue was dissolved in 1 M NH3 in MeOH (10 mL) and stirred for another 10 min, after which solvent was removed under vacuum. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-1-(2-fluorophenethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol as a white solid (21 mg, 75%). 1H NMR (400 MHz, CD3OD) δ 7.29 (td, J= 7.6, 1.8 Hz, 1H), 7.23 (tdd, J= 7.4, 5.2, 1.8 Hz, 1H), 7.10 (td, J = 7.5, 1.2 Hz, 1H), 7.05 (ddd, J = 9.7, 8.2, 1.2 Hz, 1H), 3.96 (dd, J = 11.9, 2.5 Hz, 1H), 3.88 (dd, J= 11.9, 3.1 Hz, 1H), 3.51 (ddd, J= 10.4, 9.0, 4.9 Hz, 1H), 3.37 (t, J= 12 Hz, 1H), 3.18 (t, J = 9.0 Hz, 1H), 3.09 (dd, J = 11.1, 4.9 Hz, 1H), 3.05-2.81 (m, 4H), 2.43 (t, J= 10.8 Hz, 1H), 2.30 (dt, J= 9.5, 2.9 Hz, 1H); ESI MS m/z 286.14 [M + H]+.
(2R,3R,4R,5S)-1-(3-fluorophenethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
K2CO3 (210 mg, 1.52 mmol) was added to a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (100 mg, 0.19 mmol) and 1-(2-bromoethyl)-3-fluorobenzene (194 mg, 0.95 mmol) in DMF (5 mL) in a sealed tube. The mixture was stirred at 80° C. for 18 h, and cooled to ambient temperature. The reaction mixture was poured into ice water (30 mL) and extracted with EtOAc (3 x 20 mL). The combined organic layer was washed with water (2 x 20 mL), separated, dried over Na2SO4. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography affording (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-(3-fluorophenethyl)piperidine as a white solid (71 mg, 58%). ESI MS m/z 646.32 [M + H]+.
To a solution of the above material (71 mg, 0.11 mmol) in EtOH (10 mL) was added Pd(OH)2/C (20 wt.%, 8.6 mg, 0.012 mmol) and 6N HCl (0.1 mL). The mixture was treated with hydrogen (1 atm) for 18 h. Catalyst was filtered off through celite and the solvent was evaporated under reduced pressure. The residue was dissolved in 1 M NH3 in MeOH (10 mL) and stirred for another 10 min, after which solvent was removed under vacuum. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-1-(3-fluorophenethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol as a white solid (22 mg, 70%). 1H NMR (400 MHz, CD3OD) δ 7.29 (td, J= 7.9, 6.1 Hz, 1H), 7.05 (dt, J= 7.6, 1.2 Hz, 1H), 7.00 (dt, J= 10.1, 2.1 Hz, 1H), 6.95-6.87 (m, 1H), 3.96 (dd, J= 12.0, 2.5 Hz, 1H), 3.86 (dd, J= 12.0, 3.2 Hz, 1H), 3.51 (ddd, J= 10.4, 9.0, 4.9 Hz, 1H), 3.34 (t, J= 12 Hz, 1H), 3.18 (t, J= 9.0 Hz, 1H), 3.09 (dd, J= 11.2, 4.9 Hz, 1H), 3.05-2.74 (m, 4H), 2.38 (t, J= 10.8 Hz, 1H), 2.29 (dt, J = 9.5, 2.9 Hz, 1H); ESI MS m/z 286.14 [M + H]+.
(2R,3R,4R,5S)-1-(4-fluorophenethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
K2CO3 (210 mg, 1.52 mmol) was added to a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (100 mg, 0.19 mmol) and 1-(2-bromoethyl)-4-fluorobenzene (194 mg, 0.95 mmol) in DMF (5 mL) in a sealed tube. The mixture was stirred at 80° C. for 18 h, and cooled to ambient temperature. The reaction mixture was poured into ice water (30 mL) and extracted with EtOAc (3 x 20 mL). The combined organic layer was washed with water (2 x 20 mL), separated, dried over Na2SO4. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography affording (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-(4-fluorophenethyl)piperidine as a white solid (70 mg, 57%). ESI MS m/z 646.32 [M + H]+.
To a solution of the above material (70 mg, 0.11 mmol) in EtOH (10 mL) was added Pd(OH)2/C (20 wt.%, 8.6 mg, 0.012 mmol) and 6N HCl (0.1 mL). The mixture was treated with hydrogen (1 atm) for 18 h. Catalyst was filtered off through celite and the solvent was evaporated under reduced pressure. The residue was dissolved in 1 M NH3 in MeOH (10 mL) and stirred for another 10 min, after which solvent was removed under vacuum. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-1-(4-fluorophenethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol as a white solid (16 mg, 51%). 1H NMR (400 MHz, CD3OD) δ 7.29-7.19 (m, 2H), 7.05-6.97 (m, 2H), 3.95 (dd, J= 11.9, 2.5 Hz, 1H), 3.85 (dd, J = 11.9, 3.1 Hz, 1H), 3.51 (ddd, J = 10.4, 9.0, 4.9 Hz, 1H), 3.34 (t, J = 12 Hz, 1H), 3.17 (t, J = 9.0 Hz, 1H), 3.09 (dd, J = 11.1, 4.9 Hz, 1H), 3.05-2.72 (m, 4H), 2.37 (t, J= 10.8 Hz, 1H), 2.28 (dt, J= 9.5, 2.9 Hz, 1H); ESI MS m/z 286.14 [M + H]+.
(2R,3R,4R,5S)-1-(2,6-difluorophenethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
A mixture of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (0.30 g, 0.57 mmol), 2-(2-bromoethyl)-1,3-difluorobenzene (0.40 g, 1.8 mmol) and DIPEA (0.35 g, 2.7 mmol) in anhydrous DMF (5 mL) in a sealed tube was stirred at 85° C. for 16 h. The reaction mixture was cooled to room temperature and diluted with satd. aqueous NaHCO3 (20 mL). After extraction with EtOAc (3 x 20 mL) the combined extract was washed with brine (2 x 30 mL) and dried over anhydrous Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:6 to 1:3), affording (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-(2,6-difluorophenethyl)piperidine as a pale-yellow oil (0.10 g, 26%). ESI MS m/z 664.364 [M + H]+.
At -78° C. and under N2, to a solution of the above material (0.10 g, 0.15 mmol) in anhydrous DCM (3 mL) was added BCl3 (1.0 M in DCM, 1.5 mL, 1.5 mmol), and the mixture was stirred at 0° C. for 3 h. The reaction mixture was cooled to -78° C., quenched with MeOH, and then concentrated to dryness. The residue was neutralized with 1 M NH3 in MeOH and purified on silica gel by flash chromatography (1 M NH3 in MeOH/DCM, 1:4), affording (2R,3R,4R,SS)-1-(2,6-difluorophenethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol as a white solid (0.040 g, 87%). 1H NMR (500 MHz, DMSO-d6) δ 7.33-7.24 (m, 1H), 7.10-7.00 (m, 2H), 4.72-0.67 (m, 3H), 4.15 (dd, J= 6.1, 4.2 Hz, 1H), 3.76-3.71 (m, 1H), 3.54-3.48 (m, 1H), 3.26-3.18 (m, 1H), 3.05-2.99 (m, 1H), 2.96-2.82 (m, 3H), 2.80-2.68 (m, 3H), 2.20 (t, J= 10.6 Hz, 1H), 2.06 (dt, J= 9.3, 2.9 Hz, 1H); ESI MS m/z 304.129 [M + H]+.
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(3-(trifluoromethyl)phenethyl)piperidine-3,4,5-triol
K2CO3 (210 mg, 1.52 mmol) was added to a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (100 mg, 0.19 mmol) and 1-(2-bromoethyl)-3-(trifluoromethyl)benzene (240 mg, 0.95 mmol) in DMF (5 mL) in a sealed tube. The mixture was stirred at 80° C. for 18 h, and cooled to ambient temperature. The reaction mixture was poured into ice water (30 mL) and extracted with EtOAc (3 x 20 mL). The combined organic layer was washed with water (2 x 20 mL), separated, dried over Na2SO4. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified on silica gel flash chromatography affording (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-(3-(trifluoromethyl)phenethyl)piperidine as a white solid (70 mg, 53%). ESI MS m/z 696.33 [M + H]+.
To a stirred solution of the above material (70 mg, 0.10 mmol) in anhydrous DCM (5 mL) was added BCl3 (1 M in DCM, 1.0 mL, 1.0 mmol) at -78° C. under N2. The mixture was stirred at 0° C. for 2 h before being quenched with anhydrous MeOH (1 mL). The mixture was stirred at ambient temperature for 10 min. Solvent was removed under vacuum, the residue was dissolved in 1 M NH3 in MeOH (10 mL) and stirred for another 10 min, after which solvent was removed under vacuum. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-2-(hydroxymethyl)-1-(3-(trifluoromethyl)phenethyl)piperidine-3,4,5-triol as a white solid (21 mg, 63%). 1H NMR (400 MHz, CD3OD) δ 7.59-7.44 (m, 4H), 3.97 (dd, J= 11.9, 2.5 Hz, 1H), 3.86 (dd, J= 11.9, 3.1 Hz, 1H), 3.52 (ddd, J= 10.4, 9.0, 4.9 Hz, 1H), 3.34 (t, J= 12 Hz, 1H), 3.19 (t, J= 9.0 Hz, 1H), 3.13 (dd, J= 11.1, 4.9 Hz, 1H), 3.09-2.84 (m, 4H), 2.42 (t, J= 10.8 Hz, 1H), 2.34 (dt, J = 9.5, 2.9 Hz, 1H); ESI MS m/z 336.14 [M + H]+.
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(4-(trifluoromethyl)phenethyl)piperidine-3,4,5-triol
DIPEA (0.35 mL, 1.9 mmol) was added to a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (100 mg, 0.19 mmol) and 1-(2-bromoethyl)-4-(trifluoromethyl)benzene (193 mg, 0.76 mmol) in DMF (8 mL) in a sealed tube. The mixture was stirred at 80° C. for 18 h, and cooled to ambient temperature. The reaction mixture was poured into ice water (30 mL) and extracted with EtOAc (3 x 20 mL). The combined organic layer was washed with water (2 x 20 mL), separated, dried over Na2SO4. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified on silica gel flash chromatography affording (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-(4-(trifluoromethyl)phenethyl)piperidine as a white solid (76 mg, 61%).
At -78° C. under Ar, to a solution of the above material (70 mg, 0.1 mmol) in anhydrous DCM (2 mL) was added BCl3 (1.0 mL, 1 M in DCM, 1.0 mmol). The mixture was stirred at -78 for 2 h and 0° C. for 2 h; MeOH (20 mL) was added. The mixture was stirred for an additional 2 h at 0° C., and evaporated to dryness under rotavap. The residue was purified on silica gel by flash chromatography using 10% MeOH and 2% NH3 solution in DCM, affording phenyl(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(4-(trifluoromethyl)phenethyl)piperidine-3,4,5-triol as a white foam (26 mg, 70%). 1H NMR (400 MHz, CD3OD) δ 7.58 (d, J = 8.0 Hz, 2H), 7.44 (d, J= 8.0 Hz, 2H), 3.97 (dd, J = 12.0, 2.5 Hz, 1H), 3.85 (dd, J = 12.0, 3.3 Hz, 1H), 3.51 (ddd, J= 10.4, 9.0, 4.9 Hz, 1H), 3.36-3.33 (m, 1H), 3.18 (t, J = 9.0 Hz, 1H), 3.10-2.71 (m, 5H), 2.38 (t, J= 10.8 Hz, 1H), 2.30 (dt, J= 9.5, 2.9 Hz, 1H); ESI MS m/z 336.1 [M + H]+.
Under Ar, to a solution of 2-phenylpropanal (78 mg, 0.57 mmol), (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (200 mg, 0.38 mmol) and HOAc (three drops) in anhydrous MeOH (10 mL) was added NaBH3CN (38 mg, 95%, 0.57 mmol). The mixture was stirred at room temperature for 18 h, satd. aqueous NaHCO3 (30 mL) was added, and the mixture was extracted with EtOAc (3 x 30 mL). The combined organic extract was dried over anhydrous Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography using 30% EtOAc in hexanes, affording (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-(2-phenylpropyl)piperidine (1:3 ratio of two isomers) (207 mg, 85%).
At -78° C. under Ar, to a solution of the above material (155 mg, 0.24 mmol, 1:3 ratio of two isomers) in anhydrous DCM (2 mL) was added BCl3 (3.0 mL, 1 M in DCM, 3.0 mmol). The mixture was stirred at -78 for 2 h and 0° C. for 2 h; MeOH (20 mL) was added. The mixture was stirred for an additional 2 h at 0° C., and evaporated to dryness under rotavap. The residue was purified on silica gel by flash chromatography using 10% MeOH and 2% NH3 solution in DCM, affording phenyl (2R,3R,4R,5S)-2-(hydroxymethyl)-1—((R)—2-phenylpropyl)piperidine-3,4,5-triol as a white foam (14.5 mg, 87%); 1H NMR (400 MHz, CD3OD) δ 7.32-7.22 (m, 4H), 7.19 (t, J= 7.1 Hz, 1H), 3.94-3.61 (m, 2H), 3.48 (td, J= 9.8, 4.7 Hz, 1H), 3.36 -3.32 (m, 1H), 3.27-2.86 (m, 4H), 2.49 (t, J= 8.7 Hz, 1H), 2.10 (q, J= 10.2, 9.5 Hz, 2H), 1.29 (d, J = 5.6 Hz, 3H); ESI MS m/z 282.2 [M + H]+. Also isolated was (2R,3R,4R,5S)-2-(hydroxymethyl)-1—((S)—2-phenylpropyl)piperidine-3,4,5-triol as a white foam (34 mg, 67%); 1H NMR (400 MHz, CD3OD) δ 7.68-6.63 (m, 5H), 3.82 (d, J= 11.7 Hz, 1H), 3.68 (dd, J= 11.9, 3.0 Hz, 1H), 3.37-3.28 (m, 1H), 3.27-2.94 (m, 5H), 2.66-2.43 (m, 1H), 2.24-2.11 (m, 1H), 2.03 (t, J= 10.9 Hz, 1H), 1.24 (d, J= 6.2 Hz, 3H); ESI MS m/z 282.2 [M + H]+. Each compound was isolated as a single diastereomer with the stereochemistry of the phenylpropyl group assigned randomly.
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(2-(pyridin-2-yl)ethyl)piperidine-3,4,5-triol
K2CO3 (1000 mg, 7.24 mmol) was added to a solution of (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (300 mg, 0.57 mmol) and 2-(2-bromoethyl)pyridine (900 mg, 4.86 mmol) in DMF (15 mL) in a sealed tube. The mixture was stirred at 80° C. for 18 h, and cooled to ambient temperature. The reaction mixture was poured into ice water (30 mL) and extracted with EtOAc (3 x 20 mL). The combined organic layer was washed with water (2 x 20 mL), separated, dried over Na2SO4. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography affording 2-(2-((2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidin-1-yl)ethyl)pyridine as a white solid (340 mg, 95%). ESI MS m/z 629.34 [M + H]+.
To a stirred solution of the above material (183 mg, 0.29 mmol) in anhydrous DCM (5 mL) was added BCl3 (1 M in DCM, 2.1 mL, 2.1 mmol) at -78° C. under N2. The mixture was stirred at 0° C. for 2 h before being quenched with anhydrous MeOH (1 mL). The mixture was stirred at ambient temperature for 10 min. Solvent was removed under vacuum, the residue was dissolved in 1 M NH3 in MeOH (10 mL) and stirred for another 10 min, after which solvent was removed under vacuum. The residue was purified by silica gel chromatography to give (2R,3R,4R,5S)-2-(hydroxymethyl)-1-(2-(pyridin-2-yl)ethyl)piperidine-3,4,5-triol as a white solid (63 mg, 81%). 1H NMR (400 MHz, CD3OD) δ 8.51-8.45 (m, 1H), 7.81 (td, J = 7.7, 1.8 Hz, 1H), 7.41 (d, J= 7.8 Hz, 1H), 7.35-7.24 (m, 1H), 4.07-3.92 (m, 2H), 3.59 (ddd, J = 10.5, 8.9, 4.8 Hz, 1H), 3.54-3.40 (m, 2H), 3.32-3.19 (m, 3H), 3.13 (t, J= 7.6 Hz, 2H), 2.71-2.57 (m, 2H); ESI MS m/z 269.15 [M + H]+.
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(2-(thiophen-2-yl)ethyl)piperidine-3,4,5-triol
Under Ar, to a solution of 2-(thiophen-2-yl)acetaldehyde (80 mg, 0.63 mmol), (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (221 mg, 0.42 mmol) and HOAc (three drops) in anhydrous MeOH (10 mL) was added NaBH3CN (50 mg, 95%, 0.62 mmol). The mixture was stirred at room temperature for 18 h, satd. aqueous NaHCO3 (30 mL) was added, and the mixture was extracted with EtOAc (3 x 30 mL). The combined organic extract was dried over anhydrous Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography using 30% EtOAc in hexanes, affording (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-(2-(thiophen-2-yl)ethyl)piperidine (175 mg, 66%).
At -78° C. under Ar, to a solution of the above material (175 mg, 0.27 mmol) in anhydrous DCM (2 mL) was added BCl3 (3.0 mL, 1 M in DCM, 3.0 mmol). The mixture was stirred at -78 for 2 h and 0° C. for 2 h, then MeOH (20 mL) was added. The mixture was stirred for an additional 2 h at 0° C., and evaporated to dryness under rotavap. The residue was purified on silica gel by flash chromatography using 10% MeOH and 2% NH3 solution in DCM, affording phenyl(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(2-(thiophen-2-yl)ethyl)piperidine-3,4,5-triol as a white foam (63 mg, 85%). 1H NMR (400 MHz, CD3OD) δ 7.24 (dd, J = 5.1, 1.3 Hz, 1H), 7.05-6.67 (m, 2H), 3.95 (d, J = 2.7 Hz, 2H), 3.60 (ddd, J = 10.6, 9.1, 4.9 Hz, 1H), 3.46 (t, J = 9.4 Hz, 1H), 3.31-3.01 (m, 6H), 2.88-2.44 (m, 2H); ESI MS m/z 274.1 [M + H]+.
(2R,3R,4R,5S)-2-(hydroxymethyl)-1-(2-(thiophen-3-yl)ethyl)piperidine-3,4,5-triol
Under Ar, to a solution of 2-(thiophen-3-yl)acetaldehyde (85 mg, 0.67 mmol), (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (221 mg, 0.42 mmol) and HOAc (three drops) in anhydrous MeOH (10 mL) was added NaBH3CN (50 mg, 95%, 0.63 mmol). The mixture was stirred at room temperature for 18 h, satd. aqueous NaHCO3 (30 mL) was added, and the mixture was extracted with EtOAc (3 x 30 mL). The combined organic extract was dried over anhydrous Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography using 30% EtOAc in hexanes, affording (2R,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-(2-(thiophen-3-yl)ethyl)piperidine (181 mg, 68 %).
At -78° C. under Ar, to a solution of the above material (181 mg, 0.28 mmol) in anhydrous DCM (2 mL) was added BCl3 (6.0 mL, 1 M in DCM, 6.0 mmol). The mixture was stirred at -78 for 2 h and 0° C. for 2 h, MeOH (20 mL) was added. The mixture was stirred for an additional 2 h at 0° C., and evaporated to dryness under rotavap. The residue was purified on silica gel by flash chromatography using 10% MeOH and 2% NH3 solution in DCM, affording phenyl (2R,3R,4R,5S)-2-(hydroxymethyl)-1-(2-(thiophen-3-yl)ethyl)piperidine-3,4,5-triol as a white foam (23 mg, 29%). 1H NMR (400 MHz, CD3OD) δ 7.34 (dd, J = 5.0, 2.9 Hz, 1H), 7.11 (d, J = 2.9 Hz, 1H), 7.02 (d, J = 4.8 Hz, 1H), 3.92 (qd, J= 12.2, 2.8 Hz, 2H), 3.55 (td, J = 9.9, 4.8 Hz, 1H), 3.39 (t, J = 9.5 Hz, 1H), 3.22 (t, J = 9.1 Hz, 1H), 3.15-3.05 (m, 2H), 3.01-2.94 (m, 1H), 2.90-2.85 (m, 2H), 2.42 (t, J= 10.9 Hz, 1H), 2.37-2.29 (m, 1H); ESI MS m/z 274.3 [M + H]+.
(2S,3R,4R,5S)-1-(cyclohexylmethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Under Ar, a mixture of (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (0.20 g, 0.38 mmol), (bromomethyl)cyclohexane (0.18 g, 1.0 mmol) and DIPEA (0.20 g, 1.6 mmol) in anhydrous DMF (5 mL) in a sealed tube was stirred at 85° C. for 16 h. The reaction mixture was cooled at RT and diluted with satd. aqueous NaHCO3 (20 mL). After extraction with EtOAc (2 x 30 mL) the combined extract was washed with brine (2 x 20 mL) and dried over anhydrous Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:12 to 1:7), affording (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-(cyclohexylmethyl)piperidine as pale-yellow oil (0.17 g, 71%).
At -78° C. and under Ar, to a solution of the above material (0.17 g, 0.27 mmol) in anhydrous DCM (8 mL) was added BCl3 (1.0 M in DCM, 2.0 mL, 2.0 mmol), and the mixture was stirred at 0° C. for 3 h. The reaction mixture was cooled at -78° C., quenched with MeOH, and then concentrated to dryness. The residue was neutralized with 1 M NH3 in MeOH and purified on silica gel by flash chromatography (0.5 M NH3 in MeOH/DCM, 1:5), affording (2S,3R,4R,5S)-1-(cyclohexylmethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol as a white solid (0.059 g, 83%). 1H NMR (400 MHz, DMSO-d6) δ 4.73 (d, J= 4.6 Hz, 1H), 4.64 (d, J = 4.2 Hz, 1H), 4.60 (d, J= 5.1 Hz, 1H), 4.06 (t, J= 5.0 Hz, 1H), 3.65-3.56 (m,2H), 3.44-3.38 (m, 1H), 3.30-3.20 (m, 1H), 3.11-3.02 (m, 1H), 2.81-2.72 (m, 1H), 2.58-2.30 (m, 4H), 1.75-1.55 (m, 5H), 1.46-1.33 (m, 1H), 1.24-1.05 (m, 3H), 0.85-0.70 (m, 2H); ESI MS m/z 260.187 [M + H]+.
(2S,3R,4R,5S)-2-(hydroxymethyl)-1-(((1r,4R)-4-(trifluoromethyl)cyclohexyl)methyl)piperidine-3,4,5-triol
To a stirred solution of (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (400 mg, 0.76 mmol) and (1r,4r)-4-(trifluoromethyl)cyclohexanecarbaldehyde (274 mg, 1.52 mmol) in anhydrous DCM (10 mL) was added HOAc (0.2 mL) and the mixture was stirred for 30 min. NaBH(OAc)3 (340 mg, 1.60 mmol) was added, and the resulting mixture was stirred at RT for 18 h. The reaction was quenched with NaHCO3 solution at 0° C. The mixture was extracted with EtOAc (3 x 20 mL). The combined organic layer was washed with water (2 x 10 mL), separated, and dried over Na2SO4. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography affording (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-(((1r,4S)-4-(trifluoromethyl)cyclohexyl)-methyl)piperidine as an oil (375 mg, 72%). ESI MS m/z 688.35 [M + H]+.
To a stirred solution of the above material (240 mg, 0.35 mmol) in anhydrous DCM (5 mL) was added BCl3 solution (1 M in DCM, 1.75 mL, 1.75 mmol) at -78° C. under N2. The mixture was stirred at 0° C. for 4 h before being quenched with anhydrous MeOH (1 mL). The mixture was stirred at RT for 10 min. Solvent was removed under vacuum, the residue was dissolved in 1 M NH3 in MeOH (10 mL) and stirred for another 10 min, after which solvent was removed under vacuum. The residue was purified by silica gel chromatography to give (2S,3R,4R,5S)-2-(hydroxymethyl)-1-(((1r,4S)-4-(trifluoromethyl)cyclohexyl)methyl)piperidine-3,4,5-triol as a white solid (78 mg, 68%). 1H NMR (400 MHz, CD3OD) δ 3.88-3.77 (m, 2H), 3.69 (dd, J= 9.3, 5.5 Hz, 1H), 3.55-3.46 (m, 1H), 3.39 -3.34 (m, 1H), 2.99 (q, J = 5.5 Hz, 1H), 2.72 (ddd, J = 12.6, 5.4, 1.0 Hz, 1H), 2.64-2.46 (m, 3H), 2.15-2.02 (m, 1H), 2.02-1.89 (m, 4H), 1.56-1.44 (m, 1H), 1.40-1.24 (m, 2H), 1.04-0.85 (m, 2H); ESI MS m/z 328.17 [M + H]+.
(2S,3R,4R,5S)-1-(((1s,4S)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Under Ar, a mixture of (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (0.25 g, 0.50 mmol), cis-4-(2-fluoropropan-2-yl)cyclohexanecarbaldehyde (0.12 g, 0.70 mmol) and NaBH(OAc)3 (0.21 g, 1.0 mmol) in DCM (15 mL) was stirred at RT for 3 days. The reaction mixture was diluted with satd. aqueous NaHCO3 (10 mL), and extracted with DCM (3 × 15 mL). The combined extract was dried over anhydrous Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:7 to 1:5), affording (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-(((1 s,4R)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl)piperidine as pale-yellow oil (0.31 g, 91%).
A mixture of the above material (0.31 g, 0.45 mmol), Pd(OH)2/C (20% Pd in weight, 0.10 g, 0.19 mmol) and 6 drops of concentrated HCl in MeOH (20 mL) was stirred under hydrogen at one atmosphere of pressure overnight. The mixture was filtered through a celite cake, and the filtrate was collected and concentrated to dryness. The residue was dissolved in anhydrous pyridine (3 mL) at 0° C., to which was added Ac2O (0.5 mL). The mixture was stirred at RT for 16 h, and diluted with satd. aqueous NaHCO3 (20 mL). After extraction with EtOAc (2 × 20 mL) the combined extract was dried over anhydrous Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:4 to 1:3), affording a clear oil. The clear oil was treated with 1 M NH3 in MeOH (5 mL) at RT for 16 h. After concentration under reduced pressure the residue was purified on silica gel by flash chromatography (0.5 M NH3 MeOH/DCM, 1:5), affording (2S,3R,4R,5S)-1-(((1 s,4R)-4-(2-fluoropropan-2-yl)cyclohexyl)methyl)-2-(hydroxymethyl)piperidine-3,4,5-triol (0.057 g, 39%, three steps) as a white solid. 1H NMR (400 MHz, CD3OD) δ 3.86-3.78 (m, 2H), 3.69 (dd, J = 9.3, 5.5 Hz, 1H), 3.55-3.43 (m, 1H), 3.35 (t, J = 8.9 Hz, 1H), 3.04-2.96 (m, 1H), 2.84-2.68 (m, 2H), 2.68-2.52 (m, 2H), 1.91-1.68 (m, 3H), 1.66-1.38 (m, 5H), 1.27 (d, J= 21.8 Hz, 6H), 1.26-1.10 (m, 2H); ESI MS m/z 320.233 [M + H]+.
(2S,3R,4R,5S)-1-((2,3-dihydro-1H-inden-2-yl)methyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
To a stirred solution of (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (130 mg, 0.23 mmol) and 2,3-dihydro-1H-indene-2-carbaldehyde (40 mg, 0.27 mmol) in anhydrous DCM (5 mL) was added HOAc (0.1 mL) and stirred for 30 min. NaBH(OAc)3 (73 mg, 0.35 mmol) was added, and the resulting mixture was stirred at RT for 18 h. The reaction was quenched with NaHCO3 solution at 0° C. The mixture was extracted with EtOAc (3 × 20 mL). The combined organic layer was washed with water (2 × 10 mL), separated, and dried over Na2SO4. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography affording (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-((2,3-dihydro-1H-inden-2-yl)methyl)piperidine as an oil (90 mg, 60%). ESI MS m/z 654.35 [M + H]+.
To a stirred solution of the above material (90 mg, 0.14 mmol) in anhydrous DCM (5 mL) was added BCl3 solution (1 M in DCM, 0.69 mL, 0.69 mmol) at -78° C. under N2. The mixture was stirred at 0° C. for 4 h before being quenched with anhydrous MeOH (1 mL). The mixture was stirred at RT for 10 min. Solvent was removed under vacuum, the residue was dissolved in 1 M NH3 in MeOH (10 mL) and stirred for another 10 min, after which solvent was removed under vacuum. The residue was purified by silica gel chromatography to give (2S,3R,4R,5S)-1-((2,3-dihydro-1H-inden-2-yl)methyl)-2-(hydroxymethyl)piperidine-3,4,5-triol as a white solid (23 mg, 56%). 1H NMR (400 MHz, CD3OD) δ 7.20-7.14 (m, 2H), 7.11-7.06 (m, 2H), 3.91-3.80 (m, 2H), 3.76-3.70 (m, 1H), 3.59-3.51 (m, 1H), 3.42-3.34 (m, 1H), 3.10-2.97 (m, 3H), 2.85-2.60 (m, 7H); ESI MS m/z 294.17 [M + H]+.
(2S,3R,4R,5S)-1-(2-cyclohexylethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Under Ar, a mixture of (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (0.20 g, 0.38 mmol), (2-bromoethyl)cyclohexane (0.19 g, 1.0 mmol) and DIPEA (0.20 g, 1.6 mmol) in anhydrous DMF (5 mL) in a sealed tube was stirred at 85° C. for 16 h. The reaction mixture was cooled at RT and diluted with satd. aqueous NaHCO3 (20 mL). After extraction with EtOAc (2 × 30 mL) the combined extract was washed with brine (2 × 20 mL) and dried over anhydrous Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:12 to 1:7), affording (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-(2-cyclohexylethyl)piperidine as pale-yellow oil (0.17 g, 71%).
At -78° C. and under Ar, to a solution of the above material (0.17 g, 0.27 mmol) in anhydrous DCM (8 mL) was added BCl3 (1.0 M in DCM, 2.0 mL, 2.0 mmol), and the mixture was stirred at 0° C. for 3 h. The reaction mixture was cooled at -78° C., quenched with MeOH, and then concentrated to dryness. The residue was neutralized with 1 M NH3 in MeOH and purified on silica gel by flash chromatography (0.5 M NH3 in MeOH/DCM, 1:5), affording (2S,3R,4R,5S)-1-(2-cyclohexylethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol as a white solid (0.054 g, 74%). 1H NMR (400 MHz, DMSO-d6) δ 4.71 (d, J= 4.8 Hz, 1H), 4.65 (d, J= 4.2 Hz, 1H), 4.61 (d, J= 5.1 Hz, 1H), 4.09 (s, br., 1H), 3.67-3.55 (m, 2H), 3.47-3.36 (m, 1H), 3.31-3.21 (m, 1H), 3.12-3.06 (m, 1H), 2.85-2.76 (m, 1H), 2.72-2.62 (m, 1H), 2.61-2.43 (m, 2H), 2.42-2.32 (m, 1H), 1.75-1.54 (m, 5H), 1.35-1.04 (m, 6H), 0.93-0.80 (m, 2H); ESI MS m/z 274.202 [M + H]+.
(2S,3R,4R,5S)-1-(3-cyclohexylpropyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Under Ar, a mixture of (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (0.20 g, 0.38 mmol), (3-bromopropyl)cyclohexane (0.21 g, 1.0 mmol) and DIPEA (0.20 g, 1.6 mmol) in anhydrous DMF (5 mL) in a sealed tube was stirred at 85° C. for 16 h. The reaction mixture was cooled at RT and diluted with satd. aqueous NaHCO3 (20 mL). After extraction with EtOAc (2 × 30 mL) the combined extract was washed with brine (2 × 20 mL) and dried over anhydrous Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:12 to 1:7), affording (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-(3-cyclohexylpropyl)piperidine as pale-yellow oil (0.25 g, 100%).
At -78° C. and under Ar, to a solution of the above material (0.25 g, 0.38 mmol) in anhydrous DCM (8 mL) was added BCl3 (1.0 M in DCM, 3.0 mL, 3.0 mmol), and the mixture was stirred at 0° C. for 3 h. The reaction mixture was cooled at -78° C., quenched with MeOH, and then concentrated to dryness. The residue was neutralized with 1 M NH3 in MeOH and purified on silica gel by flash chromatography (0.5 M NH3 in MeOH/DCM, 1:5), affording (2S,3R,4R,5S)-1-(3-cyclohexylpropyl)-2-(hydroxymethyl)piperidine-3,4,5-triol as a white solid (0.095 g, 87%). 1H NMR (400 MHz, DMSO-d6) δ 4.81-4.61 (m, 3H), 4.09 (s, br., 1H), 3.69-3.56 (m, 2H), 3.48-3.36 (m, 1H), 3.32-3.23 (m, 1H), 3.15-3.04 (m, 1H), 2.90-2.77 (m, 1H), 2.63-2.32 (m, 4H), 1.70-1.54 (m, 5H), 1.44-1.32 (m, 2H), 1.25-1.08 (m, 6H), 0.91-0.78 (m, 2H); ESI MS m/z 288.218 [M + H]+.
(2S,3R,4R,5S)-1-(2-fluorophenethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
A mixture of (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (7.50 g, 14.3 mmol) (J. Am. Chem. Soc. 2017, 139, 14192 -14197), 1-(2-bromoethyl)-2-fluorobenzene (4.14 g, 20.4 mmol) (Tetrahedron Asymmetry, 2001, 12, 4, 585-596), tetra-butylammonium iodide (Bu4NI) (0.450 g, 1.22 mmol) and K2CO3 (4.14 g, 30.0 mmol) in anhydrous DMF (40 mL) was stirred at 100° C. for 16 h. The reaction mixture was cooled at RT and diluted with water (300 mL). After extraction with Et2O (2 × 100 mL) the combined extract was washed with brine (3 × 100 mL) and dried over anhydrous Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:10 to 1:5), affording (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-(2-fluorophenethyl)piperidine as a pale-yellow oil (3.60 g, 39%); ESI MS m/z 646.327 [M + H]+.
At -78° C. and under N2, to a solution of the above material (3.60 g, 5.57 mmol) in anhydrous DCM (40 mL) was added BCl3 (1.0 M in DCM, 33 mL, 33 mmol), and the mixture was stirred at 0° C. for 3 h. The reaction mixture was cooled at -78° C., quenched with MeOH, and then concentrated to dryness. The residue was neutralized with 1 M NH3 in MeOH and purified on silica gel by flash chromatography (1 M NH3 in MeOH/DCM, 1:5), affording (2S,3R,4R,5S)-1-(2-fluorophenethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol as a white solid (1.48 g, 93%). 1H NMR (400 MHz, CD3OD) δ 7.26 (td, J= 7.5, 1.8 Hz, 1H), 7.22-7.16 (m, 1H), 7.07 (td, J= 7.5, 1.2 Hz, 1H), 7.04-6.99 (m, 1H), 3.94-3.75 (m, 2H), 3.67 (dd, J = 8.8, 5.2 Hz, 1H), 3.53 (ddd, J = 9.5, 8.0, 4.9 Hz, 1H), 3.38 (t, J = 8.5 Hz, 1H), 3.12-2.97 (m, 2H), 2.95-2.77 (m, 4H), 2.63 (dd, J= 12.4, 9.5 Hz, 1H); ESI MS m/z 286.139 [M + H]+.
(2S,3R,4R,5S)-1-(3-chloro-2-fluorophenethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Under Ar, a mixture of (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (0.35 g, 0.67 mmol), 2-(3-chloro-2-fluorophenyl)acetaldehyde (0.14 g, 0.81 mmol) and NaBH(OAc)3 (0.20 g, 0.94 mmol) in DCM (10 mL) was stirred at RT for 16 h. The reaction mixture was diluted with satd. aqueous NaHCO3 (10 mL), and extracted with DCM (3 × 15 mL). The combined extract was dried over anhydrous Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:9 to 1:6), affording (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-(3-chloro-2-fluorophenethyl)piperidine as pale-yellow oil (0.43 g, 94%).
At -78° C. and under Ar, to a solution of the above material (0.43 g, 0.63 mmol) in anhydrous DCM (10 mL) was added BCl3 (1.0 M in DCM, 4.0 mL, 4.0 mmol), and the mixture was stirred at 0° C. for 3 h. The reaction mixture was cooled at -78° C., quenched with MeOH, and then concentrated to dryness. The residue was neutralized with 1 M NH3 in MeOH and purified on silica gel by flash chromatography (0.5 M NH3 in MeOH/DCM, 1:5), affording (2S,3R,4R,5S)-1-(3-chloro-2-fluorophenethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol as white solid (0.15 g, 74%). 1H NMR (400 MHz, DMSO-d6) δ 7.42-7.36 (m, 1H), 7.31-7.25 (m, 1H), 7.16-7.10 (m, 1H), 4.71 (d, J= 4.9 Hz, 1H), 4.67 (d, J= 4.1 Hz, 1H), 4.65 (d, J = 5.2 Hz, 1H), 4.17 (t, J = 5.0 Hz, 1H), 3.72-3.56 (m, 2H), 3.40-3.30 (m, 1H), 3.30-3.20 (m, 1H), 3.12-3.04 (m, 1H), 2.98-2.92 (m, 1H), 2.87-2.81 (m, 1H), 2.80-2.67 (m, 4H), 2.44 (dd, J = 11.9, 9.4 Hz, 1H); ESI MS m/z 320.109 [M + H]+.
(2S,3R,4R,5S)-1-(2-([1,1′-biphenyl]-4-yl)ethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Under Ar, a mixture of (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (0.20 g, 0.38 mmol), 4-(2-bromoethyl)-1,1′-biphenyl (0.25 g, 0.96 mmol) and DIPEA (0.20 g, 1.6 mmol) in anhydrous DMF (5 mL) in a sealed tube was stirred at 85° C. for 16 h. The reaction mixture was cooled at RT and diluted with satd. aqueous NaHCO3 (20 mL). After extraction with EtOAc (2 × 30 mL) the combined extract was washed with brine (2 × 20 mL) and dried over anhydrous Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:12 to 1:7), affording (2S,3R,4R,5S)-1-(2-([1,1′-biphenyl]-4-yl)ethyl)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine as pale-yellow oil (0.18 g, 67%).
At -78° C. and under Ar, to a solution of the above material (0.18 g, 0.26 mmol) in anhydrous DCM (8 mL) was added BCl3 (1.0 M in DCM, 2.0 mL, 2.0 mmol), and the mixture was stirred at 0° C. for 3 h. The reaction mixture was cooled at -78° C., quenched with MeOH, and then concentrated to dryness. The residue was neutralized with 1 M NH3 in MeOH and purified on silica gel by flash chromatography (0.5 M NH3 in MeOH/DCM, 1:5), affording (2S,3R,4R,5S)-1-(2-([1,1′-biphenyl]-4-yl)ethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol as a white solid (0.031 g, 35%). 1H NMR (400 MHz, DMSO-d6) δ 7.69-7.61 (m, 2H), 7.60-7.52 (m, 2H), 7.50-7.40 (m, 2H), 7.37-7.27 (m, 3H), 4.48-4.60 (m, 3H), 4.19 (s, br., 1H), 3.73-3.59 (m, 2H), 3.47-3.39 (m, 1H), .3.35-3.23 (m, 1H), 3.16-3.05 (m, 1H), 3.04-2.89 (m, 2H), 2.85-2.67 (m, 4H), 2.53-2.44 (m, 1H); ESI MS m/z 344.185 [M + H]+.
(2S,3R,4R,5S)-1-(2,6-difluoro-4-(tetrahydro-2H-pyran-4-yl)phenethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Under Ar, a mixture of (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (0.20 g, 0.38 mmol), 2-(4-(3,6-dihydro-2H-pyran-4-yl)-2,6-difluorophenyl)acetaldehyde (0.12 g, 0.50 mmol) and NaBH(OAc)3 (0.15 g, 0.71 mmol) in DCM (10 mL) was stirred at RT for 16 h. The reaction mixture was diluted with satd. aqueous NaHCO3 (10 mL), and extracted with DCM (3 × 15 mL). The combined extract was dried over anhydrous Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:6 to 1:4), affording (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-(4-(3,6-dihydro-2H-pyran-4-yl)-2,6-difluorophenethyl)piperidine as pale-yellow oil (0.27 g, 75%).
A mixture of the above material (0.27 g, 0.36 mmol), Pd(OH)2/C (20% Pd in weight, 0.070 g, 0.13 mmol) and 5 drops of concentrated HCl in MeOH (20 mL) was stirred under hydrogen at one atmosphere of pressure overnight. The mixture was filtered through a celite cake, and the filtrate was collected and concentrated to dryness. The residue was neutralized with 1 M NH3 in MeOH and purified on silica gel by flash chromatography (0.5 M NH3 MeOH/DCM, 1:5), affording (2S,3R,4R,5S)-1-(2,6-difluoro-4-(tetrahydro-2H-pyran-4-yl)phenethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol (0.12 g, 86%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 6.98-6.92 (m, 2H), 4.71 (d, J= 4.8 Hz, 1H), 4.69-4.62 (m, 2H), 4.14 (t, J = 4.9 Hz, 1H), 3.97-3.82 (m, 2H), 3.72-3.51 (m, 2H), 3.39 (td, J = 11.5, 2.8 Hz, 2H), 3.40-3.30 (m, 1H), 3.30-3.20 (m, 1H), 3.12-3.03 (m, 1H), 2.98-2.56 (m, 7H), 2.42 (t, J= 10.6 Hz, 1H), 1.81-1.42 (m, 4H); ESI MS m/z 388.193 [M + H]+.
(2S,3R,4R,5S)-1-(4-butoxyphenethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Under Ar, a mixture of (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (0.20 g, 0.38 mmol), 2-(4-butoxyphenyl)acetaldehyde (0.12 g, 0.62 mmol) and NaBH(OAc)3 (0.15 g, 0.71 mmol) in DCM (10 mL) was stirred at RT for 3 days. The reaction mixture was diluted with satd. aqueous NaHCO3 (10 mL), and extracted with DCM (3 × 15 mL). The combined extract was dried over anhydrous Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:9 to 1:6), affording (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-(4-butoxyphenethyl)piperidine as pale-yellow oil (0.23 g, 86%).
A mixture of the above material (0.23 g, 0.33 mmol), Pd(OH)2/C (20% Pd in weight, 0.10 g, 0.19 mmol) and 5 drops of concentrated HCl in MeOH (20 mL) was stirred under hydrogen at one atmosphere of pressure overnight. The mixture was filtered through a celite cake, and the filtrate was collected and concentrated to dryness. The residue was neutralized with 1 M NH3 in MeOH and purified on silica gel by flash chromatography (0.5 M NH3 MeOH/DCM, 1:5), affording (2S,3R,4R,5S)-1-(4-butoxyphenethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol (0.051 g, 46%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 7.16-7.01 (m, 2H), 6.90-6.73 (m, 2H), 4.87-4.51 (m, 3H), 4.14 (s, br. 1H), 3.91 (t, J= 6.5 Hz, 2H), 3.70-3.57 (m, 2H), 3.45-3.35 (m, 1H), 3.34-3.24 (m, 1H), 3.14-3.06 (m, 1H), 2.93-2.83 (m, 2H), 2.73-2.55 (m, 4H), 2.50-2.39 (m, 1H), 1.71-1.62 (m, 2H), 1.49-1.33 (m, 2H), 0.92 (t, J= 7.4 Hz, 3H); ESI MS m/z 340.212 [M + H]+.
(2S,3R,4R,5S)-1-(4-butoxy-2,6-difluorophenethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Under N2, a mixture of (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (1.20 g, 2.29 mmol), 2-(4-butoxy-2,6-difluorophenyl)acetaldehyde (0.68 g, 3.0 mmol) and NaBH(OAc)3 (0.85 g, 4.0 mmol) in DCM (30 mL) was stirred at RT for 3 days. The reaction mixture was diluted with satd. aqueous NaHCO3 (30 mL), and extracted with DCM (3 × 20 mL). The combined extract was dried over anhydrous Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:12 to 1:7), affording (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-(4-butoxy-2,6-difluorophenethyl)piperidine as a pale-yellow oil (1.3 g, 77%). ESI MS m/z 736.3689 [M + H]+.
A mixture of the above material (1.30 g, 1.76 mmol), Pd(OH)2/C (20% Pd in weight, 0.25 g, 0.47 mmol) and concentrated HCl (0.5 mL) in MeOH (80 mL) was stirred under hydrogen at one atmosphere of pressure overnight. The mixture was filtered through a celite cake, and the filtrate was collected and concentrated to dryness. The residue was neutralized with 1 M NH3 in MeOH and subsequently purified on silica gel by flash column chromatography (0.5 M NH3 MeOH/DCM, 1:4), affording (2S,3R,4R,5S)-1-(4-butoxy-2,6-difluorophenethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol (0.58 g, 88%) as a white solid. 1H NMR (400 MHz, CD3OD) δ 6.53-6.47 (m, 2H), 3.94 (t, J= 6.4 Hz, 2H), 3.88-3.75 (m, 2H), 3.63 (dd, J = 8.9, 5.3 Hz, 1H), 3.50 (ddd, J= 9.5, 8.1, 5.0 Hz, 1H), 3.36 (t, J= 8.5 Hz, 1H), 3.06-2.90 (m, 2H), 2.88 (dd, J= 12.4, 5.0 Hz, 1H), 2.83-2.74 (m, 3H), 2.61 (dd, J= 12.4, 9.5 Hz, 1H), 1.80-1.68 (m, 2H), 1.54-1.44 (m, 2H), 0.98 (t, J = 7.4 Hz, 3H); ESI MS m/z 376.1604 [M + H]+.
(2S,3R,4R,5S)-1-((1-(4-fluorophenyl)piperidin-4-yl)methyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
To a stirred solution of (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (600 mg, 1.06 mmol) and tert-butyl 4-formylpiperidine-1-carboxylate (272 mg, 1.28 mmol) in anhydrous DCM (10 mL) was added HOAc (0.2 mL) and the mixture was stirred for 30 min. NaBH(OAc)3 (337 mg, 1.59 mmol) was added, and the resulting mixture was stirred at RT for 18 h. The reaction was quenched with NaHCO3 solution at 0° C. The mixture was extracted with EtOAc (3 × 20 mL). The combined organic layer was washed with water (2 × 10 mL), separated, and dried over Na2SO4. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography affording tert-butyl 4-(((2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidin-1-yl)methyl)piperidine-1-carboxylate as an oil (740 mg, 97%). ESI MS m/z 721.42 [M + H]+.
TFA (3 mL) was cooled to 0° C. and added to the above material (740 mg, 1.03 mmol) in DCM (6 mL). The mixture was stirred at 0° C. for 10 min, then RT for 2 h. TFA and DCM were removed under vacuum. The residue was dissolved in EtOAc (50 mL) and washed with NaHCO3 solution (2 × 20 mL) then washed with water, separated, and dried over Na2SO4. After filtration, the solvent was evaporated under reduced pressure, and the crude (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-(piperidin-4-ylmethyl)piperidine was used directly in the next step without further purification (624 mg, 98%). ESI MS m/z 621.37 [M + H]+.
To a stirred solution of the above material (228 mg, 0.37 mmol) and 4-bromofluorobenzene (128 mg, 0.74 mmol) in toluene (10 mL) was added Pd2(dba)3 (34 mg, 0.037 mmol) and RuPhos (35 mg, 0.074 mmol), followed by Cs2CO3 (361 mg, 1.11 mmol) under Ar. The mixture was stirred at 100° C. for 18 h, and then water was added at 0° C. The mixture was extracted with EtOAc (2 × 30 mL). The combined organic layer was washed with water (2 × 10 mL), separated, and dried over Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography affording (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-((1-(4-fluorophenyl)piperidin-4-yl)methyl)piperidine as an oil (208 mg, 79%). ESI MS m/z 715.39 [M + H]+.
To a stirred solution of the above material (110 mg, 0.15 mmol) in anhydrous DCM (5 mL) was added BCl3 solution (1 M in DCM, 0.75 mL, 0.75 mmol) at -78° C. under N2. The mixture was stirred at 0° C. for 4 h before being quenched with anhydrous MeOH (1 mL). The mixture was stirred at RT for 10 min. Solvent was removed under vacuum, the residue was dissolved in 1 M NH3 in MeOH (10 mL) and stirred for another 10 min, after which solvent was removed under vacuum. The residue was purified by silica gel chromatography to give (2S,3R,4R,5S)-1-((1-(4-fluorophenyl)piperidin-4-yl)methyl)-2-(hydroxymethyl)piperidine-3,4,5-triol as a white solid (25 mg, 47%). 1H NMR (400 MHz, CD3OD) δ 7.04-6.93 (m, 4H), 3.91-3.80 (m, 2H), 3.74 -3.69 (m, 1H), 3.60-3.49 (m, 3H), 3.41-3.34 (m, 1H), 3.06-2.99 (m, 1H), 2.80-2.56 (m, 6H), 1.97-1.84 (m, 2H), 1.72-1.58 (m, 1H), 1.41-1.26 (m, 2H); ESI MS m/z 355.20 [M + H]+.
(2S,3R,4R,5S)-2-(hydroxymethyl)-1—(((R)—1-(3-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol
To a solution of (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (0.78 g, 1.5 mmol) in DCM (20 mL) was added (S)-tert-butyl 3-formylpyrrolidine-1-carboxylate (0.45 g, 2.25 mmol) and HOAc (0.5 mL). After stirring at RT for 10 min, NaBH(OAc)3 (0.5 g, 2.5 mmol) was added and the mixture was stirred at RT overnight. The reaction mixture was concentrated before diluting with DCM (25 mL). Organics were washed with satd. aqueous NaHCO3, brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 3:7) affording (R)-tert-butyl 3-(((2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidin-1-yl)methyl)pyrrolidine-1-carboxylate as an oil (1.0 g, 94%). 1H NMR (400 MHz, CDCl3) δ 7.40-7.27 (m, 20H), 4.88 (d, J= 11.0 Hz, 1H), 4.82 (d, J= 11.1 Hz, 1H), 4.74 (d, J= 11.4 Hz, 1H), 4.71-4.62 (m, 3H), 4.54 (d, J= 12.1 Hz, 1H), 4.50 (d, J= 12.4 Hz, 1H), 3.73 (dd, J= 10.2, 2.5 Hz, 1H), 3.67 (td, J= 6.8, 5.8, 3.6 Hz, 1H), 3.59-3.42 (m, 3H), 3.39-3.25 (m, 3H), 3.04-2.89 (m, 1H), 2.87-2.79 (m, 1H), 2.76-2.63 (m, 1H), 2.61-2.52 (m, 2H), 2.37-2.25 (m, 1H), 1.88-1.80 (bs, 1H), 1.60-1.54 (m, 2H), 1.50 (s, 9H); ESI MS m/z 707.404 [M + H]+.
The above material (1.0 g, 1.45 mmol) was taken up in 3:7 TFA:DCM (16 mL) solution at 0° C. and stirred for 30 min. The reaction mixture was warmed to RT over 2 h before concentrated to dryness. Diluted with EtOAc (30 mL) and washed organics with satd. NaHCO3 (2 × 50 mL), dried over anhydrous Na2SO4, and concentrated to afford (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1—((S)—pyrrolidin-3-ylmethyl)piperidine as an oil (0.8 g, 90%). 1H NMR (400 MHz, CDCl3) δ 7.40-7.26 (m, 20H), 4.88 (d, J= 10.9 Hz, 1H), 4.83 (d, J= 10.9 H z, 1H), 4.76-4.62 (m, 4H), 4.56-4.49 (m, 3H), 3.85 (dd, J = 10.1, 7.1 Hz, 1H), 3.73 (dd, J = 10.2, 2.6 Hz, 1H), 3.70-3.63 (m, 1H), 3.59-3.47 (m, 2H), 3.34 (td, J = 6.6, 6.2, 2.7 Hz, 1H), 3.06-2.91 (m, 3H), 2.90-2.83 (m, 1H), 2.80-2.44 (m, 4H), 2.31 (tt, J = 13.9, 6.1 Hz, 1H), 1.84 (dtd, J= 13.2, 8.0, 5.6 Hz, 1H), 1.42 (dq, J = 13.8, 7.2 Hz, 1H); ESI MS m/z 607.350 [M + H]+.
To a solution of the above material (0.19 g, 0.31 mmol) and 2-chloro-3-(trifluoromethyl)pyridine (0.11 g, 0.62 mmol) in dry DMF (5 mL) was added K2CO3 (0.12 g, 0.93 mmol) and the reaction mixture was heated at 120° C. overnight. The reaction mixture was partitioned between EtOAc (50 mL) and water; organics were separated, and dried over anhydrous Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 2:8) affording 3-(trifluoromethyl)-2—((R)—3-(((2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidin-1-yl)methyl)pyrrolidin-1-yl) pyridine as an oil (0.1 g, 43%). 1H NMR (400 MHz, CDCl3) δ 8.32 (dd, J= 4.7, 1.7 Hz, 1H), 7.81 (dd, J= 7.8, 1.8 Hz, 1H), 7.41-7.27 (m, 20H), 6.66 (dd, J= 7.8, 4.7 Hz, 1H), 4.89 (d, J= 10.9 Hz, 1H), 4.84 (d, J= 10.9 Hz, 1H), 4.75 (d, J= 11.5 Hz, 1H), 4.70 (s, 2H), 4.68-4.62 (m, 1H), 4.58-4.49 (m, 2H), 3.88 (dd, J= 10.2, 7.1 Hz, 1H), 3.74 (dd, J= 10.4, 2.8 Hz, 1H), 3.72-3.49 (m, 6H), 3.40-3.31 (m, 2H), 2.88 (dt, J = 11.9, 5.8 Hz, 1H), 2.78 (dd, J = 12.8, 8.4 Hz, 1H), 2.67 (dd, J = 12.7, 6.6 Hz, 1H), 2.64-2.53 (m, 1H), 2.40 (dq, J = 14.6, 7.3 Hz, 1H), 1.97 (dq, J = 11.7, 5.8 Hz, 1H), 1.63 (dq, J= 12.3, 8.0 Hz, 1H); ESI MS m/z 752.362 [M + H]+.
At -78° C., under Ar, to a solution of the above material (0.1 g, 0.13 mmol) in DCM (8 mL) was added BCl3 (1.0 M in DCM, 0.8 mL, 0.8 mmol), and the mixture was stirred for 3 h while the bath temperature reached 0° C. The mixture was then cooled at -78° C., and MeOH (3 mL) was added carefully. After stirring at RT for 30 min the mixture was concentrated under reduced pressure. The resulting residue was neutralized with 1 M NH3 in MeOH solution (2 × 5 mL) and concentrated again under reduced pressure. The residue was purified on silica gel by flash chromatography (MeOH/DCM, 1:9), affording (2S,3R,4R,5S)-2-(hydroxymethyl)-1—(((R)—1-(3-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl) piperidine-3,4,5-triol (0.031 g, 60.9%) as a white solid. 1H NMR (400 MHz, CD3OD) δ 8.25 (dd, J= 4.8, 1.8 Hz, 1H), 7.87 (dd, J= 7.8, 1.8 Hz, 1H), 6.73 (dd, J= 7.8, 4.7 Hz, 1H), 3.91-3.82 (m, 2H), 3.71 (dd, J= 9.3, 5.5 Hz, 1H), 3.68-3.61 (m, 3H), 3.53 (ddd, J= 10.0, 8.5, 5.2 Hz, 1H), 3.44-3.35 (m, 2H), 3.06 (p, J= 6.1, 5.7 Hz, 1H), 2.90-2.73 (m, 3H), 2.68-2.60 (m, 1H), 2.53 (h, J= 7.6 Hz, 1H), 2.10 (dq, J= 11.9, 6.1 Hz, 1H), 1.71 (dq, J= 12.1, 7.9 Hz, 1H); ESI MS m/z 392.176 [M + H]+.
(2S,3R,4R,5S)-2-(hydroxymethyl)-1—(((R)—1-(4-(trifluoromethyl)thiazol-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol
To a stirred solution of (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1—((S)—pyrrolidin-3-ylmethyl)piperidine (0.14 g, 0.23 mmol) and 2-bromo-4-(trifluoromethyl) thiazole (0.1 g, 0.46 mmol) in DMA (5 mL) was added Cs2CO3 (0.22 g, 0.69 mmol) under Ar. The mixture was stirred at 80° C. for 18 h, and then water was added at 0° C. The mixture was extracted with EtOAc (2 × 20 mL). The combined organic layer was washed with water (2 × 20 mL), separated, and dried over Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography affording 4-(trifluoromethyl)-2—((S)—3-(((2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidin-1-yl)methyl)pyrrolidin-1-yl)thiazole as an oil (0.11 g, 63%). 1H NMR (400 MHz, CDCl3) δ 7.39-7.27 (m, 20H), 6.90 (d, J= 1.2 Hz, 1H), 4.89 (d, J= 10.9 Hz, 1H), 4.83 (d, J= 10.9 Hz, 1H), 4.75 (d, J= 11.5 Hz, 1H), 4.70-4.68 (m, 2H), 4.64 (d, J= 11.5 Hz, 1H), 4.57-4.48 (m, 2H), 3.87 (dd, J= 10.2, 7.3 Hz, 1H), 3.77-3.64 (m, 2H), 3.60-3.42 (m, 5H), 3.34-3.27 (m, 1H), 3.16 (dd, J= 10.1, 6.5 Hz, 1H), 2.84 (dd, J= 12.2, 5.4 Hz, 1H), 2.76-2.46 (m, 4H), 2.09-1.98 (m, 1H), 1.72 (dq, J= 12.7, 7.5 Hz, 1H); ESI MS m/z 758.321 [M + H]+.
At -78° C., under Ar, to a solution of the above material (0.11 g, 0.15 mmol) in DCM (5 ml) was added BCl3 (1.0 M in DCM, 0.75 mL, 0.75 mmol), and the mixture was stirred for 3 h while the bath temperature reached 0° C. The mixture was then cooled at -78° C., and MeOH (3 mL) was added carefully. After stirring at RT for 30 min the mixture was concentrated under reduced pressure. The resulting residue was neutralized with 1 M NH3 in MeOH solution (2 × 5 mL) and concentrated again under reduced pressure. The residue was purified on silica gel by flash chromatography (MeOH/DCM, 1:9), affording (2S,3R,4R,5S)-2-(hydroxymethyl) -1—(((R)—1-(4-(trifluoromethyl)thiazol-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol (0.04 g, 67%) as a white solid. 1H NMR (400 MHz, CD3OD) δ 7.14 (s, 1H), 3.90-3.82 (m, 2H), 3.71 (dd, J= 9.3, 5.5 Hz, 1H), 3.65-3.44 (m, 4H), 3.37 (dd, J= 8.9, 6.7 Hz, 1H), 3.28 (dd, J= 10.1, 6.4 Hz, 1H), 3.06 (q, J= 5.7 Hz, 1H), 2.88-2.80 (m, 2H), 2.76 (dd, J= 12.7, 8.5 Hz, 1H), 2.71-2.61 (m, 2H), 2.20 (dtd, J= 12.2, 6.9, 4.9 Hz, 1H), 1.86 (dq, J= 12.4, 7.6 Hz, 1H); ESI MS m/z 398.132 [M + H]+.
(2S,3R,4R,5S)-2-(hydroxymethyl)-1—(((S)—1-(3-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol
To a stirred solution of (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1—((R)—pyrrolidin-3-ylmethyl)piperidine (210 mg, 0.35 mmol) and 2-chloro-3-(trifluoromethyl)pyridine (127 mg, 0.70 mmol) in DMF (5 mL) was added DIPEA (0.24 mL, 1.39 mmol). The mixture was stirred at 100° C. for 18 h, and then water was added at 0° C. The mixture was extracted with EtOAc (2 × 30 mL). The combined organic layer was washed with water (2 × 10 mL), separated, and dried over Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography affording 3-(trifluoromethyl)-2—((S)—3-(((2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidin-1-yl)methyl)pyrrolidin-1-yl)pyridine as an oil (100 mg, 38%). ESI MS m/z 752.36 [M + H]+.
To a stirred solution of the above material (95 mg, 0.13 mmol) in anhydrous DCM (5 mL) was added BCl3 solution (1 M in DCM, 0.63 mL, 0.63 mmol) at -78° C. under N2. The mixture was stirred at 0° C. for 4 h before being quenched with anhydrous MeOH (1 mL). The mixture was stirred at RT for 10 min. Solvent was removed under vacuum, the residue was dissolved in 1 M NH3 in MeOH (10 mL) and stirred for another 10 min, after which solvent was removed under vacuum. The residue was purified by silica gel chromatography to give (2S,3R,4R,5S)-2-(hydroxymethyl)-1—(((S)—1-(3-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol as a white solid (30 mg, 59%). 1H NMR (400 MHz, CD3OD) δ 8.26 (dd, J= 4.9, 1.8 Hz, 1H), 7.87 (dd, J= 7.8, 1.9 Hz, 1H), 6.73 (dd, J= 7.8, 4.7 Hz, 1H), 3.90-3.82 (m, 2H), 3.76-3.59 (m, 4H), 3.58-3.49 (m, 1H), 3.44-3.34 (m, 2H), 3.11-3.03 (m, 1H), 2.90 (dd, J= 12.8, 6.8 Hz, 1H), 2.83-2.76 (m, 1H), 2.73-2.61 (m, 2H), 2.60-2.48 (m, 1H), 2.15-2.04 (m, 1H), 1.80-1.67 (m, 1H); ESI MS m/z 392.17 [M + H]+.
(2S,3R,4R,5S)-2-(hydroxymethyl)-1—(((S)—1-(4-(trifluoromethyl)thiazol-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol
To a stirred solution of (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (1.42 g, 2.71 mmol) and (R)-tert-butyl 3-formylpyrrolidine-1-carboxylate (0.60 g, 3.01 mmol) in anhydrous DCM (20 mL) was added HOAc (0.2 mL) and the mixture was stirred for 30 min. NaBH(OAc)3 (745 mg, 3.51 mmol) was added, and the resulting mixture was stirred at RT for 18 h. The reaction was quenched with NaHCO3 solution at 0° C. The mixture was extracted with EtOAc (3 × 20 mL). The combined organic layer was washed with water (2 × 10 mL), separated, and dried over Na2SO4. After filtration, the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography affording (S)-tert-butyl 3-(((2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidin-1-yl)methyl)pyrrolidine-1-carboxylate as an oil (1.51 g, 79%). ESI MS m/z 707.41 [M + H]+.
TFA (7 mL) was cooled to 0° C. and added to the above material (1.51 g, 2.13 mmol) in DCM (20 mL). The mixture was stirred at 0° C. for 10 min, then RT for 2 h. TFA and DCM were removed under vacuum. The residue was dissolved in EtOAc (80 mL) and washed with NaHCO3 solution (2 × 20 mL) then washed with water, separated, and dried over Na2SO4. After filtration, the solvent was evaporated under reduced pressure. The residue was purified on silica gel by flash chromatography affording (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1—((R)—pyrrolidin-3-ylmethyl)piperidine as an oil (886 mg, 68%). ESI MS m/z 607.35 [M + H]+.
To a stirred solution of the above material (210 mg, 0.35 mmol) and 2-bromo-4-(trifluoromethyl)thiazole (162 mg, 0.70 mmol) in DMA (5 mL) was added Cs2CO3 (457 mg, 2.40 mmol). The mixture was stirred at 80° C. for 18 h, and then water was added at 0° C. The mixture was extracted with EtOAc (2 × 30 mL). The combined organic layer was washed with water (2 × 10 mL), separated, and dried over Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography affording 4-(trifluoromethyl)-2—((S)—3-(((2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidin-1-yl)methyl)pyrrolidin-1-yl)thiazole as an oil (161 mg, 61%). ESI MS m/z 758.32 [M + H]+.
To a stirred solution of the above material (150 mg, 0.35 mmol) in anhydrous DCM (5 mL) was added BCl3 solution (1 M in DCM, 1.0 mL, 1.0 mmol) at -78° C. under N2. The mixture was stirred at 0° C. for 4 h before being quenched with anhydrous MeOH (1 mL). The mixture was stirred at RT for 10 min. Solvent was removed under vacuum, the residue was dissolved in 1 M NH3 in MeOH (10 mL) and stirred for another 10 min, after which solvent was removed under vacuum. The residue was purified by silica gel chromatography to give (2S,3R,4R,5S)-2-(hydroxymethyl)-1—(((S)—1-(4-(trifluoromethyl)thiazol-2-yl)pyrrolidin-3-yl)methyl)piperidine-3,4,5-triol as a white solid (50 mg, 63%). 1H NMR (400 MHz, CD3OD) δ 7.15-7.13 (m, 1H), 3.90-3.82 (m, 2H), 3.74-3.67 (m, 1H), 3.65-3.43 (m, 4H), 3.40-3.34 (m, 1H), 3.31-3.23 (m, 1H), 3.09-3.02 (m, 1H), 2.94-2.60 (m, 5H), 2.25-2.14 (m, 1H), 1.94-1.80 (m, 1H); ESI MS m/z 398.13 [M + H]+.
(2S,3R,4R,5S)-2-(hydroxymethyl)-1—(((R)—1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol
To a solution of (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (0.8 g, 1.5 mmol) in DCM (30 mL) was added (S)-tert-butyl 3-formylpiperidine-1-carboxylate (0.42 g, 2.0 mmol) and HOAc (0.5 mL). After stirring at RT for 10 min, NaBH(OAc)3 (0.48 g, 2.26 mmol) was added and the mixture was stirred at RT overnight. The reaction mixture was concentrated before diluting with DCM (25 mL). Organics were washed with satd. aqueous NaHCO3, brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 3:7) affording (R)-tert-butyl 3-(((2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl) piperidin-1-yl)methyl)piperidine-1-carboxylate as an oil (1.0 g, 94%). 1H NMR (400 MHz, CDCl3) δ 7.38-7.27 (m, 20H), 4.88 (d, J= 11.1 Hz, 1H), 4.82 (d, J= 11.1 Hz, 1H), 4.75 (d, J= 11.5 Hz, 1H), 4.71-4.63 (m, 3H), 4.57-4.49 (m, 2H), 3.99-3.87 (m, 2H), 3.85 (dd, J = 10.1, 6.9 Hz, 1H), 3.75-3.68 (m, 2H), 3.63-3.48 (m, 2H), 3.31-3.25 (m, 1H), 2.89-2.77 (m, 2H), 2.66-2.51 (m, 3H), 2.44 (dd, J= 13.0, 5.6 Hz, 1H), 1.73-1.57 (m, 3H), 1.46 (s, 9H), 1.45-1.33 (m, 1H), 1.07 (q, J= 10.1 Hz, 1H); ESI MS m/z 721.421 [M + H]+.
The above material (1.0 g, 1.4 mmol) was taken up in 3:7 TFA:DCM (16 mL) solution at 0° C. and stirred for 30 min. The reaction mixture was warmed to RT over 2 h before concentrated to dryness. Diluted with EtOAc (30 mL) and washed organics with satd. aqueous NaHCO3 (2 × 50 mL), dried over anhydrous Na2SO4, and concentrated to yield (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1—((S)—piperidin-3-ylmethyl)piperidine as an oil (0.8 g, 92%). 1H NMR (400 MHz, CDCl3) δ 7.85 (bs, 1H), 7.39-7.27 (m, 20H), 4.85 (d, J= 11.0 Hz, 1H), 4.81 (d, J= 10.9 Hz, 1H), 4.72-4.61 (m, 4H), 4.56-4.45 (m, 2H), 3.85 (dd, J= 10.3, 7.6 Hz, 1H), 3.70 (dd, J= 10.3, 2.6 Hz, 1H), 3.63 (dd, J = 9.2, 5.7 Hz, 1H), 3.57-3.46 (m, 2H), 3.42 (dd, J = 12.7, 3.7 Hz, 1H), 3.34-3.21 (m, 2H), 2.92 (dd, J= 11.9, 5.3 Hz, 1H), 2.72 (ddt, J= 16.3, 11.7, 5.2 Hz, 1H), 2.65-2.49 (m, 3H), 2.41 (dd, J= 13.1, 10.6 Hz, 1H), 2.05-1.93 (m, 1H), 1.83-1.69 (m, 3H), 1.11-0.96 (m, 1H); ESI MS m/z 621.362 [M + H]+.
To a solution of the above material (0.155 g, 0.25 mmol) and 2-chloro-3-(trifluoromethyl)pyridine (0.09 g, 0.5 mmol) in dry DMF (6 mL) was added K2CO3 (0.1 g, 0.75 mmol) and the reaction mixture was heated at 120° C. overnight. The reaction mixture was partitioned between EtOAc (50 mL) and water, organics were separated, and dried over anhydrous Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 2:8) affording 3-(trifluoromethyl)-2—((R)—3-(((2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidin-1-yl)methyl)piperidin-1-yl)pyridine as an oil (0.1 g, 52.2%). 1H NMR (400 MHz, CDCl3) δ 8.42 (dd, J= 4.8, 1.8 Hz, 1H), 7.85 (dd, J= 7.8, 2.0 Hz, 1H), 7.37-7.27 (m, 20H), 6.95 (dd, J= 7.8, 4.7 Hz, 1H), 4.85 (d, J= 10.9 Hz, 1H), 4.81 (d, J= 10.9 Hz, 1H), 4.73 (d, J= 11.4 Hz, 1H), 4.69-4.59 (m, 3H), 4.56-4.47 (m, 2H), 3.85 (dd, J= 10.1, 6.8 Hz, 1H), 3.77-3.63 (m, 3H), 3.62-3.45 (m, 3H), 3.25 (td, J= 6.4, 2.5 Hz, 1H), 3.02-2.87 (m, 2H), 2.65-2.54 (m, 2H), 2.54-2.45 (m, 2H), 1.90 (q, J= 5.3 Hz, 1H), 1.84-1.58 (m, 3H), 1.14-1.01 (m, 1H); ESI MS m/z 766.378 [M + H]+.
At -78° C., under Ar, to a solution of the above material (0.1 g, 0.13 mmol) in DCM (6 ml) was added BCl3 (1.0 M in DCM, 0.65 mL, 0.65 mmol), and the mixture was stirred for 3 h while the bath temperature reached 0° C. The mixture was then cooled at -78° C., and MeOH (3 mL) was added carefully. After stirring at RT for 30 min the mixture was concentrated under reduced pressure. The resulting residue was neutralized with 1 M NH3 in MeOH solution (2 × 5 mL) and concentrated again under reduced pressure. The residue was purified on silica gel by flash chromatography (MeOH/DCM, 1:9) yielding (2S,3R,4R,5S)-2-(hydroxymethyl)-1—(((R)—1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol (0.033 g, 62%) as a white solid. 1H NMR (400 MHz, CD3OD) δ 8.43 (dd, J= 4.9, 1.8 Hz, 1H), 7.98 (dd, J = 7.8, 1.9 Hz, 1H), 7.13-7.07 (m, 1H), 3.89-3.82 (m, 2H), 3.74-3.69 (m, 1H), 3.66 (dd, J = 9.4, 5.6 Hz, 1H), 3.53-3.46 (m, 2H), 3.37 (d, J = 1.9 Hz, 1H), 2.99-2.92 (m, 2H), 2.80 (dd, J= 12.2, 5.4 Hz, 1H), 2.68 (dd, J= 13.2, 5.3 Hz, 1H), 2.63-2.50 (m, 3H), 1.93 (dt, J = 9.6, 4.8 Hz, 1H), 1.88-1.76 (m, 2H), 1.76-1.63 (m, 1H), 1.21-1.10 (m, 1H); ESI MS m/z 406.189 [M + H]+.
(2S,3R,4R,5S)-2-(hydroxymethyl)-1—(((R)—1-(4-(trifluoromethyl)thiazol-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol
To a stirred solution of (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1—((S)—piperidin-3-ylmethyl)piperidine (0.16 g, 0.25 mmol) and 2-bromo-4-(trifluoromethyl) thiazole (0.11 g, 0.50 mmol) in DMA (5 mL) was added Cs2CO3 (0.24 g, 0.75 mmol) under Ar. The mixture was stirred at 80° C. for 18 h, and then water was added at 0° C. The mixture was extracted with EtOAc (2 × 20 mL). The combined organic layer was washed with water (2 × 20 mL), separated, and dried over Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography affording 4-(trifluoromethyl)-2—((R)—3-(((2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy) methyl)piperidin-1-yl)methyl)piperidin-1-yl)thiazole as an oil (0.11 g, 59.5%). 1H NMR (400 MHz, CDCl3) δ 7.41-7.27 (m, 20H), 6.89 (d, J= 1.2 Hz, 1H), 4.89 (d, J= 10.8 Hz, 1H), 4.84 (d, J= 10.8 Hz, 1H), 4.75 (d, J= 11.5 Hz, 1H), 4.72-4.63 (m, 3H), 4.58-4.50 (m, 2H), 3.96 (dt, J= 13.2, 4.2 Hz, 1H), 3.87 (dd, J= 10.2, 7.2 Hz, 1H), 3.81-3.69 (m, 3H), 3.66-3.59 (m, 1H), 3.54 (q, J = 9.9, 9.1 Hz, 1H), 3.31-3.24 (m, 1H), 3.23-3.12 (m, 1H), 2.89-2.74 (m, 2H), 2.68-2.52 (m, 3H), 1.81-1.71 (m, 3H), 1.61 (qd, J= 10.6, 10.0, 4.6 Hz, 1H), 1.18 (q, J= 10.7 Hz, 1H); ESI MS m/z 772.331 [M + H]+.
At -78° C., under Ar, to a solution of the above material (0.11 g, 0.14 mmol) in DCM (8 ml) was added BCl3 (1.0 M in DCM, 1.1 mL, 1.1 mmol), and the mixture was stirred for 3 h while the bath temperature reached 0° C. The mixture was then cooled at -78° C., and MeOH (3 mL) was added carefully. After stirring at RT for 30 min the mixture was concentrated under reduced pressure. The resulting residue was neutralized with 1 M NH3 in MeOH solution (2 × 5 mL) and concentrated again under reduced pressure. The residue was purified on silica gel by flash chromatography (MeOH/DCM, 1:9), affording (2S,3R,4R,5S)-2-(hydroxymethyl)-1—(((R)—1-(4-(trifluoromethyl)thiazol-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol (0.049 g, 85%) as a white solid. 1H NMR (400 MHz, CD3OD) δ 7.17 (s, 1H), 3.94-3.85 (m, 4H), 3.74 (dd, J = 9.4, 5.6 Hz, 1H), 3.54 (ddd, J= 10.2, 8.6, 5.2 Hz, 1H), 3.36 (d, J = 9.0 Hz, 1H), 3.20 (ddd, J = 13.4, 10.6, 3.4 Hz, 1H), 3.02 (p, J= 6.1 Hz, 1H), 2.95 (dd, J= 13.0, 9.3 Hz, 1H), 2.79 (dd, J= 12.4, 5.2 Hz, 1H), 2.74-2.55 (m, 3H), 1.94-1.75 (m, 3H), 1.70-1.58 (m, 1H), 1.30-1.22 (m, 1H); ESI MS m/z 412.144 [M + H]+.
(2S,3R,4R,5S)-2-(hydroxymethyl)-1—(((S)—1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol
To a solution of (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (0.91 g, 1.7 mmol) in DCM (30 mL) was added (R)-tert-butyl 3-formylpiperidine-1-carboxylate (0.54 g, 2.5 mmol) and HOAc (0.5 mL). After stirring at RT for 10 min, NaBH(OAc)3 (0.6 g, 2.9 mmol) was added and the mixture was stirred at RT overnight. The reaction mixture was concentrated before diluting with DCM (25 mL). Organics were washed with satd. aqueous NaHCO3, brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 3:7) affording (S)-tert-butyl 3-(((2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl) piperidin-1-yl)methyl)piperidine-1-carboxylate as an oil (1.0 g, 81%). 1H NMR (400 MHz, CDCl3) δ 7.38-7.27 (m, 20H), 4.88 (d, J= 11.0 Hz, 1H), 4.83 (d, J= 11.0 Hz, 1H), 4.77-4.67 (m, 3H), 4.65 (d, J= 11.5 Hz, 1H), 4.57-4.47 (m, 2H), 3.99-3.89 (m, 2H), 3.85 (dd, J= 10.1, 6.9 Hz, 1H), 3.73 (dd, J= 11.1, 3.6 Hz, 2H), 3.70 (d, J= 8.7 Hz, 1H), 3.60-3.48 (m, 2H), 3.37 (tt, J= 6.4, 2.3 Hz, 1H), 2.90-2.73 (m, 2H), 2.65-2.52 (m, 2H), 2.52-2.35 (m, 1H), 1.80-1.72 (bs, 1H), 1.68-1.58 (m, 2H), 1.48 (s, 9H), 1.45-1.34 (m, 1H),1.02 (q, J= 11.2 Hz, 1H); ESI MS m/z 721.417 [M + H]+.
The above material (1.0 g, 1.4 mmol) was taken up in 3:7 TFA:DCM (16 mL) solution at 0° C. and stirred for 30 min. The reaction mixture was warmed to RT over 2 h before concentrated to dryness. Diluted with EtOAc (30 mL) and washed organics with satd. NaHCO3 (2 × 50 mL), dried over anhydrous Na2SO4, and concentrated to yield (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1—((R)—piperidin-3-ylmethyl) piperidine as an oil (0.85 g, 93%). 1H NMR (400 MHz, CDCl3) δ 7.89 (bs, 1H), 7.38-7.26 (m, 20H), 4.86-4.75 (m, 2H), 4.69 (d, J= 6.8 Hz, 1H), 4.68-4.59 (m, 3H), 4.51 (d, J= 12.1 Hz, 1H), 4.46 (d, J= 12.1 Hz, 1H), 3.83 (dd, J= 10.3, 7.3 Hz, 1H), 3.72-3.66 (m, 1H), 3.62 (dd, J= 9.1, 5.6 Hz, 1H), 3.55-3.41 (m, 2H), 3.34-3.26 (m, 3H), 2.80-2.50 (m, 4H), 2.48-2.34 (m, 2H), 2.07-1.99 (m, 1H), 1.86-1.65 (m, 3H), 0.99 (q, J= 11.0 Hz, 1H); ESI MS m/z 621.368 [M + H]+.
To a solution of the above material (0.18 g, 0.29 mmol) and 2-chloro-3-(trifluoromethyl)pyridine (0.10 g, 0.58 mmol) in dry DMF (6 mL) was added K2CO3 (0.12 g, 0.87 mmol) and the reaction mixture was heated at 120° C. overnight. The reaction mixture was partitioned between EtOAc (50 mL) and water, organics were separated, and dried over anhydrous Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 2:8) affording 3-(trifluoromethyl)-2—((S)—3-(((2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy) methyl)piperidin-1-yl)methyl)piperidin-1-yl)pyridine as an oil (0.1 g, 46.8%). 1H NMR (400 MHz, CDCl3) δ 8.41 (dd, J= 4.8, 1.8 Hz, 1H), 7.84 (dd, J= 7.8, 1.9 Hz, 1H), 7.38-7.27 (m, 20H), 6.94 (dd, J= 7.8, 4.7 Hz, 1H), 4.86 (d, J= 10.9 Hz, 1H), 4.80 (d, J= 10.9 Hz, 1H), 4.74-4.60 (m, 4H), 4.54 (d, J= 12.1 Hz, 1H), 4.48 (d, J= 12.2 Hz, 1H), 3.85 (dd, J= 10.2, 6.7 Hz, 1H), 3.73 (dd, J= 10.2, 2.4 Hz, 1H), 3.68 (dd, J= 9.3, 5.8 Hz, 1H), 3.65-3.60 (m, 1H), 3.58-3.43 (m, 4H), 2.95-2.86 (m, 1H), 2.81-2.73 (m, 2H), 2.63-2.46 (m, 2H), 2.33 (dd, J = 12.7, 8.6 Hz, 1 H), 1.97 (bs, 1H), 1.81-1.56 (m, 3H), 1.10-0.97 (m, 1H); ESI MS m/z 766.37 [M + H]+.
At -78° C., under Ar, to a solution of the above material (0.1 g, 0.13 mmol) in DCM (6 ml) was added BCl3 (1.0 M in DCM, 1.0 mL, 1.0 mmol), and the mixture was stirred for 3 h while the bath temperature reached 0° C. The mixture was then cooled at -78° C., and MeOH (3 mL) was added carefully. After stirring at RT for 30 min the mixture was concentrated under reduced pressure. The resulting residue was neutralized with 1 M NH3 in MeOH solution (2 × 5 mL) and concentrated again under reduced pressure. The residue was purified on silica gel by flash chromatography (MeOH/DCM, 1:9) yielding (2S,3R,4R,5S)-2-(hydroxymethyl)-1—(((S)—1-(3-(trifluoromethyl)pyridin-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol as a white solid (0.03 g, 62%). 1H NMR (400 MHz, CD3OD) δ 8.44 (dd, J= 5.0, 1.8 Hz, 1H), 7.98 (dd, J = 7.8, 1.9 Hz, 1H), 7.14-7.07 (m, 1H), 3.92-3.80 (m, 2H), 3.70 (dd, J = 9.3, 5.1 Hz, 1H), 3.64 (dt, J= 12.6, 2.2 Hz, 1H), 3.57-3.43 (m, 2H), 3.38 (t, J= 8.7 Hz, 1H), 3.13-3.06(m, 1H), 2.96 (t, J= 11.5 Hz, 1H), 2.82 (dd, J= 13.0, 5.4 Hz, 1H).2.78-2.43 (m, 4H), 2.08-1.98 (m, 1H),1.94-1.84 (m, 1H), 1.83-1.76 (m, 1H), 1.76-1.63 (m, 1H), 1.23-1.12 (m, 1H); ESI MS m/z 406.194 [M + H]+.
(2S,3R,4R,5S)-2-(hydroxymethyl)-1—(((S)—1-(4-(trifluoromethyl)thiazol-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol
To a stirred solution of (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-((R)-piperidin-3-ylmethyl)piperidine (0.15 g, 0.24 mmol) and 2-bromo-4-(trifluoromethyl) thiazole (0.11 g, 0.48 mmol) in DMA (5 mL) was added Cs2CO3 (0.23 g, 0.72 mmol) under Ar. The mixture was stirred at 80° C. for 18 h, and then water was added at 0° C. The mixture was extracted with EtOAc (2 × 20 mL). The combined organic layer was washed with water (2 × 20 mL), separated, and dried over Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography affording 4-(trifluoromethyl)-2—((S)—3-(((2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidin-1-yl)methyl)piperidin-1-yl)thiazole as an oil (0.12 g, 64.7%). 1H NMR (400 MHz, CDCl3) δ 7.43-7.27 (m, 20H), 6.90 (s, 1H), 4.90 (d, J = 10.9 Hz, 1H), 4.84 (d, J= 10.9 Hz, 1H), 4.78-4.64 (m, 4H), 4.55 (d, J= 12.2 Hz, 1H), 4.51 (d, J = 12.1 Hz, 1H), 3.96-3.80 (m, 3H), 3.78-3.71 (m, 2H), 3.61 (ddd, J = 10.2, 8.7, 5.6 Hz, 1H), 3.51 (t, J= 9.2 Hz, 1H), 3.44-3.38 (m, 1H), 3.14 (ddd, J= 13.7, 11.1, 3.1 Hz, 1H), 2.82-2.74 (m, 3H), 2.65 (dd, J= 11.9, 10.3 Hz, 1H), 2.40 (dd, J= 12.8, 8.3 Hz, 1H), 1.93-1.82 (m, 1H), 1.83-1.69 (m, 2H), 1.66-1.54 (m, 1H), 1.14 (ddd, J= 18.1, 10.2, 5.8 Hz, 1H); ESI MS m/z 772.329 [M + H]+.
At -78° C., under Ar, to a solution of the above material (0.12 g, 0.15 mmol) in DCM (8 ml) was added BCl3 (1.0 M in DCM, 1.3 mL, 1.3 mmol), and the mixture was stirred for 3 h while the bath temperature reached 0° C. The mixture was then cooled at -78° C., and MeOH (3 mL) was added carefully. After stirring at RT for 30 min the mixture was concentrated under reduced pressure. The resulting residue was neutralized with 1 M NH3 in MeOH solution (2 × 5 mL) and concentrated again under reduced pressure. The residue was purified on silica gel by flash chromatography (MeOH/DCM, 1:9), affording (2S,3R,4R,5S)-2-(hydroxymethyl)-1—(((S)—1-(4-(trifluoromethyl)thiazol-2-yl)piperidin-3-yl)methyl)piperidine-3,4,5-triol (0.056 g, 90%) as a white solid. 1H NMR (400 MHz, CD3OD) δ 7.18 (s, 1H), 3.97-3.89 (m, 2H), 3.88-3.85 (m, 2H), 3.72 (dd, J= 9.1, 5.3 Hz, 1H), 3.56 (ddd, J = 9.3, 8.2, 5.5 Hz, 1H), 3.37 (t, J = 8.7 Hz, 1H), 3.16 (ddd, J = 12.9, 11.0, 3.3 Hz, 1H), 3.05 (q, J= 5.7 Hz, 1H), 2.89 (dd, J= 13.0, 9.8 Hz, 1H), 2.82-2.75 (m, 1H), 2.74-2.64 (m, 2H), 2.56 (dd, J = 13.0, 8.4 Hz, 1H), 1.99-1.85 (m, 2H), 1.80 (dt, J = 13.3, 3.9 Hz, 1H), 1.70-1.58 (m, 1H), 1.30-1.21 (m, 1H); ESI MS m/z 412.154 [M + H]+.
(2S,3R,4R,5S)-1-(((1s,4R)-4-(difluoromethyl)cyclohexyl)methyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Under Ar to a solution of cyclohexane-1,4-diyldimethanol (2.00 g, 13.9 mmol) in anhydrous DCM (60 mL) cooled at 0° C. was added DIPEA (2.06 g, 16.0 mmol) and benzoyl chloride (1.97 g, 14.0 mmol). The mixture was stirred at RT for 16 h, and then diluted with satd. aqueous NaHCO3 (50 mL). After extraction with DCM (3 × 30 mL) the combined extract was dried over anhydrous Na2SO4. After filtration the solvent was evaporated under vacuum, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:3 to 1:2) to give (4-(hydroxymethyl)cyclohexyl)methyl benzoate as a pale-yellow oil (1.51 g, 43%).
A mixture of the above material (0.950 g, 3.83 mmol) and DMP (2.12 g, 5.0 mmol) in DCM (30 mL) was stirred at RT for 1 h, forming a white suspension. Hexanes (40 mL) was added, and the suspension was filtered through a Celite cake. The filtrate was collected and concentrated under vacuum, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:4), affording (4-formylcyclohexyl)methyl benzoate as a colorless oil (0.50 g, 53%).
Under Ar to a solution of the above material (0.50 g, 2.0 mmol) in anhydrous DCM (10 mL) cooled at -78° C. was added DAST (0.80 g, 5.0 mmol), and the mixture was stirred at -78° C. for 30 min and then at RT for 5 h. The mixture was cooled at -78° C. and quenched with satd. aqueous NaHCO3 (20 mL). The organic layer was collected, and the aqueous was extracted with DCM (3 × 20 mL). The combined extract was dried over anhydrous Na2SO4. After filtration the solvent was evaporated under vacuum, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:10), affording (4-(difluoromethyl)cyclohexyl)methyl benzoate as a colorless oil (0.40 g, 75%).
A mixture of the above material (0.40 g, 1.5 mmol) and K2CO3 (0.45 g, 0.33 mmol) in MeOH (25 mL) was stirred for 16 h. The solvent was removed under vacuum, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:2), affording (4-(difluoromethyl)cyclohexyl)methanol as a clear liquid (0.21 g, 86%).
To solution of the above material (0.21 g, 1.3 mmol) in acetone (25 mL) cooled at 0° C. was added a solution of CrO3 (0.60 g. 6.0 mmol) in 2.0 M aqueous H2SO4 (6 mL) precooled at 0° C. The mixture was stirred at 0° C. for 1 h, and at RT for 16 h. Then isopropanol (5 mL) was added, and the mixture was stirred for another 1 h. After concentration under vacuum the mixture was diluted with water (50 mL) and extracted with DCM (3 × 20 mL). The combined extract was dried over anhydrous Na2SO4. After filtration the solvent was evaporated under vacuum, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:1 to 3:1), affording 4-(difluoromethyl)cyclohexanecarboxylic acid as a white solid (0.22 g, 96%). 1H NMR indicated the solid contains a mixture of cis and trans isomers in a ratio of cis:trans = 0.32:0.68).
A mixture of 4-(difluoromethyl)cyclohexanecarboxylic acid (0.050 g, 0.28 mmol), (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (0.147 g, 0.281 mmol) (Lahav et al. JAm Chem Soc 2017, 139, 14192 -14197), HATU (0.20 g, 0.53 mmol) and DIPEA (0.11 g, 0.85 mmol) in DMF (5 mL) was stirred at RT for 16 h. The mixture was diluted with satd. aqueous NaHCO3 (20 mL) and extracted with EtOAc (3 × 15 mL). The combined extract was washed with brine (2 × 20 mL) and dried over anhydrous Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified and separated on silica gel by flash chromatography (EtOAc/hexanes, 1:5 to 1:3), affording ((1r,4S)-4-(difluoromethyl)cyclohexyl)((2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidin-1-yl)methanone (0.13 g, 68%) and ((1s,4R)-4-(difluoromethyl)cyclohexyl)((2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidin-1-yl)methanone (0.055 g, 29%), both as white solids. ESI MS m/z 684.352 [M + H]+.
Under Ar to a solution of ((1r,4R)-4-(difluoromethyl)cyclohexyl)((2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidin-1-yl)methanone (0.14 g, 0.20 mmol) in anhydrous Et2O (10 mL) cooled at 0° C. was added LAH (0.050 g, 1.3 mmol), and the mixture was stirred at 0° C. for 4 h. The reaction was then quenched with water and diluted with satd. aqueous NaHCO3 (20 mL). After extraction with Et2O (3 × 30 mL) the combined extract was dried over anhydrous Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:12 to 1:7) to give (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-(((1s,4R)-4-(difluoromethyl)cyclohexyl)methyl)piperidine as a colorless oil (0.10 g, 73%). ESI MS m/z 670.372 [M + H]+.
A mixture of the above material (0.10 g, 0.15 mmol), Pd(OH)2/C (20% Pd in weight, 0.050 g, 0.094 mmol) and 2 drops of conc. HCl in MeOH (15 mL) was stirred under hydrogen (1 atm.) overnight. The mixture was filtered through a Celite cake, and the filtrate was collected and concentrated to dryness. The residue was neutralized with 1 M NH3 in MeOH and purified on silica gel by flash chromatography (0.5 M NH3 MeOH/DCM, 1:5), affording (2S,3R,4R,5S)-1-(((1s,4R)-4-(difluoromethyl)cyclohexyl)methyl)-2-(hydroxymethyl)piperidine-3,4,5-triol (0.033 g, 72%) as a white solid. 1H NMR (500 MHz, CD3OD) δ 5.75 (td, J= 57.1, 5.3 Hz, 1H), 3.90-3.79 (m, 2H), 3.70 (dd, J= 9.3, 5.5 Hz, 1H), 3.55-3.48 (m, 1H), 3.39-3.33 (m, 1H), 3.04-2.99 (m, 1H), 2.78-2.70 (m, 2H), 2.65-2.57 (m, 2H), 1.90-1.76 (m, 2H), 1.64-1.46 (m, 8H); ESI MS m/z 310.184 [M + H]+.
(2S,3R,4R,5S)-1-(((1r,4S)-4-(difluoromethyl)cyclohexyl)methyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Under Ar to a solution of ((1r,4S)-4-(difluoromethyl)cyclohexyl)((2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidin-1-yl)methanone (0.25 g, 0.37 mmol) in anhydrous THF (10 mL) cooled at 0° C. was added LAH (0.050 g, 1.3 mmol), and the mixture was stirred at 0° C. for 4 h. The reaction was then quenched with water and diluted with satd. aqueous NaHCO3 (20 mL). After extraction with Et2O (3 × 30 mL) the combined extract was dried over anhydrous Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:12 to 1:7) to give (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-(((1r,4S)-4-(difluoromethyl)cyclohexyl)methyl)piperidine as a colorless oil (0.075 g, 30%). ESI MS m/z 670.377 [M + H]+.
A mixture of the above material (0.075 g, 0.11 mmol), Pd(OH)2/C (20% Pd in weight, 0.050 g, 0.094 mmol) and 2 drops of conc. HCl in MeOH (20 mL) was stirred under hydrogen (1 atm.) overnight. The mixture was filtered through a Celite cake, and the filtrate was collected and concentrated to dryness. The residue was neutralized with 1 M NH3 in MeOH and purified on silica gel by flash chromatography (0.5 M NH3 MeOH/DCM, 1:5), affording (2S,3R,4R,5S)-1-(((1r,4S)-4-(difluoromethyl)cyclohexyl)methyl)-2-(hydroxymethyl)piperidine-3,4,5-triol (0.021 g, 60%) as a white solid. 1H NMR (400 MHz, CD3OD) δ 5.71 (td, J = 57.1, 4.5 Hz, 1H), 3.89-3.77 (m, 2H), 3.70 (dd, J = 9.2, 5.4 Hz, 1H), 3.56-3.48 (m, 1H), 3.40-3.33 (m, 1H), 3.03-2.96 (m, 1H), 2.73 (dd, J= 12.4, 5.4 Hz, 1H), 2.65-2.46 (m, 3H), 2.00-1.81 (m, 4H), 1.80-1.62 (m, 1H), 1.55-1.41 (m, 1H), 1.26-1.10 (m, 2H), 1.00-0.82 (m, 2H); ESI MS m/z 310.183 [M + H]+.
(2S,3R,4R,SS)-1-(((1s,4R)-4-(1,1-difluoroethyl)cyclohexyl)methyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
To a solution of cis/trans-4-(hydroxymethyl)cyclohexanecarboxylic acid (3.20 g, 20.2 mmol) in anhydrous MeOH (50 mL) was added SOCl2 (4.8 g, 40 mmol) dropwise, and the mixture was stirred at RT for 4 h. The solvent was then removed under vacuum, and the residue was diluted with satd. aqueous NaHCO3 (40 mL). After extraction with DCM (3 × 40 mL) the combined extract was dried over anhydrous Na2SO4. After filtration the solvent was evaporated under vacuum to give a clear liquid. The liquid was dissolved in anhydrous DMF (30 mL) and cooled at 0° C., and imidazole (2.72 g, 40.0 mmol) and TBDMSCl (4.52 g, 30.0 mmol) was then added. After stirred at RT for 16 h the mixture was diluted with brine (100 mL) and extracted with EtOAc (3 × 40 mL). The combined extract was washed with brine (2 × 100 mL) and dried over anhydrous Na2SO4. After filtration the solvent was evaporated under vacuum, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:9), affording a colorless oil. Under Ar the oil was dissolved in anhydrous THF 50 mL), and the solution was cooled at 0° C. LAH (1.00 g, 26.3 mmol) was added portion-wise, and the mixture was stirred at 0° C. for 1 h. Wet sodium sulfate heptahydrate (50 g) was added to quench the reaction, and the suspension was stirred for 30 min. After filtration the solvent was evaporated under vacuum, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:4 to 1:2) to give a mixture of cis and trans-(4-(((tert-butyldimethylsilyl)oxy)methyl)cyclohexyl)methanol as a colorless oil (4.6 g, 88%, 3 steps).
Under Ar to a solution of DMSO (1.95 g, 25.0 mmol) in anhydrous DCM (80 mL) cooled at -78° C. was added a solution of oxalyl chloride (1.93 g, 15.0 mmol) in anhydrous DCM (20 mL). After addition the mixture was stirred -78° C. for 1 h, and a solution of the above material (2.58 g, 10.0 mmol) in anhydrous DCM (20 mL) was added. After the mixture was stirred at -78° C. for 1 h Et3N (5.4 mL, 40 mmol) was added, and the mixture was stirred at -78° C. for 30 min, and then at RT for 30 min. The mixture was then diluted with satd. aqueous NaHCO3 (50 mL) and the organic layer was collected. The aqueous layer was extracted with DCM (50 mL) and the combined organic extract was dried over anhydrous Na2SO4. After filtration the solvent was evaporated under vacuum, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:9), affording 4-(((tertbutyldimethylsilyl)oxy)methyl)-cyclohexanecarbaldehyde as a colorless oil (2.30 g, 90%).
Under Ar to a solution of the above material (2.30 g, 9.00 mmol) in anhydrous THF (40 mL) cooled 0° C. was added MeMgCl (3.0 M in THF, 4.0 mL, 12 mmol), and the mixture was stirred at RT for 16 h. The mixture was quenched with icy water, diluted with satd. aqueous NH4Cl (30 mL), and extracted with EtOAc (2 × 50 mL). The combined extract was dried over anhydrous Na2SO4. After filtration the solvent was evaporated under vacuum, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:4), affording 1-(4-(((tert-butyldimethylsilyl)oxy)methyl)cyclohexyl)ethanol as a colorless oil (2.40 g, 98%).
A mixture of the above material (2.40 g, 8.80 mmol) and DMP (5.60 g, 13.2 mmol) in DCM (50 mL) was stirred at RT for 3 h, forming a white suspension. Hexanes (50 mL) was added, and the suspension was filtered through a Celite cake. The filtrate was collected and concentrated under vacuum, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:15 to 1:6), affording 1-(4-(((tertbutyldimethylsilyl)oxy)methyl)cyclohexyl)ethanone as a colorless oil (2.11 g, 89%).
Under Ar to a solution of the above material (2.11 g, 7.8 mmol) in anhydrous THF (30 mL) cooled at 0° C. was added TBAF (1.0 M in THF, 10.0 mL, 10.0 mmol), and the mixture was stirred at RT for 3 h. After diluted with satd. aqueous NaHCO3 (40 mL) the mixture was extracted with EtOAc (2 × 30 mL), and the combined extract was dried over anhydrous Na2SO4. After filtration the solvent was evaporated under vacuum, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 2:3 to 1:1), affording 1-(4-(hydroxymethyl)cyclohexyl)ethanone as a clear liquid (1.10 g, 92%).
Under Ar to a solution of the above material (1.10 g, 7.20 mmol) in anhydrous DCM (25 mL) cooled at 0° C. was added DMAP (0.25 g, 2.0 mmol), DIPEA (1.93 g, 15.0 mmol) and benzoyl chloride (1.40 g, 10.0 mmol). The mixture was stirred at RT for 16 h, and diluted with satd. aqueous NaHCO3 (30 mL). After extraction with DCM (3 × 30 mL) the combined extract was dried over anhydrous Na2SO4. After filtration the solvent was evaporated under vacuum, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:6 to 1:3) to give (4-acetylcyclohexyl)methyl benzoate as a pale-yellow oil (1.85 g, 99%).
Under Ar to a solution of the above material (1.70 g, 6.53 mmol) in anhydrous DCM (15 mL) was added DAST (5.74 g, 35.9 mmol), and the mixture was stirred at RT for 1 h, and then heated at reflux for 4 days. The mixture was cooled at -78° C., and quenched with satd. aqueous NaHCO3 (50 mL). After extracted with DCM (2 × 50 mL) the combined extract was dried over anhydrous Na2SO4. After filtration the solvent was evaporated under vacuum, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:11 to 1:9), affording (4-(1,1-difluoroethyl)cyclohexyl)methyl benzoate as a pale-yellow oil (1.45 g, 79%).
A mixture of the above material (1.45 g, 5.13 mmol) and K2CO3 (1.5 g, 11 mmol) in MeOH (40 mL) was stirred for 16 h. The solvent was removed under vacuum, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:4 to 1:2), affording (4-(1,1-difluoroethyl)cyclohexyl)methanol as a clear liquid (0.85 g, 93%).
To solution of the above material (0.85 g, 4.8 mmol) in acetone (40 mL) cooled at 0° C. was added a solution of CrO3 (1.5 g, 15 mmol) in 2.0 M aqueous H2SO4 (10 mL) precooled at 0° C. The mixture was stirred at 0° C. for 1 h, and at RT for 16 h. Then isopropanol (5 mL) was added, and the mixture was stirred for another 1 h. After concentration under vacuum the mixture was diluted with water (50 mL) and extracted with DCM (3 × 30 mL). The combined extract was dried over anhydrous Na2SO4. After filtration the solvent was evaporated under vacuum, affording 4-(1,1-difluoroethyl)cyclohexanecarboxylic acid as a white solid (0.90 g, 98%). 1H NMR indicated the solid contained a mixture of cis and trans isomers in a ratio of cis:trans = 0.35:0.65).
A mixture of 4-(1,1-difluoroethyl)cyclohexanecarboxylic acid (0.192 g, 1.00 mmol) and (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidine (0.340 g, 0.649 mmol), HATU (0.46 g, 1.2 mmol) and DIPEA (0.19 g, 1.5 mmol) in DMF (10 mL) was stirred at RT for 16 h. The mixture was diluted with satd. aqueous NaHCO3 (20 mL) and extracted with EtOAc (3 × 20 mL). The combined extract was washed with brine (2 × 20 mL) and dried over anhydrous Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified and separated on silica gel by flash chromatography (EtOAc/hexanes, 1:6 to 1:4), affording ((1r,4S)-4-(1,1-difluoroethyl)cyclohexyl)((2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidin-1-yl)methanone (0.28 g, 62%) and ((1 s,4R)-4-(1,1-difluoroethyl)cyclohexyl)((2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidin-1-yl)methanone (0.13 g, 29%), both as white solids.
Under Ar to a solution of ((1s,4R)-4-(1,1-difluoroethyl)cyclohexyl)((2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidin-1-yl)methanone (0.13 g, 0.19 mmol) in anhydrous Et2O (15 mL) cooled at 0° C. was added LAH (0.050 g, 1.3 mmol), and the mixture was stirred at 0° C. for 4 h. The reaction was then quenched with water and diluted with satd. aqueous NaHCO3 (20 mL). After extraction with Et2O (3 × 20 mL) the combined extract was dried over anhydrous Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:12 to 1:7) to give (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-(((1s,4R)-4-(1,1-difluoroethyl)cyclohexyl)methyl)piperidine as a colorless oil (0.099 g, 76%). ESI MS m/z 684.385 [M + H]+.
A mixture of the above material (0.099 g, 0.14 mmol), Pd(OH)2/C (20% Pd in weight, 0.050 g, 0.094 mmol) and 2 drops of conc. HCl in MeOH (20 mL) was stirred under hydrogen (1 atm.) overnight. The mixture was filtered through a Celite cake, and the filtrate was collected and concentrated to dryness. The residue was neutralized with 1 M NH3 in MeOH and purified on silica gel by flash chromatography (0.5 M NH3 MeOH/DCM, 1:5), affording (2S,3R,4R,SS)-1-(((1s,4R)-4-(1,1-difluoroethyl)cyclohexyl)methyl)-2-(hydroxymethyl)piperidine-3,4,5-triol (0.034 g, 72%) as a white solid. 1H NMR (400 MHz, DMSO-d6) 4.74 (d, J= 4.6 Hz, 1H), 4.65 (d, J= 4.2 Hz, 1H), 4.61 (d, J= 5.1 Hz, 1H), 4.10 (t, J= 5.3 Hz, 1H), 3.69-3.58 (m, 2H), 3.47-3.38 (m, 1H), 3.31-3.22 (m, 1H), 3.14-3.04 (m, 1H), 2.86-2.75 (m, 1H), 2.65 (dd, J= 13.0, 8.3 Hz, 1H), 2.58-2.38 (m, 3H), 1.85-1.47 (m, 9H), 1.47-1.32 (m, 2H), 1.30-1.18 (m, 2H); ESI MS m/z 324.199 [M + H]+.
(2S,3R,4R,SS)-1-(((1r,4S)-4-(1,1-difluoroethyl)cyclohexyl)methyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
Under Ar to a solution of ((1r,4S)-4-(1,1-difluoroethyl)cyclohexyl)((2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)piperidin-1-yl)methanone (0.27 g, 0.39 mmol) in anhydrous Et2O (20 mL) cooled at 0° C. was added LAH (0.080 g, 2.1 mmol), and the mixture was stirred at 0° C. for 4 h. The reaction was then quenched with water and diluted with satd. aqueous NaHCO3 (20 mL). After extraction with Et2O (3 × 30 mL) the combined extract was dried over anhydrous Na2SO4. After filtration the solvent was evaporated under reduced pressure, and the residue was purified on silica gel by flash chromatography (EtOAc/hexanes, 1:12 to 1:7) to give (2S,3R,4R,5S)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-1-(((1r,4S)-4-(1,1-difluoroethyl)cyclohexyl)methyl)piperidine as a colorless oil (0.23 g, 86%). ESI MS m/z 684.381 [M + H]+.
A mixture of the abover material (0.23 g, 0.34 mmol), Pd(OH)2/C (20% Pd in weight, 0.080 g, 0.15 mmol) and 3 drops of conc. HCl in MeOH (25 mL) was stirred under hydrogen (1 atm.) overnight. The mixture was filtered through Celite, and the filtrate was collected and concentrated to dryness. The residue was neutralized with 1 M NH3 in MeOH and purified on silica gel by flash chromatography (0.5 M NH3 MeOH/DCM, 1:5), affording (2S,3R,4R,5S)-1-(((1r,4S)-4-(1,1-difluoroethyl)cyclohexyl)methyl)-2-(hydroxymethyl)-piperidine-3,4,5-triol (0.092 g, 85%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 4.74 (d, J= 4.6 Hz, 1H), 4.64 (d, J= 4.2 Hz, 1H), 4.60 (d, J= 5.0 Hz, 1H), 4.09 (t, J= 5.1 Hz, 1H), 3.67-3.58 (m, 2H). 3.42 (dt, J = 9.6, 5.1 Hz, 1H), 3.29-3.20 (m, 1H), 3.12-3.03 (m, 1H), 2.82-2.74 (m, 1H), 2.57-2.33 (m, 4H), 1.90-1.64 (m, 5H), 1.54 (t, J= 19.4 Hz, 3H), 1.45-1.30 (m, 1H), 1.19-1.04 (m, 2H), 0.89-0.74 (m, 2H); ESI MS m/z 324.198 [M + H]+.
Examples 33-310, as indicated in Table 1, are synthesized according to procedures analogous to the schemes and examples outlined herein.
Stable GBA2-expressing HEK293T cells were generated as follows. The PCR-amplified human GBA2 (GBA2 nucleotide accession number BC011363) using the following primers: Sense 5’---CGC AAA TGG GCG GTA GGC GTG---3’ and antisense 5’---TAG TCA GCC ATG GGG CGG AGA ---3’) was cloned into pLenti-GIII-CMV by ABM Inc. The correctness of the construct was verified by sequencing. Lentivirus particles containing GBA2 in the pLenti-GIII-CMV plasmid were prepared using a third Generation Virus Packaging Mix (ABM cat# LV053-G074) in HEK293T cells and supplied as a virus particle suspension. The virus suspension was used for infection of HEK293T cells. Cell populations stably expressing human GBA2 were selected using puromycin for several weeks as determined by activity assays and western blot.
Various concentrations of test compounds were prepared in DMSO and then diluted into buffer consisting of 100 mM citric acid, 200 mM disodium phosphate with 1% v/v C10E6, pH 5.5. Cellular homogenates (0.25 mg/mL) of the stable HEK293T-overexpressing GBA2 cell line were preincubated for 10 min on ice with an inhibitor of GCase (20 µM (6R,7R,8S)-8-ethyl-4-azaspiro[2.5]octane-6,7-diol). The reaction solution consisted of 20 µL of 750 µM 4-methylumbelliferone-β-D glucopyranoside in 5% DMSO in the same buffer, 20 µL of GBA2-cellular homogenate pre-treated with (6R,7R,8S)-8-ethyl-4-azaspiro[2.5]octane-6,7-diol and 20 µL of various concentrations of test compound in 10% DMSO in the same buffer. The final concentrations in the reaction were 0.083 mg/mL GBA2-cellular homogenate, 250 µM 4-methylumbelliferone-β-D glucopyranoside, and various concentrations of inhibitor. The inhibitor and GBA2-cellular homogenate were preincubated together for 5 min at 37° C. The reaction was initiated by addition of substrate and allowed to proceed for 20 min at 37° C. to assess GBA2 activity. Reactions were stopped by the addition of an equal volume (60 µL) of 0.5 M NaOH, 0.3 M glycine, pH 10.5. Fluorescence was measured on a Biotek Synergy H4 plate reader at wavelengths of 365 nm for excitation and 450 nm for emission. Incubations without added enzyme or added inhibitors were used to define no enzyme activity and maximal enzyme activity, respectively. IC50 values were determined by fitting the data to a log[inhibitor concentration] versus response curve using GraphPad Prism. IC50 values were calculated as the concentration of inhibitor required to inhibit GBA2 activity by 50%.
The compounds of the invention tested exhibit IC50 values for inhibition of GBA2 in the range 0.1 nM - 50 µM.
Representative data from the GBA2 inhibition assay described above are shown in Table 3, where the symbol “***” indicates IC50 < 100 nM; the symbol “**” indicates 100 nM < IC50 < 1 µM; and the symbol “*” indicates 1 µM < IC50 < 25 µM.
The present invention has been described with regard to one or more embodiments. However, it will be apparent to persons skilled in the art that a number of variations and modifications can be made without departing from the scope of the invention as defined in the claims.
Therefore, although various embodiments of the invention are disclosed herein, many adaptations and modifications may be made within the scope of the invention in accordance with the common general knowledge of those skilled in this art. Such modifications include the substitution of known equivalents for any aspect of the invention in order to achieve the same result in substantially the same way. It is to be understood that specific embodiments may be combined in any manner and in any number to create additional embodiments and any permutations and combinations of the embodiments should be considered disclosed by the description of the present application unless the context indicates otherwise. Numeric ranges are inclusive of the numbers defining the range. Recitation of numeric ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. The terms “a” and “an” and “the”″ and similar reference used in the context of describing the invention are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. In the description, the word “comprising” is used as an open-ended term, substantially equivalent to the phrase “including, but not limited to,” and the word “comprises” has a corresponding meaning. It is to be however understood that, where the words “comprising” or “comprises,” or a variation having the same root, are used herein, variation or modification to “consisting” or “consists,” which excludes any element, step, or ingredient not specified, or to “consisting essentially of” or “consists essentially of,” which limits to the specified materials or recited steps together with those that do not materially affect the basic and novel characteristics of the claimed invention, is also contemplated. Citation of references herein shall not be construed as an admission that such references are prior art to the present invention. All publications are incorporated herein by reference as if each individual publication was specifically and individually indicated to be incorporated by reference herein and as though fully set forth herein. The invention includes all embodiments and variations substantially as hereinbefore described and with reference to the examples.
This application is a U.S. National Phase Patent Application of International Application Number PCT/IB2021/053864, filed on May 6, 2021, which claims benefit of U.S. Provisional Application No. 63/021,432. filed May 7, 2020, the entire content of each of which is incorporated herein by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/IB2021/053864 | 5/6/2021 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 63021432 | May 2020 | US |
